AZAQUINOLINE DERIVATIVES

Abstract

Processes for the preparation of said compounds, intermediate compounds useful for the preparation of said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for the preparation of pharmaceutical compositions for the treatment, control, and / or prevention of diseases, especially helminth infections, as a single agent or in combination with other active ingredients. Claim 1: A compound of general formula (1), wherein A is a compound of formula (2) or (3); or is 0, 1, 2, 3, or 4; R is selected from the group consisting of hydrogen, halogen, cyano, nitro, -OH, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-halogenalkyl-C₁₋₄,-S(O)-C₁₋₄ alkyl-halogen and -SO₂-C₁₋₄ alkyl-halogen having from 1 to 5 halogen atoms; X, Y are independently selected from the group consisting of CR⁷R⁸, O, S, and N-R⁹, characterized in that at least one of X and Y is CR⁷R⁸, or X, Y jointly form a ring member selected from the group consisting of -C(O)-O-, -C(O)-NR⁹-, -S(O)-NR⁹-, -SO₂-NR⁹- and -SO₂-O-; T is selected from the compounds of the group of formulas (4); R¹ is selected from the group consisting of hydrogen, cyano, -CHO, -OH, C₁₋₄ alkyl, C₁₋₄ halogen alkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogen alkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, C₃₋₆ halogen cycloalkyl having 1 to 5 halogen atoms, C₃₋₄ alkenyl, C₃₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cycloalkyl-C₃₋₆-alkyl-C₁₋₃, cyano-C₁₋₄-alkyl, -NH-alkyl-C₁₋₄, -N(alkyl-C₁₋₄)₂, NH₂-alkyl-C₁₋₄-, alkyl-C₁₋₄-NH-alkyl-C₁₋₄-, (alkyl-C₁₋₄-)₂N-alkyl-C₁₋₄-, alkyl-C₁₋₄-C(O)-,halogenalkyl-C₁₋₄-C(O)- having 1 to 5 halogen atoms, alkoxy-C₁₋₄-C(O)-, benzyloxy-C(O)-, alkoxy-C₁₋₄-alkyl-C₁₋₄-C(O)-, -SO₂-alkyl-C₁₋₄, and -SO₂-halogenalkyl-C₁₋₄ having 1 to 5 halogen atoms; phenyl-C₁₋₄-alkyl, optionally substituted by 1, 2, 3, 4 or 5 substituents selected independently from the group consisting of halogen, -OH, -NO₂, cyano, halogen-C₁₋₄alkyl having 1 to 5 halogen atoms, alkoxy-C₁₋₄, halogenalkoxy-C₁₋₄ having 1 to 5 halogen atoms, -NH₂, -NH(alkyl-C₁₋₄), -N(alkyl-C₁₋₄)₂, -S-alkyl-C₁₋₄, -S(O)-alkyl-C₁₋₄, -SO₂-alkyl-C₁₋₄, -S-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; C₁₋₄ alkyl-heterocyclyl, characterized in that the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered alkyl-heterocycloalkanes,5-membered heteroaryl and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, -NO₂, cyano, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; R² is selected from the group consisting of hydrogen, halogen, cyano, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂; -NR¹²R¹³; -OR¹⁴; -SR¹⁵, -S(O)R¹⁵, -SO₂R¹⁵; C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₄-alkenyl, C₃₋₆-cycloalkenyl,alkynyl-C₂₋₄ or phenyl-C₁₋₄ alkyl, each of which is optionally substituted by 1, 2, 3, 4 or 5 substituents selected independently from the group consisting of halogen, -OH, -NO₂, cyano, C₁₋₄-alkyl-C(O)-, C₁₋₄-alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄-alkyl), -C(O)-N(C₁₋₄-alkyl)₂, C₁₋₄-alkyl, C₁₋₄-halogenalkyl having from 1 to 5 halogen atoms, C₁₋₄-alkoxy, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms; C₁₋₄-alkyl-heterocyclyl, characterized in that the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents selected independently from the group consisting of halogen, -OH, -NO₂, cyano, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; phenyl that is optionally substituted by 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, -OH, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-alkyl-C₁₋₄,-S-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄-C(O)-alkoxy, -C(O)-NH₂, -C(O)-NH(C₁₋₄-alkyl), -C(O)-N(C₁₋₄-alkyl)₂, C₁₋₄-alkyl, C₁₋₄-alkyl-C(O)-, C₁₋₄-halogen having from 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ halogenalkoxy having from 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl,-S-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms, and 4- to 10-membered heterocycloalkyl; R³ is selected from the group consisting of hydrogen, halogen, or C₁₋₄ alkyl; R⁴ is selected from the group consisting of hydrogen, halogen, -OH, cyano, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkyl-C(O)-, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-alkyl-C₁₋₄; R⁵ is selected from the group consisting of hydrogen, halogen, -OH, cyano, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkyl-C(O)-, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl,-SO₂-alkyl-C₁₋₄; R⁶ is selected from the group consisting of hydrogen, halogen, -OH, cyano, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₂₋₄ alkoxy, C₁₋₄ alkyl-C(O)-, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl; R⁷ is selected from the group consisting of hydrogen, -OH, halogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; R⁸ is selected from the group consisting of hydrogen, -OH, halogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; or R⁷ and R⁸ together with the carbon atom to which they are attached form a 3- to 6-membered ring selected from the group consisting of C₃₋₆ cycloalkyl and 3- to 6-membered heterocycloalkyl; R⁹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, and C₁₋₄ alkoxy; R⁹⁰ is selected from the group consisting of hydrogen, -OH,C₁₋₄ alkyl and C₁₋₄ alkoxy; R¹¹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; or R¹⁰ and R¹¹ together with the carbon atom to which they are attached form a 3- to 6-membered ring selected from the group consisting of C₃₋₆ cycloalkyl and 3- to 6-membered heterocycloalkyl; R¹² and R¹³ are independently selected from the group consisting of hydrogen, -OH, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -NH(-C(O)-C₁₋₄ alkyl), -N(C₁₋₄ alkyl)(-C(O)-C₁₋₄ alkyl), C₁₋₄ alkoxy, C₁₋₄ alkoxy-C(O)-; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ phenyl alkyl, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, -NH-C(O)-C₁₋₄ alkyl, -N(C₁₋₄ alkyl)(-C(O)-C₁₋₄ alkyl), C₁₋₄ alkyl, C₁₋₄ halogen alkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy,C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₂₋₄ halogenalkyl having 1 to 5 halogen atoms, -S(O)-C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, -SO₂-C₁₋₄ halogenalkyl having 1 to 5 halogen atoms and (alkoxy-C₁₋₄)₂P(=O)-; C₁₋₄ alkyl-heterocyclyl, characterized in that the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, and C₁₋₄ haloalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl,C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ halogen alkyl having 1 to 5 halogen atoms, -S(O)-C₁₋₄ halogen alkyl having 1 to 5 halogen atoms, and -SO₂-C₁₋₄ halogen alkyl having 1 to 5 halogen atoms; phenyl, benzo-cycloalkyl-C₅₋₆, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, hydroxy-C₁₋₄ alkyl, halogenalkoxy-C₁₋₄ having 1 to 5 halogen atoms, cycloalkyl-C₃₋₆, -NH₂, -NH(alkyl-C₁₋₄), -N(alkyl-C₁₋₄)₂, -S-alkyl-C₁₋₄, -S(O)-alkyl-C₁₋₄, -SO₂-alkyl-C₁₋₄, -S-halogenalkyl-C₁₋₄ having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; R¹⁴ is selected from the group consisting of -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ phenylalkyl, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having from 1 to 5 halogen atoms, C₁₋₄ alkoxy, halogenalkoxy-C₁₋₄ having 1 to 5 halogen atoms, cycloalkyl-C₃₋₆, -NH₂, -NH(alkyl-C₁₋₄), N(alkyl-C₁₋₄)₂, -S-alkyl-C₁₋₄, -S(O)-alkyl-C₁₋₄, -SO₂-alkyl-C₁₋₄, -S-halogenalkyl-C₁₋₄ having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; C₁₋₄ alkyl-heterocyclyl, characterized in that the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, and C₁₋₄ haloalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ halogenalkyl having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, -OH, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms, and -SO₂-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms; and a bicyclic monocyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms; R¹⁵ is selected from the group consisting of C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ phenyl alkyl, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂,-C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms; C₁₋₄ alkyl-heterocyclyl, characterized in that the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄-alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl,halogen-C₁₋₄ having 1 to 5 halogen atoms, alkoxy-C₁₋₄, hydroxy-C₁₋₄, halogenalkoxy-C₁₋₄ having 1 to 5 halogen atoms, cycloalkyl-C₃₋₆, -NH₂, -NH(alkyl-C₁₋₄), -N(alkyl-C₁₋₄)₂, -S-alkyl-C₁₋₄, -S(O)-alkyl-C₁₋₄, -SO₂-alkyl-C₁₋₄, -S-halogenalkyl-C₁₋₄ having 1 to 5 halogen atoms, -S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, -OH, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, C₁₋₄ halogenalkoxy having 1 to 5 halogen atoms, C₃₋₆ cycloalkyl, -NH₂, -NH(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂, -S-C₁₋₄ alkyl, -S(O)-C₁₋₄ alkyl, -SO₂-C₁₋₄ alkyl, -S-C₁₋₄ alkyl halogen having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, C₁₋₄ alkoxy-C(O)-, -C(O)-NH₂, -C(O)-NH(C₁₋₄ alkyl), -C(O)-N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ halogenalkyl having 1 to 5 halogen atoms, C₁₋₄ alkoxy, hydroxy-C₁₋₄ alkyl, halogenalkoxy-C₁₋₄ having 1 to 5 halogen atoms, cycloalkyl-C₃₋₆, -NH₂, -NH(alkyl-C₁₋₄), -N(alkyl-C₁₋₄)₂, -S-alkyl-C₁₋₄, -S(O)-alkyl-C₁₋₄, -SO₂-alkyl-C₁₋₄, -S-halogenalkyl-C₁₋₄ having 1 to 5 halogen atoms,-S(O)-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms and -SO₂-C₁₋₄ alkyl-halogen having 1 to 5 halogen atoms; Q is selected from the group consisting of 6- or 10-membered aryl and 5- to 10-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, SF₅, cyano, -CHO, nitro, oxo, C₁₋₄ alkyl, hydroxyalkyl,

Description

DESCRIPTIVE MEMORY The present invention encompasses novel azaquinoline derivatives of the general formula (I), as described herein, processes for the preparation of said compounds, useful intermediates for the manufacture of said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for the preparation of pharmaceutical compositions for the control, treatment and / or prevention of diseases, especially for the control, treatment and / or prevention of infections with helminths, more particularly infections with gastrointestinal and extraintestinal nematodes , in animals and humans, formulations containing said compounds and methods for the control, treatment and / or prevention of infections with helminths, more particularly infections with gastrointestinal and extraintestinal nematodes, in animals and humans as a single agent or in combination with others active ingredients. BACKGROUND OF THE INVENTION The appearance of resistance against all commercial anthelmintics seems to be a growing problem in the field of veterinary medicine. The widespread use of anthelmintics to manage nematode control produced a significant selection of highly resistant worm populations. Therefore, the spread of resistance against all classes of anthelmintic drugs threatens effective worm control in cattle, goats, sheep, and horses. In addition, the successful prevention of canine heartworm disease, which currently relies solely on the use of macrocyclic lactones, is in jeopardy, as loss of efficacy of numerous macrocyclic lactones has been reported in some regions of the United States, especially those areas of high exposure to canine heartworm infection. Finally, experimental studies of infection with Dirofilaria immitis larvae for suspected cases of loss of efficacy in the field in the Lower Mississippi Delta provided in vivo confirmation of the existence of resistance to macrocyclic lactones. Although today the resistance of human helminths against anthelmintics seems to be rare, in the treatment of human helminths the spread of resistance to anthelmintics in the veterinary field should be considered, as mentioned above. Repeated treatments at insufficient doses against filariasis can lead to highly resistant genotypes, and resistance to certain anthelmintics (eg, praziquantel, benzimidazole, and niclosamide) has already been described. -2Therefore, anthelmintics capable of breaking resistance with new molecular modes of action are urgently required. An object of the present invention is to provide compounds that can be used as anthelmintics in the medical, especially veterinary field, with satisfactory or improved anthelmintic activity against a broad spectrum of helminths, particularly in relatively low doses, for the control, treatment and / or prevention of infections with helminths in animals and humans, preferably without adverse toxic effects for the treated organism. Some cinnoline carboxamides are described in US 20070142328A1 as agents suitable for the treatment and / or prophylaxis of anxiety disorders, cognitive disorders and / or mood disorders or the like. Furthermore, WO 2013148603 describes cinnolines and their activity as Bruton's tyrosine kinase (BTK) inhibitors for the treatment of BTK-associated diseases, disorders or conditions. The recently published document WO 2018 / 087036 discloses quinoline derivatives and their use in the control, treatment and / or prevention of diseases, such as infections with helminths. However, the state of the art does not describe the new azaquinoline derivatives of the general formula (I) of the present invention as described and defined in this document. It has now been discovered that the compounds of the present invention have surprising and advantageous properties, which constitutes the basis of the present invention. In particular, the compounds of the present invention have surprisingly been found to interact effectively with Slo-1 of nematodes. This interaction is characterized by achieving paralysis / inhibition, particularly of gastrointestinal nematodes, free nematodes, and filarial worms, for which data is given in the biological experiments section. Therefore, the compounds of the present invention can be used as anthelmintics for the control, treatment and / or prevention of gastrointestinal and extraintestinal helminth infections, particularly gastrointestinal and extraintestinal infections with nematodes, including filarial worms. DESCRIPTION OF THE INVENTION -3 According to a first aspect, the present invention encompasses compounds of the general formula (I): in which: A is Al or A2, A1 A2 / or is 0, 1, 2, 3 or 4, R is selected from the group consisting of hydrogen, halogen, cyano, nitro, -OH, alkyl-CiC«, halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cj-Có, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S (O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-Ci-C4-halogenoalkyl, -S(O)-Ci-C4-halogenoalkyl and -Ci-C4-SO2halogenoalkyl having 1 to 5 halogen atoms, X, Y are independently selected from the group consisting of CR7R8, O, S, and N-R9, characterized in that at least one of X and Y is CR7R8, or X, Y together form a ring member selected from the group consisting of -C(O)O-, -C(O)-NR9-, -S(O)-NR9-, -SO2-NR9- and -SO2- OT is selected from T1-T6 R1 is selected from the group consisting of hydrogen, cyano, -CHO, -OH, Ci-C4 alkyl, haloCi-C4 alkyl having 1 to 5 halogen atoms, Ci-C4 alkoxy, Ci-C4 haloalkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, halogenocycloalkyl-C3-Có having 1 to 5 halogen atoms, alkenyl-C3-C4, alkynyl-C3-C4, alkoxy-Ci-C4-alkyl -Ci-C4, cycloalkyl-Cs-Cs-Ci-Cs-alkyl, cyano-Ci-C4-alkyl, -NH-Ci-C4-alkyl, -N(Ci-C4-alkyl)2, NH2-Ci-C4-alkyl -, alkyl-Ci-C4-NHalkyl-Ci-C4-, (alkyl-Ci-C4-)2N-alkyl-Ci-C4-, alkyl-Ci-C4-C(O)-, haloalkylCj-C4-C( O)- having 1 to 5 halogen atoms, Ci-C4-alkoxy-C(O)-, benzyloxy-C(O)-, Ci-C4-alkoxy-Ci-C4-alkyl-C(O)- , -SO2-Ci-C4-alkyl, and -SO2-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms; phenyl-Ci-C4-alkyl, optionally substituted by 1,2,3,4 or 5 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloCi-C4alkyl having 1 to 5 atoms halogen, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, -NH2, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, -S- Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -Ci-C4-shalogenoalkyl having 1 to 5 halogen atoms, -S(O)-Ci-C4-haloalkyl -CiC4 having 1 to 5 halogen atoms and -S02-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and -5-6-membered heteroaryl, each of which is optionally substituted with 1,2, or 3 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloalkyl-Ci-C4 having 1 to 5 atoms halogen, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S- Ci-C4-alkyl, -S(0)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(0)halogenoalkyl- Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-CiC4 having 1 to 5 halogen atoms, R2 is selected from the group consisting of hydrogen, halogen, cyano, -COOH, alkoxy-Ci-C4-C(O)-, -C(0)-NH2, -C(O)-NH(C1-C4alkyl), -C(O)-N(Ci-C4-alkyl)2; -NRI2R13; -OR14; -SR15, -S(O)R15, -SO2R'5; alkyl-Ci-Có, cycloalkyl-Cs-Có, alkenyl-C2-C4, cycloalkenyl-Cj-Có, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted by 1, 2 , 3, 4, or 5 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, alkyl-Ci-C4-C(O)-, alkoxy-Ci-C4-C(O)-, -C (0)-NH2, -C(O)-NH(CiC4-alkyl), -C(0)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having from 1 5 halogen atoms, Ci-C4-alkoxy, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Ci-C4-Salkyl, -S(O)-alkyl -Ci-C4, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms halogen and -SO2-halogenoCi-C4alkyl having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(0)-Ci-C4-alkyl, - SO2Ci-C4alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(0) -6-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SCh-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; phenyl which is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-C]-C4, halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, Cs-Ce-cycloalkyl, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4-alkyl having 1 to 5 halogen atoms, -S(O )Ci-C4-halogenalkyl having 1 to 5 halogen atoms and -S02-Ci-C4-halogenalkyl having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents. independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH (C1-C4-alkyl), -C(0)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, Ci-C4-alkyl-C(O)-, haloCi-C4-alkyl having 1 to 5 atoms halogen, Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2 , -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)Ci-C4-alkyl, -SO2-Ci-C4-alkyl , -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -SO2halogenoCi-C4alkyl having 1 5 halogen atoms, and 4 to 10 membered heterocycloalkyl, R3 is selected from the group consisting of hydrogen, halogen, or alkyl-Ci-C4, R4 is selected from the group consisting of hydrogen, halogen, -OH, cyano, C1-C4-alkyl, Cs-C6-cycloalkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy-alkyl- Ci-C4, Ci-C4-alkoxy, Ci-C4-alkyl-C(O)-, -NH2, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, -S-alkyl- Ci-C4, -S(O)-Ci-C4-alkyl, -S02-Ci-C4-alkyl, R5 is selected from the group consisting of hydrogen, halogen, -OH, cyano, Ci-C4-alkyl, Cs-Ce-cycloalkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy-alkyl- Ci-C4, Ci-C4-alkoxy, Ci-C4-alkyl-C(O)-, -NH2, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, -S-alkyl- Ci-C4, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -7R6 is selected from the group consisting of hydrogen, halogen, -OH, cyano, C1-C4-alkyl, Cs-C6-cycloalkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy-alkyl -Ci-C4, -Ci-C4-alkoxy, -Ci-C4-alkyl-C(0)-, -NH2, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, -S-alkyl -Ci-C4, -S(0)-Ci-C4-alkyl, -SO2-C¡-C4-alkyl, R7 is selected from the group consisting of hydrogen, -OH, halogen, C1-C4 alkyl, and C1-C4 alkoxy, R8 is selected from the group consisting of hydrogen, -OH, halogen, C1-C4-alkyl, and C1-C4-alkoxy, or R7 and R8 form, together with the carbon atom to which they are attached, a 3- to 6-membered ring selected from the group consisting of cycloalkyl-Ca-Cs and 3- to 6-membered heterocycloalkyl, R9 is selected from the group consisting of hydrogen, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, and Ci-C4-alkoxy, R10 is selected from the group consisting of hydrogen, -OH, alkyl-Ci-C4 and alkoxy-Ci-C4, R11 is selected from the group consisting of hydrogen, C1-C4-alkyl, and C1-C4-alkoxy, or R'° and R11 form, together with the carbon atom to which they are attached, a 3- to 6-membered ring selected from group consisting of cycloalkyl-Cs-Có and 3- to 6-membered heterocycloalkyl, r!2 and j^i3 are independently selected from the group consisting of hydrogen, -OH, -NH2, -NH(alkyl-Ci-C4), - N(Ci-C4-alkyl)2, -NH(-C(O)-CjC4-alkyl), -N(Ci-C4-alkyl)(-C(0)-Ci-C4-alkyl), Ci-alkoxy -C4, alkoxy-Ci-C4-C(O)-; alkyl-Ci-C4, cycloalkyl-Cj-Cs, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, - COOH, Ci-C4-alkoxy-C(0)-, -C(0)-NH2, C(O)-NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl) 2, -NH-C(O)-Ci-C4-alkyl, -N(Ci-C4-alkyl)(-C(O)-Ci-C4-alkyl), Ci-C4-alkyl, haloCi-C4-alkyl having 1-5 halogen atoms, C1-C4-alkoxy, 1-5 halogen-Ci-C4-alkoxy, cycloalkyl-Cj-Có, -NH2, -NH(Ci-C4-alkyl), -N (C1-64-alkyl)2, -S-C1-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4-alkyl having from 1 to 5 halogen atoms, -S(0)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms -8halogen, -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and (alkoxy-CiC4)2P(=O)-; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(0)-NH2, -C(O) -NH(C1-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy , hydroxy-Ci-C4-alkyl, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Ca-Ce, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl) 2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms, -S(0)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -SO2-halogenoCi-C4alkyl having 1 to 5 halogen atoms; phenyl, benzo-cycloalkyl-Cs-Có, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, haloalkyl-Ci -C4 having 1 to 5 halogen atoms, C1-C4-alkoxy, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl ), -N(Ci-C4-alkyl)2, -S-C¡-C4-alkyl, -S(O)Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoalkyl-Ci- C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(Ci-C4-alkyl), - C(O)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, haloalkoxy -Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Ci-C4-Salky , -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci- C4 having 1 to 5 halogen atoms and -S02-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -9R14 is selected from the group consisting of -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2; alkyl-Ci-C4, cycloalkyl-Cs-Cs, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, - COOH, Ci-C4-alkoxy-C(0)-, -C(O)-NH2, C(0)-NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl) 2, Ci-C4-alkyl, haloCi-C4alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-haloalkoxy having 1 to 5 halogen atoms, cycloalkyl-Cj-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -S02-alkyl- Ci-C4, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci- C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(0)- NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, alkoxy-Ci- C4, hydroxy-Ci-C4-alkyl, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, -NH2, -NH(Ci-C4-alkyl), -N(Ci-alkyl -C4)2, -Salkyl-Ci-C4, -S(0)-alkyl-Ci-C4, -SO2-alkyl-Ci-C4, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms , -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -S02-halogenoalkyl-Cj-C4 having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, Cj-C6-cycloalkyl, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4-alkyl having 1 to 5 halogen atoms, -S(O )Ci-C4-halogenalkyl having 1 to 5 halogen atoms and -S02-Ci-C4-halogenalkyl having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl. -10 members, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O )-, -C(O)-NH2, -C(O)-NH(Ci-C4-alkyl), -C(0)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-alkyl -C4 having 1 to 5 halogen atoms, Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, haloCi-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, - S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, R15 is selected from the group consisting of Ci-C4-alkyl, Cs-Có-cycloalkyl, phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, C(O)-NH(Ci-C4-alkyl), -C(O)- N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenoalkoxy having 1 to 5 halogen atoms halogen, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-alkyl -C4, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -S02-halogenoCi-C4alkyl having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(0)-NH2, -C(0) -NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy , hydroxy-Ci-C4-alkyl, halogeno-Ci-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, -NH2, -NH(Ci-C4-alkyl), -N(C-alkyl) C4)2, -S-Ci-C4-alkyl, -S(0)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 carbon atoms halogen, -S(O)-halogeno-C,-C4alkyl having 1 to 5 halogen atoms and -SO2-halogenoCi-C4alkyl having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, -11 haloCi-C4alkyl having 1 to 5 halogen atoms, Ci-C4alkoxy, Ci-C4haloalkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH>, NH( -Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoalkyl -Ci-C4 having 1 to 5 halogen atoms, -S(O)halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SCh-halogenoalkyl-CiC4 having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of in halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(alkyl-Ci-C4 ), -C(O)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, hydroxy-Ci-alkyl C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Salkyl- Ci-C4, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoalkyl -Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, Q is selected from the group consisting of 6- or 10-membered aryl and 5- to 10-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen , SF5, cyano, -CHO, nitro, oxo, Ci-C4-alkyl, Ci-C4-hydroxyalkyl, Ci-C4-halogenoalkyl having 1 to 5 halogen atoms, hydroxy, C-C4-alkoxy, C3-cycloalkyl -C6-Ci-C4-alkoxy, cyano-Ci-C4-alkoxy, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl) 2, -NH-S02-(Ci-C4-alkyl), -N(S02-[Ci-C4-alkyl])(Ct-C4-alkyl), (Ci.C4-alkoxyimino)-Ci-C4-alkyl, 4 to 6 membered heterocyclyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, methyl and cyano, -CH2-O-(Ci-C4-alkyl), -CH2-NH( alkyl-Ci-C4), -CH2-N(alkyl€1-64)2, methyl substituted with a 4 to 6 membered heterocyclyl which itself is optionally substituted with 1 or 2 substitut Fluxes selected from the group consisting of fluorine, chlorine, bromine, methyl, and cyano, -CH2-S-(Ci-C4-alkyl), -CH2-S(O)-(Ci-C4-alkyl), CH2-SC> 2-(Ci-C4-alkyl), -S-(Ci-C4-alkyl), -S(0)-(Ci-C4-alkyl), -SO2-(Ci-C4-alkyl), -S-( haloalkyl-Ci-C4) having 1 to 5 halogen atoms, -S(O)(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, -SC>2-(halogenoalkyl-Ci -12C4) having 1 to 5 halogen atoms, -CONH(Ci-C4-alkyl), -CONH(Cj-Có-cycloalkyl), -NHCO(Ci-C4-alkyl), -NHCO(C3-C6-cycloalkyl) , -NHCO(halogenoalkyl-CiC4) having 1 to 5 halogen atoms, where when Y is O, S or N-R9, none of R7, R8, R'° and R11 is -OH, and where when X is O, S or N-R9, neither of R7 and R8 is -OH, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. DEFINITIONS The term "substituted" means that one or more hydrogen atoms in the designated atom or group is replaced with a selection from the indicated group, provided that the normal valence of the designated atom is not exceeded under the existing circumstances. Combinations of substituents and / or variables are permissible. The term "optionally substituted" means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Typically, it is possible for the number of optional substituents, when present, to be 1, 2, 3, 4 or 5, in particular 1, 2 or 3. As used herein, the term one or more, for example in the definition of the substituents of the compounds of the general formula (I) of the present invention, means 1, 2, 3, 4 or 5, particularly 1 , 2, 3 or 4, more particularly 1, 2 or 3, even more particularly 1 or 2 , As used herein, an oxo substituent represents an oxygen atom, which is attached to a carbon atom or sulfur atom by a double bond. The term "ring substituent" means a substituent attached to an aromatic or non-aromatic ring that replaces an available hydrogen atom on the ring. If a compound substituent is composed of one or more parts, for example, (Ci-C4-alkoxy)-(C1-C4-alkyl), it is possible for the position of a given part to be in any suitable position of that compound substituent, i.e. , the C1-C4-alkoxy part can be attached to any carbon atom of the C1-C4-alkyl part of said -(Ci-C4-alkoxy)-(Ci-C4-alkyl) group. a hyphen to -13beginning or at the end of said compound substituent indicates the point of attachment of said compound substituent to the rest of the molecule. If a ring, comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulfur atoms, for example, is substituted with a substituent, it is possible for said substituent to be attached at any suitable position on said ring, either is attached to a suitable carbon atom and / or to a suitable heteroatom. As used herein, the position through which a respective substituent is connected to the rest of the molecule in a drawn structure may be represented by a pound sign (#) or a dashed line in said substituent. The term comprising when used in the description includes consisting of. If any item is referred to within this text as being mentioned herein, it means that it can be mentioned anywhere in this text. The terms mentioned in this text have the following meanings: The term "halogen atom" means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom. The term "alkyl-Ci-Có" means a monovalent, saturated, linear or branched hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms. The term "Ci-C-t-alkyl" means a linear or branched saturated monovalent hydrocarbon group having 1, 2, 3 or 4 carbon atoms, for example, a methyl, ethyl, "-propyl, isopropyl, "-butyl, sec- butyl, isobutyl or tert-butyl, or an isomer thereof. In particular, said group has 1, 2 or 3 carbon atoms ("alkyl-Ci-Cj"), for example, a methyl, ethyl, -propyl or isopropyl group. The term "hydroxyalkyl-Ci-CJ' means a monovalent, saturated, linear or branched hydrocarbon group in which the term "alkyl-Ci-Ci" is defined above, and in which 1 or 2 hydrogen atoms are replaced with a hydroxy group, for example, a hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 2,3-dihydroxypropyl, l,3-dihydroxypropan-2-yl, 3-hydroxy2-methylpropyl, 2-hydroxy-2-methyl-propyl, l-hydroxy-2-methyl-propyl. The term “-NH(Ci-C4-alkyl)” or “-N(Ci-C4-alkyl)2” means a monovalent, saturated, linear or branched group in which the term “Ci-C4-alkyl” is as a methylamino, ethylamino, β-propylamino, isopropylamino, Λζ / V-dimethylamino, jV-methyl-Netylamino or 7V,7V-diethylamino group is defined above, for example. -14 The term “-S-alkyl-Ci-C4”, “-S(O)-alkyl-Ci-C4” or “-SO2-alkyl-Ci-C4” means a saturated, linear or branched group in which the term "Ci-C4-alkyl" is as defined above, for example, a methylsulfanyl, ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl, sec-butylsulfanyl, isobutylsulfanyl or / erc-butylsulfanyl group, a methylsulfmyl, ethylsulfinyl, n -propylsulfinyl, isopropylsulfinyl, rc-butylsulfinyl, seobutylsulfinyl, isobutylsulfinyl or tert-butylsulfinyl, or a methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, .sec-butylsulfonyl, isobutylsulfonyl or Zerc-butylsulfonyl group. The term "Ci-C4-halogenoalkenyl" means a monovalent, saturated, linear or branched hydrocarbon group in which the term Ci-C4 alkyl is as defined above, and in which one or more of the hydrogen atoms are replaced, identically or different, with a halogen atom. Particularly, said halogen atom is a fluorine atom. More particularly, all of the halogen atoms mentioned are fluorine atoms (fluoroalkyl-Ci-C4). Said haloCi-C4alkyl group is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl or 1,3difluoropropan- 2-i 1. The term "Ci-C4-alkoxy" means a linear or branched saturated monovalent group of the formula O-(Ci-C4-alkyl), in which the term "Ci-C4-alkyl" is as defined above, e.g. example, a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, or erc-butoxy group, or an isomer thereof. The term haloCi-C4alkoxy means a monovalent, saturated, linear or branched alkoxy-Ci-C4 group as defined above, in which one or more of the hydrogen atoms are replaced, identically or differently, with a hydrogen atom. halogen. Particularly, said halogen atom is a fluorine atom. Said halogenoalkoxy-Ci-C4 group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy. The term "C2-C4-alkenyl" means a linear or branched, monovalent hydrocarbon group containing a double bond and having 2, 3 or 4 carbon atoms. Said C2-C4-alkenyl group is, for example, unethenyl (or vinyl), a prop-2-en-1-yl (or "allyl") group, prop-1-en-1-yl, but-3- enyl, but-2-enyl, but-l-enyl, prop-l-en-2-yl (or “isopropenyl”), 2-methylprop-2-enyl, l-methylprop-2enyl, 2-methylprop-l- enyl or a 1-methylprop-l-enyl. Particularly, said group is allyl. The term "C2-C4-alkynyl" means a linear monovalent hydrocarbon group containing a triple bond and containing 2, 3 or 4 carbon atoms. Said C2-C4-alkynyl group is, for -15example, an ethynyl, prop-l-ynyl, prop-2-ynyl (or propargyl), but-l-ynyl, but-2-ynyl, but3-ynyl or l-methylprop-2-ynyl group. Particularly, said alkynyl group is prop-l-ynyl or prop-2-ynyl. The term "cycloalkyl-Cs-Cs" means a monocyclic, monovalent, saturated hydrocarbon ring containing 3, 4, 5 or 6 carbon atoms ("cycloalkyl-Cs-Ce"). Said cycloalkyl-Cs-Cfi group is, for example, a monocyclic hydrocarbon ring, for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group, The term halocycloalkyl-Cs-Có means a monocyclic, saturated, monovalent hydrocarbon ring in which the term cycloalkyl Cs-Có is as defined above, and in which one or more of the hydrogen atoms are replaced, identically or differently, by a halogen atom. Particularly, said halogen atom is a fluorine or chlorine atom. Said halogenocycloalkyl-Cs-Có group is, for example, a monocyclic hydrocarbon ring substituted with one or two fluorine or chlorine atoms, for example, a 1-fluoro-cyclopropyl, 2-fluorocyclopropyl, 2,2-difluorocyclopropyl, 2,3- -difluorocyclopropyl, 1-chlorocyclopropyl, 2-chlorocyclopropyl, 2,2-dichlorocyclopropyl, 2,3-dichlorocyclopropyl, 2-fluoro-2-chlorocyclopropyl and 2-fluoro-3-chlorocyclopropyl. The term “-NHfcycloalkyl-Cs-Có)” or “-N(Ci-C4-alkyl)(C3-C6-cycloalkyl)” means a linear or branched, saturated, monovalent group in which the term “Ci-alkyl- C4" and the term "cycloalkyl-Cs-Có" are each as defined supra, for example a cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, 7V-methyl-N-cyclopropylamino, jV-ethyl-jVcyclopropylamino, JV-methyl- N-cyclobutylamino, / V-ethylW-cyclobutylamino, jV-methyl-N-cyclopentylamino, jV-ethyl-jV-cyclopentylamino, / V-methyl-N-cyclohexylamino or JV-ethyl-7Vcyclohexylamino. The term "benzo-cycloalkyl-Cs-Có" means a monovalent bicyclic hydrocarbon ring wherein a monovalent saturated monocyclic hydrocarbon ring containing 5 or 6 carbon atoms (Cs-Cs cycloalkyl) is annealed to a phenyl ring. Said benzo-cycloalkyl-CsC6 group is, for example, a bicyclic hydrocarbon ring, for example, an indane (i.e., 2,3-dihydro-1 / / -indene) or tetralin (i.e., 1,2,3, 4-tetrahydronaphthalene). The term "spirocycloalkyl" means a monovalent, saturated bicyclic hydrocarbon group in which the two rings share a common carbon atom, and wherein said bicyclic hydrocarbon group contains 5, 6, 7, 8, 9, 10 or 11 carbon atoms, it is possible for said spirocycloalkyl group to be attached to the rest of the molecule through any of the carbon atoms except the spiro carbon atom. Said spirocycloalkyl group is, for example, -16spiro[2.2]pentyl, spiro[2.3]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, spiro[2.6]nonyl, spiro[3.3]heptyl, spiro[3.4]octyl, spiro[3.5]nonyl, spiro [3.6]decyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[4.6]undecyl or spiro[5.5]undecyl. The term "heterocycloalkyl" means a saturated or partially saturated, monocyclic or bicyclic heterocycle with 4, 5, 6, 7, 8, 9 or 10 ring atoms in total (a 4- to 10-membered heterocycloalkyl group), particularly 4, 5 or 6 ring atoms (a 4- to 6-membered heterocycloalkyl group), containing one or two identical or different ring heteroatoms from the N, O, and S series, said heterocycloalkyl group may be attached to the remainder of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. Said heterocycloalkyl group, without being limited herein, can be a 4-membered ring, such as azetidinyl, oxetanyl, or thietanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidothiolanyl, 1,2oxazolidinyl, 1,3-oxazolidinyl, 1,3-thiazolidinyl or 1,2,4-triazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1,4-dioxanyl or 1,2-oxazinanyl, for example; or a 7-membered ring, such as azepanil, 1,4-diazepanyl or 1,4-oxazepanyl, for example; or a 7-membered bicyclic ring, such as 6-oxa-3-azabicyclo[3.1.1]heptane, for example; or an 8-membered bicyclic ring, such as 5,6-dihydro-4H-furo[2,3-c]pyrrole or 8-oxa-3-azabicyclo[3.2.1]octane, for example; or a 9-membered bicyclic ring, such as octahydro-1H-pyrrolo[3,4-b]pyridine, 1,3-dihydro-isoindole, 2,3-dihydro-indole, or 3,9-dioxa-7-azabicyclo[ 3.3.1 ]nonan, for example; or a 10-membered bicyclic ring, such as decahydroquinoline or 3,4-dihydroisoquinoline, for example. The term "heterospirocycloalkyl" means a bicyclic saturated heterocycle with 6, 7, 8, 9, 10, or 11 ring atoms in total, in which the two rings share a common ring carbon atom, which heterospirocycloalkyl contains one or two identical or different ring heteroatoms of the series: N, O, S; it is possible for said heterospirocycloalkyl group to be attached to the rest of the molecule through any of the carbon atoms except the spiro carbon atom or, if present, a nitrogen atom. Said heterospirocycloalkyl group is, for example, azaspiro[2.3]hexyl, azaspiro[3.3]heptyl, oxaazaspiro[3.3]heptyl, thiaazaspiro[3.3]heptyl, oxaspiro[3.3]heptyl, oxazaspiro[5.3]nonyl, oxazaspiro[4.3]octyl, oxaazaspiro[2.5]octyl, azaspiro[4.5]decyl, oxazaspiro[5.5]undecyl, diazaspiro[3.3]heptyl, thiazaspiro[3.3]heptyl, thiazaspiro[4.3]octyl, azaspiro[5.5]undecyl, or one -17 of the additional homologous scaffolds such as spiro[3.4]-, spiro[4.4]-, spiro[2.4]-, spiro[2.5]-, spiro[2.6]-, spiro[3.5]-, spiro[3.6]-, spiro[4.5]- and spiro[4.6]. The term "6- or 10-membered aryl" means a monovalent, monocyclic or bicyclic aromatic ring having 6 or 10 ring carbon atoms, for example, a phenyl or naphthyl group. The term "heteroaryl" means a monovalent, monocyclic, bicyclic or tricyclic aromatic ring having 5, 6, 9 or 10 ring atoms (a 5- to 10-membered heteroaryl group), particularly 5 or 6 ring atoms (a 5- to 10-membered heteroaryl group). 5 to 6-membered), containing at least one ring heteroatom and optionally one, two or three additional ring heteroatoms from the series: N, O and / or S, and which is attached via a carbon atom in the ring or optionally through a nitrogen atom in the ring (if valency allows). Said heteroaryl group may be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl. The term "heterocyclyl" means a heterocycle selected from the group consisting of heterocycloalkyl and heteroaryl. Particularly, the term "4 to 6 membered heterocyclyl" means a heterocycle selected from the group consisting of 4 to 6 membered heterocycloalkyl and 5 to 6 membered heteroaryl. In general, and unless otherwise indicated, heteroaryl or heteroarylene groups include all their possible isomeric forms, for example, tautomers and positional isomers with respect to the point of attachment with the rest of the molecule. Thus, for some illustrative non-limiting examples, the term "pyridinyl" includes pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl. The term “C1-C4”, as used herein, for example, in the context of the definition of “Ci-C4-alkyl”, “Ci-C4-halogenoalkyl”, “Ci-C4-hydroxyalkyl”, "Ci-C4-alkoxy" or "Ci-C4-halogenoalkoxy" means an alkyl group having a finite number of carbon atoms from 1 to 4, ie, 1, 2, 3 or 4 carbon atoms. In addition, as used herein, the term "C3-C6", as used herein, for example, in the context of the definition of cycloalkyl-Cs-Có or halocycloalkyl-Cs-Có, means a group cycloalkyl having a finite number of carbon atoms from 3 to 6, ie 3, 4, 5 or 6 carbon atoms. -18When a range of values ​​is provided, that range comprises each value and subrange within that range. For example: C1-C4 comprises Cb C2, C3, C4, C1-C4, C1-C3, C1-C2, C2-C4, C2-C3, and C3-C4; C2-C6 comprises C2, C3, C4, C$, Ce, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5 , and Cs-Céj C3-C4 comprises C3, C4, and C3-C4; C3-C10 comprises C3, C4, C5, Ce, C7, Cs, C9, Cío, C3-C10, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4, C4- C10, C4-C9, C4-C8, C4-C7, C4-C6, C4-C5, C5-C10, C5-C9, C5-C8, C5-C7, Cs-Ce, Ce-Cio, Ce-Cg, Ce-Cs, Ce-C?, C7-C10, C7-C9, C7-C8, Cs-Cio, C8-C9 and C9-C10; Cs-Cs comprises C3, C4, Cs, Ce, C7, Cs, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4, C4-C8, C4-C7, C4-C6, C4- C5, Cs-Cs, C5-C7, Cs-Ce, Ce-Ce, Ce-C? and C?-Cs; Cs-Ce comprises C3, C4, Cs, Ce, Cs-Ce, C3-C5, C3-C4, C4-C6, C4-C5, and Cs-Ce; C4-C8 comprises C4, Cs, Ce, C7, Cs, C4-C8, C4-C7, C4-C6, C4-C5, Cs-Cs, Cs-C?, Cs-Ce, Ce-Cs, C6-C7 and C?-Cs; C4-C7 comprises C4, Cs, Ce, C7, C4-C7, C4-C6, C4-C5, C5-C7, Cs-Ce and Ce-C?; C4-Ce comprises C4, Cs, Ce, C^-Ce, C4-C5 and Cs-Ce; C5-C10 comprises C5, Ce, C7, Cs, C9, Cío, C5-C10, C5-C9, Cs-Cs, C5-C7, Cs-Ce, Ce-Cio, Ce-Cg, CeCs, Ce-C? , C7-C10, C7-C9, C7-C8, Cs-Cio, Cs-Cg and C9-C10; Ce-Cio includes Ce, C7, Cs, C9, Cío, Ce-Cio, C6-C9, Ce-Cs, Ce-C?, C7-C10, C7-C9, C?-Cs, Cs-Cio, C8- C9 and C9-C10. As used herein, the term "leaving group" means an atom or a group of atoms that moves in a chemical reaction as a stable species that carries the bonding electrons with it. In particular, said leaving group is selected from the group comprising: halide, especially fluoride, chloride, bromide or iodide, (methylsulfonyl)oxy, [(trifluoromethyl)sulfonyl]oxy, [(nonafluorobutyl)sulfonyl]oxy, (phenylsulfonyl) oxy, [(4-methylphenyl)sulfonyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl)sulfonyl]oxy, [(2-nitrophenyl)sulfonyl]oxy, -19[(4-isopropylphenyl)sulfonyl]oxy, [(2,4,6-triisopropylphenyl)sulfonyl]oxy, [(2,4,6-trimethylphenyl)sulfonyl]oxy, [(4- / erc-butylphenyl)sulfonyl ]oxy and [(4-methoxyphenyl)sulfonyl]oxy. An oxo substituent in the context of the invention means an oxygen atom, which is attached to a carbon atom via a double bond. It is possible that compounds of the general formula (I) exist as isotopic variants. Therefore, the invention includes one or more isotopic variants of the compounds of the general formula (1), in particular deuterium-containing compounds of the general formula (I). The term isotopic variant of a compound or a reagent is defined as a compound that exhibits an unnatural ratio of one or more of the isotopes that make up said compound. The term isotopic variant of the general formula (1) is defined as a compound of the general formula (I) that exhibits an unnatural ratio of one or more of the isotopes constituting said compound. The term "unnatural ratio" means a ratio of said isotope that is greater than its natural abundance. The natural abundances of isotopes that apply in this context are described in Isotopic Compositions of the Elements 1997, Pure Appl. Chem., 70(1), 217-235, 1998. Examples of such isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, such as 2H (deuterium), 3H (tritium), C, 13C, 14C, 15N, 17O, 18O, 32P, 33P, 33S, 34S, 35S, 36S, 18F, 36C1, 82Br, 123I, 124I, 125I, 129I, and I31I, respectively. With regard to the treatment and / or prevention of the disorders specified herein, the isotopic variant(s) of the compounds of the general formula (I) preferably contain deuterium ("deuterium-containing compounds of the general formula (I)"). Isotopic variants of the compounds of the general formula (I) into which one or more radioactive isotopes, such as 3H or 14C, are incorporated are useful, for example in drug and / or tissue substrate distribution studies. These isotopes are particularly preferred for ease of incorporation and detectability. Positron emitting isotopes such as I8F or HC can be incorporated into a compound of general formula (I). These isotopic variants of the compounds of the general formula (I) are useful for in vivo imaging applications. The deuterium-containing and 13C-containing compounds of the general formula (I) can be used in mass spectrometric analysis in the context of preclinical or clinical studies. -20 The isotopic variants of the compounds of general formula (I) can generally be prepared by procedures known to a person skilled in the art, such as those described in the schemes and / or examples of the present invention, substituting a reagent for a variant isotopic of said reagent, preferably by a reagent containing deuterium. Depending on the desired deuteration sites, in some cases deuterium can be incorporated from D2O directly into compounds or into reagents that are useful for synthesizing such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds and acetylenic bonds is a fast route for deuterium incorporation. Metal catalysts (i.e., Pd, Pt, and Rh) in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in hydrocarbon-containing functional groups. A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as eg, C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA and CombiPhos Catalysts, Inc., Princeton, NJ, USA. The term deuterium-containing compound of general formula (1) is defined as a compound of general formula (I), in which one or more hydrogen atom(s) is / are substituted by one or more deuterium atoms and in which the abundance of deuterium at each deuterated position of the compound of the general formula (I) is greater than the natural abundance of deuterium, which is approximately 0.015%. Particularly, in a deuterium-containing compound of the general formula (1), the abundance of deuterium at each deuterated position of the compound of the general formula (I) is more than 10%, 20%, 30%, 40%, 50%. , 60%, 70% or 80%, preferably greater than 90%, 95%, 96% or 97%, and even more preferably greater than 98% or 99% at said positions. It is understood that the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at other deuterated positions. The selective incorporation of one or more deuterium atoms in a compound of the general formula (I) can alter the physicochemical properties (such as for example acidity [CL Perrin, et al., J. Am. Chem. Soc., 2007, 129, 4490], basicity [CL Perrin et al., J. Am. Chem. Soc. 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J, Pharm, 1984, 19(3), 271]) and / or the metabolic profile of the molecule and may result in changes in the ratio of parent compound to metabolites or in the amounts of metabolites formed. Such changes may give rise to certain therapeutic advantages and may therefore be preferred in some circumstances. Reduced rates of metabolism and metabolic change, where the ratio of metabolites changes, have been reported (AE Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). These changes in exposure to -21 parent drug and metabolites can have important consequences with respect to the pharmacodynamics, tolerability and efficacy of a deuterium-containing compound of the general formula (I). In some cases, deuterium substitution reduces or eliminates the formation of an unwanted or toxic metabolite and enhances the formation of a desired metabolite (for example Nevirapine: AM Sharma et al., Chem. Res. Toxicol., 2013, 26, 410 Efavirenz: AE Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169,102). In other cases, the main effect of deuteration is to reduce the rate of systemic elimination. As a result, the biological half-life of the compound is increased. Potential clinical benefits would include the ability to maintain similar systemic exposure with reduced peak levels and increased trough levels. This could result in minor side effects and greater efficacy, depending on the pharmacokinetic / pharmacodynamic relationship of the particular compound. ML-337 (C.J. Wenthur et al., J. Med. Chem., 2013, 56, 5208) and Odanacatib (K. Kassahun et al., WO2012 / 112363) are examples of this deuterium effect. Even other cases have been reported in which reduced rates of metabolism result in increased drug exposure without changing the systemic elimination rate (for example, Rofecoxib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; Telaprevir: F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs that show this effect may have reduced dosage requirements (eg, fewer number of doses or lower doses to achieve the desired effect) and / or may produce lower metabolite loads. A compound of the general formula (1) may have multiple potential sites of attack for metabolism. To optimize the above-described effects on physicochemical properties and metabolic profile, deuterium-containing compounds of the general formula (I) can be selected which have a certain pattern of one or more deuterium-hydrogen exchanges. In particular, the deuterium atoms of deuterium-containing compounds of the general formula (I) are attached to a carbon atom and or are located at those positions of the compound of the general formula (I), which are attack sites for metabolizing enzymes. such as for example cytochrome P450. In cases where the plural form of the words compounds, salts, polymorphs, hydrates, solvates and the like is used herein, it is to be taken to mean also the singular, compound, salt, polymorph, isomer, hydrate, solvate. and the like. The term "stable compound" or "stable structure" means a compound robust enough to survive isolation at a useful degree of purity from a reaction mixture. -22y formulation into an effective therapeutic agent. The compounds of the present invention optionally contain one or more asymmetric centers, depending on the location and nature of the various desired substituents. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can lead to racemic mixtures in the case of a single asymmetric center and diastereomeric mixtures in the case of multiple asymmetric centers. . In certain cases, it is possible that asymmetry is also present due to restricted rotation around a given bond, eg, the central bond joining two substituted aromatic rings of the specified compounds. Those compounds which produce the most desirable biological activity are preferred. Also included within the scope of the present invention are separate, pure or partially purified racemic or diastereomeric isomers, stereoisomers or mixtures of the compounds of the present invention. Purification and separation of such materials can be accomplished using conventional techniques known in the art. Those isomers which produce the most desirable biological activity are preferred. These separate, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. Purification and separation of such materials can be accomplished using conventional techniques known in the art. Optical isomers can be obtained by resolution of the racemic mixtures according to conventional procedures, for example, by the formation of diastereoisomeric salts using an optically active acid or base or the formation of covalent diastereomers. Examples of suitable acids include tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers based on their physical and / or chemical differences by procedures known in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are released after the separated diastereomeric salts. A different procedure for the separation of optical isomers involves the use of chiral chromatography (eg, HPLC columns using a chiral phase), with or without conventional derivatization, optimally chosen to maximize the separation of the enantiomers. Suitable HPLC columns using a chiral phase are commercially available, such as those made by Daicel, for example, Chiracel OD and Chiracel OJ, for example, among many others, -23select them routinely. Enzymatic separations, with or without derivatization, are also useful. The optically active compounds of the present invention can also be obtained by chiral synthesis using optically active starting materials. In order to distinguish different types of isomers from each other, reference is made to Section E of the IUPAC Standards (Pure Appl Chem 45, 11-30, 1976). The present invention includes all possible stereoisomers of the compounds of the present invention as individual stereoisomers, or as any mixture of such stereoisomers, for example (R)- or (S)-, in any ratio. Isolation of a single ester isomer, eg a single enantiomer or a single diastereomer, of a compound of the present invention can be accomplished by any suitable state-of-the-art method, such as chromatography, especially chiral chromatography, for example. Furthermore, the compounds of the present invention can exist as tautomers. For example, any compound of the present invention that contains a substitution pattern that results in an α-CH moiety in azaquinoline that has increased C-H acidity can exist as a tautomer, or even a mixture in any amount of the two. tautomers. The present invention includes all possible tautomers of the compounds of the present invention as individual tautomers or as any mixture of such tautomers, in any ratio. Furthermore, the compounds of the present invention may exist as N-oxides, which are defined as at least one nitrogen of the compounds of the present invention is oxidized. The present invention includes all possible N-oxides. The present invention also encompasses useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and / or co-precipitates. The compounds of the present invention may exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as a structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, can exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, eg a hydrate, hemi-, (semi), mono-, sesqui-, di-, tri-, tetra-, penta-, etc., solvates or hydrates are possible, respectively. The present invention includes all of these hydrates or solvates. -24 Furthermore, the compounds of the present invention may exist in the free form, for example in the form of a free base, or in the form of a free acid, or in the form of a zwitterion or may exist in the form of a salt. Said salt may be any salt, whether an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, commonly used in pharmacy, or used, for example, to isolate or purify the compounds of the present invention. The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see S.M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19. A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid addition salt with an inorganic, or mineral acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy- 2-naphthoic, nicotinic, pamoic, pectinic, 3-phenylpropionic, pivalic, 2-hydroxyethanesulfonic, itaconic, trifluoromethanesulfonic, dodecylsulfonic, ethanesulfonic, benzenesulfonic, para-toluenesulfonic, methanesulfonic nico, 2-naphthalenesulfonic, naphthalenedisulfonic, camphorsulfonic, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic acids or thiocyanic acid, for example. Furthermore, another suitable pharmaceutically acceptable salt of a compound of the present invention that is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium, magnesium or strontium salt. , or an aluminum or zinc salt, or an ammonium salt derived from ammonia or from a primary, secondary or tertiary organic amine having 1 to 20 carbon atoms, such as ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, jV-methylmorpholine, arginine, lysine, 1,2-ethylenediamine, / V-methylpiperidine, N-methyl-glucamine, AUV-dimethyl-glucamine , A-ethyl-glucamine, 1,6-hexanediamine, glucosamine, -25sarcosine, serinol, 2-amino-1,3-propanediol, 3-amino-1,2-propanediol, 4-amino-1,2,3-butanetriol, or a salt with a quaternary ammonium ion having 1 to 20 carbon atoms, such as tetramethylammonium, tetraethylammonium, tetra(»-propyl)ammonium, tetra(n-butyl)ammonium, / V-benzyl-A,A / Atrimethylammonium, choline or benzalkonium. Those skilled in the art will further recognize that acid addition salts of the claimed compounds can be prepared by reacting the compounds with the appropriate inorganic or organic acid by any of the known procedures. Alternatively, the alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the invention with the appropriate base by a variety of known procedures. The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of such salts, in any ratio. In the present text, in particular in the Experimental Section, for the synthesis of intermediates and examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form salt, as obtained by the respective preparation and / or purification process, is in most cases unknown. Unless otherwise specified, suffixes to chemical names or structural formulas relating to salts, such as hydrochloride, trifluoroacetate, sodium salt, or x HC1, x CF3COOH, x Na+, for example, signify a salt form, the stoichiometry of which is not specified. This applies analogously to cases where synthesis intermediates or example compounds or salts thereof have been obtained by the described preparation and / or purification procedures as solvates, such as hydrates, with unknown stoichiometric composition (if applicable). defines). Additionally, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, whether individual polymorphs, or as a mixture of more than one polymorph, in any ratio. In addition, the present invention also includes prodrugs of the compounds according to the invention. Herein the term prodrugs designates compounds that can be biologically active or inactive, but are converted (eg metabolically or hydrolytically) into compounds according to the invention during their residence time in the body. -26 According to a second embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is Al or A2, A1 or A2 is 0, 1, 2, 3 or 4, R is selected from the group consisting of hydrogen, halogen, cyano, nitro, -OH, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenalkoxy having has 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S( 0)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-Ci-C4-halogenoalkyl, -S(O)-Ci-C4-halogenoalkyl and -Ci-C4-SO2halogenoalkyl having 1 to 5 atoms halogen, X, Y are independently selected from the group consisting of CR7R8,0, S, and N-R9, wherein at least one of X and Y is CR7R8, or X, Y together form a ring member selected from the group consisting of -C(O)O-, -C(O)-NR9-, -S(O)-NR9-, -SO2-NR9- and -SO2- EITHER-, T is selected from T1 - T6 as defined above R' is selected from the group consisting of hydrogen, cyano, -CHO, -OH, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci- C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, halocycloalkyl-Cs-Có having 1 to 5 halogen atoms, alkenyl-C3-C4, alkynyl-C3-C4, alkoxy-Ci-C4- alkyl-Ci-C4, cycloalkyl-Ci-Ce-alkyl-Ci-Cs, cyano-Ci-C4-alkyl, -NH-alkyl-Ci-C4, -N(alkyl-Ci-C4)2, NH2-alkyl-Ci- C4-, alkyl-Ci-C4-NHalkyl-Ci-C4-, (alkyl-Ci-C4-)2N-alkyl-Ci-C4-, alkyl-Ci-C4-C(O)-, haloCi-C4-C alkyl (O)- having 1 to 5 halogen atoms, Ci-C4-alkoxy-C(O)-, benzyloxy-C(O)-, Ci-C4-alkoxy-Ci-C4-alkyl-C(0) -, -S02-Ci-C4-alkyl, and -SO2-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms; -27phenyl-Ci-C4-alkyl, optionally substituted by 1,2,3, 4, or 5 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloCi-C4alkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, -NH2, -NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, -S -Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -Ci-C4-shalogenoalkyl having 1 to 5 halogen atoms, -S(O)- haloalkyl-CiC4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-C¡-C4-alkyl, -SO2Ci-C4alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)halogenoCi-C4alkyl having 1 to 5 halogen atoms and -S02-halogenoalkyl- CiC4 having 1 to 5 halogen atoms, R2 is selected from the group consisting of hydrogen, halogen, cyano, -COOH, alkoxy-Ci-C4-C(0)-, -C(0)-NH2, -C(O)-NH(Ci-C4 alkyl), -C(O)-N(Ci-C4-alkyl)2; -NRI2R13; -OR14; -SR15, -S(O)R15, -SO2R15; alkyl-Ci-Có, cycloalkyl-Cs-Có, alkenyl-C2-C4, cycloalkenyl-Cj-Có, alkynyl-C2-C4 or phenyl-alkyl-C)-C4, each of which is optionally substituted by 1, 2,3,4 or 5 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, alkyl-G-G-QO)-, alkoxy-Ci-C4-C(O)-, -C(O) -NH2, -C(O)-NH(CiC4-alkyl), -C(O)-b¡(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Ci-C4-Salkyl, -S(O)-Ci-alkyl -C4, -SO2-alkyl-Ci-C4, -S-halogenoalkyl-Ci-C4 which -28 has 1 to 5 halogen atoms, -S(0)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SCh-halogenoalkyl-Ci-Ci having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, -OH, -NO2, cyano, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, - SO2Ci-C4alkyl, -S-Ci-C4halogenalkyl having 1 to 5 halogen atoms, -S(O)Ci-C4halogenalkyl having 1 to 5 halogen atoms and -S02CiC4halogenalkyl having 1 to 5 halogen atoms; phenyl which is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy -Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, - S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms, -S(O) halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents. independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH (C1-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, Ci-C4-alkyl-C(O)-, haloCi-C4-alkyl having 1 to 5 atoms halogen, Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cj-Có, -NH2 , -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)Ci-C4-alkyl, -SO2-Ci-C4-alkyl , -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(0)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -SO2-29halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and 4-membered heterocycloalkyl, R3 is selected from the group consisting of hydrogen, halogen, or alkyl-Ci-C4, R4 is selected from the group consisting of hydrogen, halogen, cyano, alkyl-Cj-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, R5 is selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, R6 is selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, R7 is selected from the group consisting of hydrogen, -OH, fluorine, alkyl-Ci-C4 and alkoxy-CiC4, R8 is selected from the group consisting of hydrogen, -OH, fluorine, alkyl-Ci-C4 and alkoxy-CiC4, R9 is selected from the group consisting of hydrogen, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, and Ci-C4-alkoxy, R10 is selected from the group consisting of hydrogen, -OH, alkyl-Ci-C4 and alkoxy-Ci-C4, R is selected from the group consisting of hydrogen, C1-C4-alkyl, and C1-C4-alkoxy, r!2 and ri3 are independently selected from the group consisting of hydrogen, -OH, -NH2, -NH(Ci-alkyl- C4), -N(Ci-C4-alkyl)2, -NH(-C(O)-Ci-C4-alkyl), Ci-C4-alkoxy; alkyl-Ci-C4, cycloalkyl-Cj-Có, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, - COOH, Ci-C4-alkoxy-C(O)-, -C(O)-NH2, C(O)-NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl) 2, -NH-C(O)-Ci-C4-alkyl, -N(Ci-C4-alkyl)-(-C(O)-Ci-C4-alkyl), Ci-C4-alkyl, haloCi-C4-alkyl which has 1 to 5 halogen atoms, Ci-C4-alkoxy, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), - N(Ci-C4-alkyl)2, -S-C1-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4-alkyl having of 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms -30halogen, -SC>2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and (alkoxy-CjC4)2P(=O)-; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O) -NH(C1-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy , hydroxy-Ci-C4-alkyl, halogeno-Ci-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-alkyl€ 4)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 carbon atoms halogen, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -SO2-halogenoCi-C4alkyl having 1 to 5 halogen atoms; phenyl, benzo-cycloalkyl-Cs-Có, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, haloalkyl-Ci -C4 having 1 to 5 halogen atoms, C1-C4-alkoxy, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl ), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms, -S(O)-Ci-C4 haloalkyl having 1 to 5 halogen atoms and -SO2Ci-C4 haloalkyl having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen , cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(Ci-C4-alkyl), -C(O)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, haloalkoxy-Cj-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Salkyl-Ci- C4, -S(O)-C]-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoalkyl- Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -31 RM is selected from the group consisting of -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2; Ci-C4-alkyl, Cs-Cs-cycloalkyl, phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, - COOH, Ci-C4-alkoxy-C(O)-, -C(O)-NH2, C(O)-NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl) 2, Ci-C4 alkyl, C1-C4 haloalkyl having 1 to 5 halogen atoms, C]-C4 alkoxy, Ci-C4 haloalkoxy having 1 to 5 halogen atoms, Cs-Ce cycloalkyl , -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-alkyl -Ci-C4, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci -C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)- NH(Ci-C4-alkyl), -C(0)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, alkoxy-Ci- C4, hydroxy-Ci-C4-alkyl, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Cá, -NH2, -NH(Ci-C4-alkyl), -N(Ci-alkyl -C4)2, -Salkyl-Ci-C4, -S(O)-alkyl-Ci-C4, -SO2-alkyl-Ci-C4, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms , -S(0)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -SO2-halogenoCi-C4alkyl having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, Cs-C6-cycloalkyl, -NH2, NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4-alkyl having 1 to 5 halogen atoms, -S(O )Ci-C4-halogenalkyl having 1 to 5 halogen atoms and -SO2-Ci-C4-halogenalkyl having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl. -32 members, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -C00H, alkoxy-Ci-C4-C(O )-, -C(O)-NH2, -C(O)-NH(C,-C4-alkyl), -C(0)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloalkyl- Ci-C4 having 1 to 5 halogen atoms, Ci-C4 alkoxy, hydroxy-Ci-C4 alkyl, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2 , -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, R15 is selected from the group consisting of Ci-C4-alkyl, Cs-Có-cycloalkyl, phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, -C00H, alkoxy-Ci-C4-C(O)-, -C(0)-NH2, C(0)-NH(Ci-C4-alkyl), -C(0)- N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenoalkoxy having 1 to 5 halogen atoms halogen, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-alkyl -C4, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(0)-, -C(0)-NH2, -C(O) -NH(Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy , hydroxy-Ci-C4-alkyl, halogenoCi-C4-alkox having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -S02-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having 1 to 5 halogen atoms, -S (O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; phenyl, which is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, alkyl-Ci-C4, -33Ci-C4-halogenalkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenalkoxy having 1 to 5 halogen atoms, C3-C6-cycloalkyl, -NH2, NH(alkyl- Ci-C4), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoalkyl-Ci -C4 having 1 to 5 halogen atoms, -S(O)halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SCh-halogenoalkyl-CiC4 having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of in halogen, cyano, nitro, -OH, oxo, thiono, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(0)-NH(alkyl-Ci-C4 ), -C(O)N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, hydroxy-Ci-alkyl C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -Salkyl- Ci-C4, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoalkyl -Ci-C4 having 1 to 5 halogen atoms and -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, Q is a substituted phenyl ring of the formula (Ql) (Q1) in which: Z1, Z2, Z3, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SF5, cyano, -CHO, nitro, alkyl-Ci-C4, haloalkyl-CiC4 having 1 to 5 halogen atoms, hydroxy , Cl-C4-alkoxy, cycloalkyl-C3Có-Ci-C4-alkoxy, cyano-Ci-C4-alkoxy, haloCi-C4alkoxy having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH-SO2-(C1-C4-alkyl), -N(SO2-[Ci-C4-alkyl)(Ci-C4-alkyl), (Ci-C4-alkoxyimino)- alkyl-CiC4, 4 to 6 membered heterocyclyl, which is optionally substituted with 1 or 2 -34 substituents selected from the group consisting of fluoro, chloro, bromo, methyl, and cyano, -CH2-O-(Ci-C4-alkyl), CH2-NH(C1-C4-alkyl), -CH2-N(Cl-alkyl -C4)2, methyl substituted with a 4 to 6 membered heterocyclyl which itself is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, methyl and cyano, CH2-S-(alkyl- Ci-C4), -CH2-S(O)(Ci-C4-alkyl), -CH2-SC>2-(Ci-C4-alkyl), -S-(Ci-C4-alkyl), -S(O )-(CiC4-alkyl), -SO2-(Ci-C4-alkyl), -S-(halogenoCi-C4alkyl) having 1 to 5 halogen atoms, -S(0)-(halogenoalkyl-Ci- C4) having 1 to 5 halogen atoms, -SO2-(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, CONH(Ci-C4-alkyl), CONH(C3-C6-cycloalkyl), -NHCO(Ci-C4-alkyl), NHCO(C3-C6-cycloalkyl), -NHCO(halogenoCi-C4-alkyl) having 1 to 5 halogen atoms, or Z1 and Z2 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z3, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SFs, cyano, CHO, nitro, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, hydroxy, alkoxy- Ci-C4, cycloalkyl-Cs-Có-alkoxy-Ci-C4, cyano-alkoxy-Ci-C4, alkoxy-Ci-C4-C(O)-, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, - NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH-S02-(Ci-C4-alkyl), -N(SO2-[Ci-C4-alkyl])(Ci-C4-alkyl ), (Ci-C4-alkoxyimino)-Ci-C4-alkyl, 4- to 6-membered heterocycloalkyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl or cyano, CH2-O-(Ci-alkyl -C4), CH2-NH(Ci-C4-alkyl), -CH2-N(Ci-C4-alkyl)2, methyl substituted with a 4- to 6-membered heterocycloalkyl which itself is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl, or cyano, CH2-S-(Ci-C4-alkyl), -CH2-S(O)-(Ci-C4-alkyl), -CH2-SO2-(Ci-C4-alkyl ), -S-(alkyl-Ci -C4), -S(O)-(Ci-C4-alkyl), -SO2(Ci-C4-alkyl), -S-(halogenoCi-C4-alkyl) having 1 to 5 halogen atoms, -S (O)-(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, -SO2(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, CONH(Ci-35C4-alkyl), CONH / cycloalkyl-Ca-Ce), -NHCO(alkyl-Ci-C4), -NHCO(cycloalkyl-C3Có), -NHCO(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, or Z2 and Z3 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z1, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SF5, cyano, CHO, nitro, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, hydroxy, alkoxy- Ci-C4, cycloalkyl-Cj-Ce-alkoxy-Ci-C4, cyano-alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, -NH(Ct-C4-alkyl), -N( Ci-C4-alkyl)2, -NH-SO2-(Ci-C4-alkyl), N(SO2-[Ci-C4-alkyl])(Ci-C4-alkyl), (Ci-C4-alkoxyimino)-alkyl -Ci-C4, 4 to 6-membered heterocycloalkyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl, or cyano, -CH2Q-(Ci-C4-alkyl), CH2-NH(alkyl- Ci-C4), -CH2-N(Ci-C4-alkyl)2, methyl substituted with a 4- to 6-membered heterocycloalkyl which itself is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, methyl or cyano, CH2-S-(Ci-C4-alkyl), -CH2-S(O)-(Ci-C4-alkyl), -CH2-SO2-(Ci-C4-alkyl), -S-(Ci-C4-alkyl ), -S(O)-(alkyl -Ci-C4), -SO2(Ci-C4-alkyl), -S-(Ci-C4-halogen-alkyl) having 1 to 5 halogen atoms, -S(O)-(Ci-C4-halogen-alkyl) having has 1 to 5 halogen atoms, -SO2(halogenoalkyl-Ci-C4) which has 1 to 5 halogen atoms, CONH(alkyl-Ci4), CONH(cycloalkyl-C3-C6), -NHCO(alkyl-Ci -C4), -NHCO(cycloalkyl-C3Ce), -NHCO(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, or Q is a pyridine ring of the formula (Q2) (Q2) -36in which: Z6, Z7, Z8, and Z9 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C4-Cj-alkoxy, C1-C4-halogenalkoxy- Ci-C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, or Q is a pyrimidine ring of the formula (Q3) (Q3) in which: Z'°, Z11, and Z12 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C4-Ci-alkoxy, C1-C4-halogenalkoxy- Ci-C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, or Q is a pyridine ring of the formula (Q4) in which: Z13, Z14, Z15 and Z16 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenalkoxy- Ci-C4 having 1 to 5 halogen atoms, hydroxyCi-C4alkyl, NH2, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -NH-CO-Ci-C4alkyl , and monocyclic heterocycles selected from the group of 4- to 7-membered heterocycloalkyl or 5-membered heteroaryls having at least one nitrogen atom through which the heteroaryl ring extends. -37 connects to the pyridine ring, each of which is optionally substituted with 1,2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, alkyl-Ci-C4, haloalkyl- Ci-C4 having 1 to 5 halogen atoms, Ci-C4 alkoxy, haloalkoxy-C¡-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce, -NH2, -NH(alkyl-Ci -C4), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-C)-C4-alkyl, -SO2-Ci-C4-alkyl, -S(halogenoalkyl -Ci-C4) having 1 to 5 halogen atoms, -S(O)(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, -SO2(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, or Q is a pyridine ring of the formula (Q5) in which: Z17, Z18, Z19, and Z20 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-haloalkoxy -C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, or Q is a 5-membered aromatic heterocycle of the formula (Q6) (Q6) in which: -38G1 -G4 are independently selected from the group consisting of N, O, S, C-Z21, and NZ22, wherein not more than one of G' - G4 is O, not more than one of G1 - G4 is S, not more of one of G1-G4 is N-Z22, and wherein each Z21 is independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, C1-C4 alkoxy, C1-C4 haloalkoxy having 1 to 5 halogen atoms, and each Z22 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl having 1 to 5 halogen atoms halogen, alkyl-CiC4-cycloalkyl-C3-C6, alkoxy-Ci-C4-alkyl-Ci-C4, or Q is a 5-membered aromatic heterocycle of the formula (Q7) (Q7) in which: U1 -U4 are independently selected from the group consisting of N and C-Z23, where no more than three of U1 - U4 are N, and where each Z23 is independently selected from the group consisting of hydrogen, halogen, cyano, C-alkyl ]-C4, haloCi-C4alkyl having 1 to 5 halogen atoms, Ci-C4alkoxy, haloCi-C4alkoxy having 1 to 5 halogen atoms, wherein when Y is O, S or N -R9, none of R7, R8, R10 and R11 is -OH, and where when X is O, S or N-R9, none of R7 and R8 is -OH, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. -39 According to a third embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is Al or A2, A1 or A2 is 0, 1 or 2, R is selected from the group consisting of hydrogen, halogen, Ci-C4-alkyl, and Ci-C4-alkoxy, cyano, haloCi-C4-alkyl having 1 to 5 halogen atoms, X, Y are independently selected from the group consisting of CR7R8,0, S, and N-R9, wherein at least one of X and Y is CR7R8, T is selected from T1 - T6 as defined above R1 is selected from the group consisting of hydrogen, Ci-C4-alkyl, Cs-Có-cycloalkyl, C3-C4-alkenyl, C3-C4-alkynyl, Ci-C4-alkoxy-Ci-C4-alkyl, Cs-cycloalkyl- Ce-C1-C3 alkyl, cyano-Ci-C4 alkyl, R2 is selected from the group consisting of hydrogen, halogen, cyano, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(C)-C4 alkyl) , -C(O)-N(Ci-C4-alkyl)2; -NR12R13; -OR14; -SR15, -S(O)R15, -SO2R15; Ci-C4-alkyl, Cs-Có-cycloalkyl, C2-C4-alkenyl, Ca-Có-cycloalkenyl, C2-C4-alkynyl or phenyl-Ci-C4-alkyl, each of which is optionally substituted by 1, 2 , 3, 4, or 5 substituents independently selected from the group consisting of halogen, -OH, cyano, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(alkyl -Ci-C4), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, -NH2, -NH (Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-alkyl -40C4, -SO2-Ci-C4-alkyl, -S-halogenoCi-C4alkyl having 1 to 5 halogen atoms, -S(O)-halogenoCi-C4alkyl having 1 to 5 halogen atoms and -SO2halogenoCi-C4alkyl having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected substituents from the group consisting of halogen, cyano, -OH, oxo, -COOH, alkoxy-C>-04-0(0)-, -C(O)-NH2, -C(0)-NH(alkyl-C >-C4), C(O)-N(C>-C4-alkyl)2, C>-C4-alkyl, Ci-C4-alkyl-C(O)-, haloC>-C4-alkyl having from 1 to 5 halogen atoms, C>-C4-alkoxy, hydroxy-C>-C4-alkyl, C>-C4-alkoxy-C>-C4-alkyl, C>-C4-halogenalkoxy having 1 to 5 halogen atoms , C3-C6 cycloalkyl, -NH2, -NH(C>-C4-alkyl), -N(C>-C4-alkyl)2, and 4- to 10-membered heterocycloalkyl, R3, is selected from the group consisting of hydrogen, halogen, or C>-C4-alkyl, R4 is selected from the group consisting of hydrogen, halogen, cyano, C>-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, C>-C4-alkoxy, R5 is selected from the group consisting of hydrogen, halogen, cyano, C>-C4-alkyl, haloC>-C4-alkyl having 1 to 5 halogen atoms, C>-C4-alkoxy, R6 is selected from the group consisting of hydrogen, halogen, cyano, C>-C4-alkyl, haloC>-C4-alkyl having 1 to 5 halogen atoms, C>-C4-alkoxy, R7 is selected from the group consisting of hydrogen and alkyl-C>-C4, R8 is selected from the group consisting of hydrogen and alkyl-C>-C4, R9 is alkyl-C>-C4, R'° is selected from the group consisting of hydrogen, -OH, alkyl-C>-C4 and alkoxy-C>-C4, R is hydrogen, r>2 and r13 are independently selected from the group consisting of hydrogen, -NH(-C(O)-C>-C4-alkyl), C>-C4-alkoxy; alkyl-C>-C4, cycloalkyl-Cs-Ce, phenyl-alkyl-C>-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the -41 group consisting of halogen, -OH, cyano, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, C(O)-NH(alkyl-Ci-C4), -C(O)-N(Ci-C4-alkyl)2, -NH-C(O)-Ci-C4-alkyl, -N(Ci-C4-alkyl)-(-C(O)-Ci-C4-alkyl ), alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-alkyl- C4, -S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -SO2-halogenoalkyl-Ci-C4 having it has 1 to 5 halogen atoms and (alkoxy-CiC4)2P(=O)-; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, -OH, oxo, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenalkoxy having 1 to 5 halogen atoms; phenyl, benzo-cycloalkyl-Cs-Có, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 having of 1 to 5 halogen atoms, Ci-C4-alkoxy, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen , cyano, -OH, oxo, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenalkoxy having 1 to 5 halogen atoms, R14 is selected from the group consisting of alkyl-Ci-C4, cycloalkyl-Cs-Có, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, Ci-C4 alkyl, haloCi-C4 alkyl having 1 to 5 halogen atoms, Ci-C4 alkoxy, Ci-C 4 haloalkoxy having 1 to 5 halogen atoms, cycloalkyl -C3-C&; Y -42heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, -OH, oxo, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, halogenalkoxy-Ci- C4 having 1 to 5 halogen atoms; R15 is selected from the group consisting of Ci-C4-alkyl, phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano 0-C1-C4-alkyl, haloCi-C4alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, haloCi-C4alkoxy having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl having 1 to 5 halogen atoms, C1-C4 alkoxy, C1-C4 haloalkoxy having 1 to 5 atoms halogen; Q is a substituted phenyl ring of the formula (Ql) (Q1) in which: Z', Z2, Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 has 1 to 5 halogen atoms, hydroxy, alkoxy-Ci -C4, haloalkoxy-Ci-C4 has 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(C1-04-alkyl)2, 4- to 6-membered heterocyclyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, methyl, and cyano, -S-(Ci-C4-alkyl), S(0)-(Ci-C4-alkyl), -SO2-(Ci-C4-alkyl) -Ci-C4), or -43Z1 and Z2 form, together with the carbon atoms to which they are connected, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may be optionally substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-alkoxy- C4-C(O)-, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, or Z2 and Z3 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z1, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-haloalkoxy- C4 having 1 to 5 halogen atoms, or Q is a pyridine ring of the formula (Q2) (Q2) in which: Z6, Z7, Z8, and Z9 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenalkoxy- Cj-C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Cj-C4-alkyl)2, or Q is a pyrimidine ring of the formula (Q3) (Q3) in which: Z'°, Z11, and Z12 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C4-Ci-alkoxy, C1-C4-halogenalkoxy- Ci-C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(C1-64-alkyl)2, or Q is a pyridine ring of the formula (Q4) in which: Z13, Z14, Z15 and Z16 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenalkoxy- Ci-C4 having 1 to 5 halogen atoms, hydroxyCi-C4alkyl, NH2, -NH(Ci-C4alkyl), -N(61-64alkyl)2, -NH-CO-Ci-C4alkyl , and monocyclic heterocycles selected from the group of 4- to 7-membered heterocycloalkyl or 5-membered heteroaryls having at least one nitrogen atom through which the heteroaryl ring is connected to the pyridine ring, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci -C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-63-66, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S -Ci-C4-alkyl, -S(O )-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S(halogenoalkyl-61-64) having 1 to 5 halogen atoms, -S(O)-45(halogenoCi-C4-alkyl) having 1 to 5 halogen atoms, -SO2(halogenoalkyl-Cj-Cu having 1 to 5 halogen atoms, or Q is a pyridine ring of the formula (Q5) in which: Z17, Z18, Z19 and Z20 are independently selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, halo-Ci-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-haloalkoxy -C4 having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, or Q is a 5-membered aromatic heterocycle of the formula (Q6) (Q6) in which: G1 - G4 are independently selected from the group consisting of N, O, S, C-Z21, and NZ22, wherein no more than one of G1 - G4 is O, no more than one of G1 - G4 is S, no more than one of G1-G4 is N-Z22, and wherein each Z21 is independently selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, Ci-C4-halogenalkyl having 1 to 5 halogen atoms, and alkoxy- Ci-C4, and each Z22 is independently selected from the group consisting of hydrogen, Ci-C4 alkyl, haloCi-C4 alkyl having 1 to 5 halogen atoms, Ci-C4 alkyl-C3-C6 cycloalkyl, Ci-C6 alkoxy C4-alkyl-Ci-C4, or -46Q is a 5-membered aromatic heterocycle of the formula (Q7) (Q7) in which: U1 - U4 are independently selected from the group consisting of N and C-Z23, where no more than three of U1 - U4 are N, and where each Z23 is independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci -C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, wherein when Y is O, S or N-R9, R10 is not -OH, and stereoisomers, tautomers, N- oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to a fourth embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is Al or A2, A1 A2 is either 0 or 1, R is selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4, and alkoxy-CiC4, X is selected from the group consisting of CR7R8, O, S, and N-R9, -47Y is CR7R8, T is selected from Τ' - T6 as defined above R1 is hydrogen or alkyl-Ci-C4, R2 is selected from the group consisting of hydrogen, halogen, -NR12R13; -OR14; -SR15, -S(O)R15, -SO2R15; alkyl-Ci-C4, cycloalkyl-Cs-Có, alkenyl-C2-C4 or cycloalkenyl-Cs-Có, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of halogen, cyano, alkoxy-Ci-C4-C(O)- and C(O)-NH2; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected substituents from the group consisting of halogen, -OH, oxo, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, alkyl-Ci-C4, alkyl-C¡C4-C(O )-, haloCi-C4alkyl having 1 to 5 halogen atoms, hydroxy-C1-C4alkyl, Ci-C4alkoxy-Ci-C4alkyl, -NH2, -N(Ci-C4alkyl)2, and 4 to 10 membered heterocycloalkyl, R3 is selected from the group consisting of hydrogen, halogen, or alkyl-Ci-C4, R4 is selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, R5 is selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, R6 is selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, R7 is selected from the group consisting of hydrogen and alkyl-Ci-C4, -48R8 is selected from the group consisting of hydrogen and alkyl-Ci-C4, R9 is alkyl-Ci-C4, R10 is selected from the group consisting of hydrogen, -OH and alkyl-Ci-C4, R is hydrogen, ri2 and ri3 are independently selected from the group consisting of hydrogen, -NH(-C(O)-Ci-C4-alkyl), Ci-C4-alkoxy; alkyl-Ci-C4, cycloalkyl-Cs-Có, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, -COOH, alkoxy-Ci-C4-C(O)-, -C(0)-NH2, -C(O)N(alkyl-Ci-C4)2, -NH-C(O)-alkyl-Ci-C4, alkyl -Ci-C4, -Ci-C4-alkoxy, -Ci-C4-cycloalkyl, -NH2, -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-alkyl-Ci-C4, and (alkoxy-Ci-C4)2P(=O)-; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, -OH, oxo, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, and Ci-C4-alkoxy; phenyl and benzo-cycloalkyl-Cs-Ci, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C» having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4-halogenalkoxy having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen , -OH, oxo, cyano, C1-C4 alkyl, C1-C4 haloalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-C4 haloalkoxy having 1 to 5 halogen atoms, R14 is selected from the group consisting of -49Ci-C4-alkyl, Cs-Ce-cycloalkyl, phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, alkyl- Ci-C4, alkoxy-Ci-C4 and cycloalkyl-Cs-Có; and 4 to 10 membered heterocycloalkyl, R15 is selected from the group consisting of -Ci-C4 alkyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of -OH and -COOH; and a 6-membered heteroaryl, Q is a substituted phenyl ring of the formula (Q1) (Q1) in which: Z1 is selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4 and alkoxy-Ci-C4, Z2 is selected from the group consisting of hydrogen, halogen, -OH, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH (C3-C6-cycloalkyl), N(Ci-C4-alkyl)(C3-C6-cycloalkyl), haloCi-C4alkyl having 1 to 5 halogen atoms, haloCi-C4alkoxy having 1 to 5 halogen atoms, -S-(Ci-C4-alkyl) and a 4- to 6-membered heterocycloalkyl, and Z3 is selected from the group consisting of hydrogen, halogen, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl) and -N(Cj-C4-alkyl)2, Z4 is selected from the group consisting of hydrogen, halogen, -OH, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH (C3-C6-cycloalkyl), N(Ci-C4-alkyl)(C3-C6-cycloalkyl), haloCi-C4-alkyl having 1 to 5 -50 halogen atoms, halogenoalkoxy-Ci-C4 having 1 to 5 halogen atoms, -S-(Ci-C4-alkyl) and a 4- to 6-membered heterocycloalkyl, - Z5 is selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4 and alkoxy-Ci-C4, Q is a pyridine ring of the formula (Q4) in which: Z13, Z14, Z15 and Z16 are independently selected from the group consisting of hydrogen, halogen, cyano, Ci-C4 alkyl, Ci-C4 alkoxy, Ci-C4 hydroxyalkyl, NH2, NH(Ci-C4 alkyl), -N(Ci-C4-alkyl)2, -NH-CO-Ci-C4-alkyl, and monocyclic heterocycles selected from the group of 4- to 7-membered heterocycloalkyl or 5-membered heteroaryls having at least one nitrogen atom through of which the heteroaryl ring is connected to the pyridine ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, -OH, oxo, thiono, 0-C1-alkyl -C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -NH2, -NH (Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S- (halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, -S(O)-(halogenoalkyl uyl-Ci-C4) having 1 to 5 halogen atoms, -SO2-(halogenoCi-C4alkyl) having 1 to 5 halogen atoms, or Q is a pyridine ring of the formula (Q5) in which: Z17, Z18, Z19, and Z20 are independently selected from the group consisting of hydrogen, halogen, C1-C4-alkyl, and C1-C4-alkoxy, or Q is a 5-membered aromatic heterocycle of the formula (Q6) (Q6) in which: G1 - G4 are independently selected from the group consisting of N, O, S, C-Z21, and NZ22, wherein not more than one of G1 - G4 is O, not more than one of G' - G4 is S, not more than one of G1-G4 is N-Z22, and wherein each Z21 is independently selected from the group consisting of hydrogen, halogen, cyano, Ci-C4-alkyl, Ci-C4-halogenalkyl having 1 to 5 halogen atoms, and alkoxy -Ci-C4, and each Z22 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, haloCi-C4 alkyl having 1 to 5 halogen atoms, Ci-C4 alkyl-cycloalkyl-C3-C6, alkoxy-Ci -C4-alkyl-Ci-C4, or Q is a 5-membered aromatic heterocycle of the formula (Q7) (Q7) -52in which: U1 - U4 are independently selected from the group consisting of N and C-Z23, where no more than three of U1 - U4 are N, and where each Z23 is independently selected from the group consisting of hydrogen, halogen, cyano, alkyl- Ci-C4, haloCi-C4alkyl having 1 to 5 halogen atoms, Ci-C4alkoxy, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. A particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) according to the second, third or fourth embodiment supra, in which: Q is a substituted phenyl ring of the formula (Q1) (Q1) in which: Z', Z2, Z3, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SF5, cyano, -CHO, nitro, alkyl-Ci-C4, haloalkyl-CiC4 having 1 to 5 halogen atoms, hydroxy, Ci-C4-alkoxy, CsC6-cycloalkyl-Ci-C4-alkoxy, cyano-Ci-C4-alkoxy, haloCi-C4-alkoxy having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl) , -N(Ci-C4-alkyl)2, -NH-SO2-(C1-C4-alkyl), -N(SO2-[Ci-C4-alkyl)(Ci-C4-alkyl), (Ci-C4-alkoxyimino) -Ci-C4-alkyl, 4 to 6-membered heterocyclyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, chlorine, bromine, methyl and cyano, -CH2-O-(Ci-C4-alkyl), CH2-NH(Ci-C4-alkyl), -CH2-N(C1-C4-alkyl)2, methyl substituted with a 4 to 6 membered heterocyclyl which itself is optionally substituted with 1 or 2 substituents selected from the group that -53consists of fluorine, chlorine, bromine, methyl and cyano, CH2-S-(Ci-C4-alkyl), -CH2-S(O)(Ci-C4-alkyl), -CH2-SO2-(Ci-alkyl- C4), -S-(Cj-C4-alkyl), -S(O)-(Ci-C4-alkyl), -SO2-(Ci-C4-alkyl), -S-(halogeno-Ci-C4-alkyl) having de 1 to 5 halogen atoms, -S(0)-(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, -SO2-(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, CONH(Ci-C4-alkyl), CONH(C3-C6-cycloalkyl), -NHCO(Ci-C4-alkyl), NHCO(C3-C6-cycloalkyl), -NHCO(halogeno-Ci-C4-alkyl) having of 1 to 5 halogen atoms, or Z1 and Z2 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z3, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SFs, cyano, CHO, nitro, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, hydroxy, alkoxy- Ci-C4, cycloalkyl-Cs-Ce-alkoxy-Ci-C4, cyano-alkoxy-Ci-C4, alkoxy-Ci-C4-C(0)-, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, - NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH-SO2-(Ci-C4-alkyl), -N(SO2-[Ci-C4-alkyl])(Ci-C4-alkyl ), (Ci-C4-alkoxyimino)-Ci-C4-alkyl, 4- to 6-membered heterocycloalkyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl or cyano, CH2-O-(Ci-alkyl -C4), CH2-NH(Ci-C4-alkyl), -CH2-N(Ci-C4-alkyl)2, methyl substituted with a 4- to 6-membered heterocycloalkyl which itself is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl or cyano, CH2-S-(Ci-C4-alkyl), -CH2-S(O)-(Ci-C4-alkyl), -CH2-SO2-(C1-C4-alkyl) , -S-(alkyl-Ci- C4), -S(O)-(Ci-C4-alkyl), -SO2(Ci-C4-alkyl), -S-(halogenoCi-C4-alkyl) having 1 to 5 halogen atoms, -S( O)-(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, -SO2(Ci-C4-halogenalkyl) having 1 to 5 halogen atoms, CONH(Ci-C4-alkyl), CONH(cycloalkyl- C3-C6), -NHCO(Ci-C4-alkyl), -NHCO(C3Ce-cycloalkyl), -NHCO(Ci-C4-halogenoalkyl) having 1 to 5 halogen atoms, or -54Z2 and Z3 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which can be optionally substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z1, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, SFs, cyano, CHO, nitro, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, hydroxy, alkoxy- Ci-C4, cycloalkyl-Cs-Có-Ci-C4-alkoxy, cyano-Ci-C4-alkoxy, haloCi-C4-alkoxy having 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N( Ci-C4-alkyl)2, -NH-SO2-(Ci-C4-alkyl), N(SO2-[Ci-C4-alkyl])(Ci-C4-alkyl), (Ci-C4-alkoxyimino) -Ci-C4-alkyl, 4 to 6-membered heterocycloalkyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine, methyl or cyano, -CH20-(Ci-C4-alkyl), -CH2-NH (Ci-C4-alkyl), -CH2-N(Ci-C4-alkyl)2, methyl substituted with a 4- to 6-membered heterocycloalkyl which itself is optionally substituted with 1 or 2 substituents selected from the group consisting of fluorine , methyl or cyano, -CH2-S-(Ci-C4-alkyl), -CH2-S(O)-(Ci-C4-alkyl), -CH2-SO2-(Ci-C4-alkyl), -S-(Ci-C4-alkyl) -C.-C4), -S(O)- (Ci-C4-alkyl), -SO2(Ci-C4-alkyl), -S-(Ci-C4-halogen-alkyl) having 1 to 5 halogen atoms, -S(O)-(Ci-C4-halogen ) having 1 to 5 halogen atoms, -SO2(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, -CONH(Ci-C4 alkyl), -CONHfcycloalkyl-Cs-Có), -NHCO(alkyl -Ci-C4), -NHCO(cycloalkylCa-Ce), -NHCO(halogenoalkyl-Ci-C4) having 1 to 5 halogen atoms, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof , and mixtures thereof. A particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) according to the second, third or fourth embodiment supra, in which: Q is a substituted phenyl ring of the formula (Ql) (Q1) in which: Z1, Z2, Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 has 1 to 5 halogen atoms, hydroxy, alkoxy-Ci- C4, haloalkoxy-Ci-C4 has 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH(cycloalkyl-C3Có), -N(alkyl- Ci-C4)(cycloalkyl-C3-C6), 4 to 6 membered heterocyclyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, methyl and cyano, -S-(alkyl- Ci-C4), -S(O)-(C1-C4 alkyl), -SC>2-(Ci-C4 alkyl), or Z' and Z2 form, together with the carbon atoms to which they are attached, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may be optionally substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-alkoxy- C4-C(O)-, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, or Z2 and Z3 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z1, Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenalkyl having 1 to 5 atoms -56of halogen, C1-C-t-alkoxy, C1-C4-halogenoalkoxy having 1 to 5 halogen atoms, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. A particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) according to the second, third or fourth embodiment supra, in which: Q is a substituted phenyl ring of the formula (Ql) (Q1) in which: Z1 is selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4 and alkoxy-Ci-C4, Z2 is selected from the group consisting of hydrogen, halogen, -OH, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NHCcycloalkyl -Cs-Ce), N(Ci-C4-alkyl)(C3-C6-cycloalkyl), haloCi-C4alkyl having 1 to 5 halogen atoms, haloCi-C4alkoxy having 1 to 5 halogen atoms halogen, -S-(Ci-C4-alkyl) and a 4- to 6-membered heterocycloalkyl, and Z3 is selected from the group consisting of hydrogen, halogen, C1-C4-alkyl, C1-C4-alkoxy, -NH(Ci-C4-alkyl) and -N(Ci-C4-alkyl)2, Z4 is selected from the group consisting of hydrogen, halogen, -OH, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -NH (cycloalkyl-C3-Có), N(alkyl-Ci-C4)(cycloalkyl-C3-C6), haloalkyl-Ci-C4 having 1 to 5 halogen atoms, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, -S-(Ci-C4-alkyl) and a 4- to 6-membered heterocycloalkyl, -57Z5 is selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4, and alkoxy-Ci-C4 According to a fifth embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is selected from the group consisting of Ome -58T is selected from T1 - T6 as defined above R1 is hydrogen or methyl, R2 is selected from the group consisting of hydrogen, chloro, fluoro, bromo, -NRI2R13; -OR14; -SR15, -S(O)R15, -SO2R'5; methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, propendo, cyclopentenyl, cyclohexenyl, each of which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of cyano, ethoxy-C(O)-, and - C(O)NH2; and a monocyclic or bicyclic heterocycle selected from the group consisting of azetidine, pyrrolidine, pyrazolidine, imidazolidine, 1,2,4-triazolidine, piperidine, piperazine, tetrahydropyridine, dihydro-2 / / -pyran, tetrahydropyran, 1,2-oxazolidine, 1,2-oxazine, morpholine, thiomorpholine, 3,4-dihydroisoquinoline, 2,3-dihydro-indole, 1,3-dihydro-isoindole, 3,9-dioxa-7-azabicyclo[3.3.1]nonane, 6- oxa-3-azabicyclo[3.1.1]heptane, 8-oxa-3azabicyclo[3.2.1]octane, imidazole, pyrazole, 1,2,4-triazolo, 1,2,3-triazolo, 4-oxa-7azaspiro[ 2.5]octane, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of fluoro, chloro, cyano, -OH, oxo, -COOH, methoxy-C(O)-, ethoxy-C(O)-, tert-butoxy-C(O)-, -C(0)-NH2, methyl, methyl-C(O)-, trifluoromethyl, hydroxymethyl-, methoxymethyl-, -NH2, -NMe2, pyrrolidine, R3 is hydrogen, chlorine or methyl, R4 is selected from the group consisting of hydrogen, fluoro, chloro, cyano, methyl, methoxy, and trifluoromethyl, R5 is selected from the group consisting of hydrogen, fluoro, chloro, and methyl, R6 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, and methoxy, Ri2 and j^i3 are independently selected from the group consisting of hydrogen, -NH(-C(O)-methyl), methoxy; -59methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopropyl, cyclobutyl, benzyl, 1-phenylethyl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of fluoro, -OH, -COOH , methoxyC(O)-, ethoxy-C(O)-, tert-butoxy-C(O)-, -C(O)-NH2, -C(O)-NMe2, -NH-C(O)-methyl , methyl, methoxy, cyclopropyl, -NH2, NMe2, S-methyl, S(O)-methyl, SO2-methyl, and (EtO)2P(=O)-; heterocyclyl-methyl, heterocyclyl-ethyl, wherein the heterocyclyl substituent is selected from the group consisting of pyrrolidine, morpholine, pyrazole, 1,2,4-oxadiazole, pyridine, each of which is optionally substituted with 1 substituent independently selected from group consisting of fluorine, chlorine, -OH, oxo, and methyl; phenyl; and a monocyclic or bicyclic heterocycle selected from the group of oxetane, thiethane, pyrrolidine, morpholine, tetrahydropyran, pyridine, and pyrazole, each of which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, chloro, -OH , oxo, methyl; R14 is selected from the group consisting of methyl, ethyl, isopropyl, butyl, cyclopentyl, benzyl, each of which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, -OH, methyl, methoxy, and cyclopentyl ; and a monocyclic or bicyclic heterocycle selected from the group consisting of pyrrolidine and tetrahydropyran, R15 is selected from the group consisting of methyl and ethyl, each of which is optionally substituted with 1 substituent independently selected from the group consisting of -OH and -COOH; and pyridine, Q is a substituted phenyl ring of the formula (Q1) in which: Z1 and Z5 are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, and methoxy, Z2 and Z4 are independently selected from the group consisting of hydrogen, fluoro, chloro, -OH, methyl, ethyl, -NHMe, -NMe2, trifluoromethyl, methoxy, trifluoromethoxy, -SMe, and morpholinyl, and Z3 is independently selected from the group consisting of hydrogen, fluorine, chlorine, methyl, methoxy, and -NMe2, and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures thereof. According to a sixth embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: T, A and R1 to R15 have the meaning defined for the fifth embodiment of the first aspect above, and where Q is a pyridine ring of the formula (Q4) (Q4) ,14 in which: Z'3, Z'4, Z'5 and Z'6 are independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, methyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, NH2, -NHMe NMe2, -NH- C(O)-Me, morpholinyl, or Q is a pyridine ring of the formula (Q5) in which: Z17, Z18, Z19, and Z20 are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, methoxy, and ethoxy, or Q is selected from the group consisting of (Q6-1) (Q6-5) (Q6-6) z21 (Q6-7) (Q6-8) (Q6-9) (Q6-10) (Q6-11) (Q6-12) (Q6-19) (Q6-20) (Q6-21) (Q6-22) (Q6-23) (Q6-24) (Q6-25) (Q6-26) (Q6-27) (Q6-28) (Q6-29) (Q6-31) (Q6-32) (Q6-33) (Q6-34) (Q6-35) (Q6-30) (Q6-36) n—z22 NW (Q6-37) (Q6-38) in which: each Z21 is independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, methyl, trifluoromethyl, methoxy, and Z22 is hydrogen, methyl, or Q is selected from the group consisting of (Q7-1) (Q7-2) (Q7-3) (Q7-4) (Q7-5) (Q7-6) (Q7-7) (Q7-8) (Q7-9) in which: each Z23 is independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, methyl, trifluoromethyl, methoxy, or Q is selected from the group consisting of OMe and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In an alternate embodiment of the fifth and sixth embodiments of the first aspect of the present invention above, A is selected from the group consisting of: Ome In another alternate embodiment of the fifth and sixth embodiments of the first aspect of the present invention above, A is selected from the group consisting of: preferably A is According to a seventh embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is selected from the group consisting of: # # preferably A is # is selected from T1 - T6 as defined above -65R1 is hydrogen or methyl, R2 is selected from the group consisting of hydrogen, chloro, fluoro, bromo, -NH2, -NH(CH3), -N(CH3)2, methoxy, ethoxy, methyl, ethyl, propyl, isopropyl, cyclopropyl; and a monocyclic heterocycle selected from the group consisting of azetidine, pyrrolidine, pyrazolidine, imidazolidine, 1,2,4-triazolidine, piperazine, 1,2-oxazolidine, morpholine, thiomorpholine, tetrahydropyran, imidazolo, pyrazolo, 1,2,3- triazolo, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of fluoro, -OH, oxo, -COOH, methoxy-C(O)-, ethoxy-C(O) -, tert-butoxy-C(O)-, -C(0)-NH2, methyl, methyl-C(O)-, trifluoromethyl, hydroxymethyl-, methoxymethyl-, -NH2, -NMe2, pyrrolidine, R3 is hydrogen, R4 is selected from the group consisting of hydrogen, chloro, fluoro, methyl, methoxy, and trifluoromethyl, R5 is selected from the group consisting of hydrogen, chlorine, fluorine, and methyl, R6 is selected from the group consisting of hydrogen, fluorine, methyl, and methoxy, Q is a substituted phenyl ring of the formula (Ql) (QD in which: Z1 and Z5 are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, and methoxy, -66Z2 and Z4 are independently selected from the group consisting of hydrogen, fluoro, chloro, -OH, methyl, ethyl, -NHMe, -NMe2, trifluoromethyl, methoxy, trifluoromethoxy, -SMe, and morpholinyl, and Z3 is independently selected from the group consisting of hydrogen, fluorine, chlorine, methyl, methoxy and -NMe2 and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to an eighth embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is T is selected from T1 - T6 as defined above R1 is hydrogen or methyl, R2 is selected from the group consisting of hydrogen, chloro, fluoro, bromo, -NH2, -NH(CH3), -n(ch3)2, methoxy, ethoxy, methyl, ethyl, propyl, isopropyl, cyclopropyl; and a monocyclic heterocycle selected from the group consisting of tetrahydropyran, morpholine, and 2-fluoro azetidine, R3 is hydrogen, R4 is selected from the group consisting of hydrogen, chloro, fluoro, methyl, methoxy, and trifluoromethyl, -67R5 is selected from the group consisting of hydrogen, chlorine, fluorine, and methyl, R6 is selected from the group consisting of hydrogen, fluorine, methyl, and methoxy, Q is selected from the group consisting of phenyl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1,3-benzoxazol-7-yl, 1H-indol-4-yl, 1- methyl-1H-benzimidazol-6-yl, 2,3,4-trifluorophenyl, 2.3.4- trichlorophenyl, 2,3,5-trifluorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trifluorophenyl, 2,3,6-trichlorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2, 4,5-trifluorophenyl, 2,4,5-trichlorophenyl, 2,4,6-trifluorophenyl, 2,4,6-trichlorophenyl, 2,4,6-trifluoro-3-methoxyphenyl, 2,4,6-trichloro-3- methoxyphenyl, 2,4-difluoro-3-hydroxyphenyl, 2,4-dichloro-3-hydroxyphenyl, 2,4-difluoro-3-methoxyphenyl, 2,4-dichloro-3-methoxyphenyl, 2,4-difluoro-3(dimethylamino)phenyl, 2,4-dichloro-3-(dimethylamino)phenyl, 2,5-difluoro-4 -methoxyphenyl, 2,5-dichloro-4-methoxyphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-fluoro-3-chlorophenyl, 2-chloro-3-fluorophenyl, 2-fluoro-3-(dimethylamino)phenyl, 2-chloro-3 -(dimethylamino)phenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-5-fluorophenyl, 2-fluoro-4(dimethylamino)phenyl, 2-chloro-4-(dimethylamino)phenyl, 2 -chloro-6-fluorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-fluoro-3-(trifluoromethoxy)phenyl, 2-chloro-3(trifluoromethoxy)phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 2-chloro-3 -(trifluoromethyl)phenyl, 3-(dimethylamino)phenyl, 3-(methylamino)phenyl, 3-(trifluoromethoxy)phenyl, 3,4,5-trifluorophenyl, 3,4,5-trichlorophenyl, 3,4-difluoro-5-( dimethylamino)phenyl, 3,4-dichloro-5(dimethylamino)phenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,4-difluoro-2-methoxyphenyl, 3,4-dichloro-2-methoxyphenyl, 3,5-difluoro-4-(dimethylamino)phenyl, 3,5-dichloro-4(dimethylamino)phenyl, 3,5-difluoro-4-chlorophenyl, 3,5-dichloro -4-fluorophenyl, 3,5difluorophenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 3-fluoro-2-chloro-5-methylphenyl, 3-chloro2-fluoro-5-methylphenyl, 3-chloro-2-methylphenyl , 3-fluoro-4-(dimethylamino)-5-chlorophenyl, 3fluoro-4-(dimethylamino)phenyl, 3-chloro-4-(dimethylamino)phenyl, 3-chloro-4-fluorophenyl, 3fluoro-4-methylphenyl, 3 -chloro-4-methylphenyl, 3-fluoro-5-(dimethylamino)phenyl, 3-chloro-5-(dimethylamino)phenyl, 3-fluoro-5-(methylsulfanyl)phenyl, 3-chloro-5-(methylsulfanyl)phenyl, 3fluoro-5-(morpholin-4-yl)phenyl, 3-chloro-5-(morpholin-4-yl)phenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 3-chloro-5-(trifluoromethyl)phenyl, 3 -fluoro-5-ethylphenyl, 3-chloro-5-ethylphenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5-methoxyphenyl, 3fluoro-5-methylphenyl, 3-fluorophenyl, 3-chlorophenyl , 3-fluoro-4-methoxyphenyl, 3-chloro-4-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-chloro-5-methylfe Nyl, 4-fluoro-3(dimethylamino)phenyl, 4-chloro-3-(dimethylamino)phenyl, 4-fluoro-3-methoxyphenyl, 4-chloro-3-methoxyphenyl, 5-chloro-2,4-difluorophenyl, 5-fluoro -2,4-dichlorophenyl, 5-fluoro-2-chloro-3 -68methylphenyl, 5-chloro-2-fluoro-3-methylphenyl, 5-fluoro-2-chloro-4-methylphenyl, 5-chloro-2fluoro-4-methylphenyl, 5-chloro-2-fluorophenyl, 5-chloro-2 -methoxyphenyl and 5-fluoro-2-methoxyphenyl, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to a ninth embodiment of the first aspect, the present invention encompasses compounds of the general formula (I), supra, in which: A is #· T is selected from T1 - T6 as defined above R' is hydrogen or methyl, R2 is selected from the group consisting of hydrogen, chloro, fluoro, bromo -NH2, -NH(CH3), -N(CH3)2, methoxy, ethoxy, methyl, ethyl, propyl, isopropyl, cyclopropyl; and a monocyclic heterocycle selected from the group consisting of tetrahydropyran, morpholine, and 2-fluoro azetidine, R3 is hydrogen, R4 is selected from the group consisting of hydrogen, chloro, fluoro, methyl, methoxy, and trifluoromethyl or, R5 is selected from the group consisting of hydrogen, chlorine, fluorine, and methyl, R6 is selected from the group consisting of hydrogen, fluorine, methyl, and methoxy, -69Q is selected from the group consisting of phenyl, 2,3,4-trifluorophenyl, 2,3,4-trichlorophenyl, 2.3.5- trifluorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trifluorophenyl, 2,3,6-trichlorophenyl, 2,3difluorophenyl, 2,3-dichlorophenyl, 2,4,5-trifluorophenyl, 2, 4,5-trichlorophenyl, 2,4,6-trifluorophenyl, 2,4,6-trichlorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-fluoro-3-chlorophenyl, 2-chloro-3-fluorophenyl, 2-chloro- 4-fluorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro- 5-fluorophenyl, 2-chloro-6-fluorophenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4,5-trifluorophenyl, 3.4.5- trichlorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,5-difluoro-4-chlorophenyl, 3,5-dichloro-4-fluorophenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3- chloro-4-fluorophenyl, 3chloro-5-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 5-chloro-2,4-difluorophenyl, 5-fluoro-2,4-dichlorophenyl, 5-chloro-2-fluorophenyl, and stereoisomers, tautomers , N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to a tenth embodiment of the first aspect, the present invention encompasses compounds of the general formula (II): (II) in which: T is selected from T1 - T6 as defined above preferably T is sectioned from T1, T2 or T3 as defined above, and R1 to R6 and R12 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II) supra, in which: -70T is Τ1 as defined above: T1 ,and A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II) supra, in which: T is T2 as defined above: A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II) supra, in which: T is T3 as defined above: ,Y A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II) supra, in which: T is T4 as defined above'. R2 Q, and A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II) supra, in which: T is T5 as defined above. T5 ,and A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to another particular embodiment of the first aspect, the present invention encompasses compounds of the general formula (I) or (II), supra, in which: T is T6 as defined above. R2 Q t6 ,y A and R1 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. Other embodiments of the first aspect of the present invention: In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: is Al or A2, A1 or A2 is 0, 1 or 2, R is selected from the group consisting of hydrogen, halogen, Ci-C4-alkyl, and C¡C4-alkoxy, cyano, haloCi-C4-alkyl having 1 to 5 halogen atoms, T is selected from T1 - T6 as defined above X, Y are independently selected from the group consisting of CR7R8,0, S, and N-R9, wherein at least one of X and Y is CR7R8, R7 is selected from the group consisting of hydrogen and alkyl-Ci-C4, R8 is selected from the group consisting of hydrogen and alkyl-Ci-C4, R9 is alkyl-Ci-C4, R'° is selected from the group consisting of hydrogen, -OH, alkyl-Ci-C4, and alkoxy-Ci-C4, and R11 is hydrogen, where when Y is O, S or N-R9, R'° is not -OH, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: T is selected from T1 - T6 as defined above A is Al or A2, A1 A2 -74o is 0 or 1, R is selected from the group consisting of halogen, alkyl-Ci-C4, and alkoxy-Ci-C4, X is selected from the group consisting of CR7R8, O, S, and N-R9, And it's CR7R8, R7 is selected from the group consisting of hydrogen and alkyl-Ci-C4, R8 is selected from the group consisting of hydrogen and alkyl-Ci-C4, R9 is alkyl-Ci-C4, R'° is selected from the group consisting of hydrogen, -OH and alkyl-Ci-C4, and R is hydrogen, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (1), supra, in which: T is selected from T1 above and A is selected from the group consisting of preferably A is and R1 to R9 and R12 to R15 have the meaning defined for any embodiment of the first aspect supra', and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (1), supra, in which: T is selected from T2 above and A is selected from the group consisting of preferably A is and R1 to R9 and R12 to R15 have the meaning defined for any embodiment of the first aspect supra, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: T is selected from T3 above and A is selected from the group consisting of preferably A is and R1 to R' and R12 to R'5 have the meaning defined for any embodiment of the first aspect above; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: is selected from T4 supra and is selected from the group consisting of preferably A is and R1 to R9 and R12 to R'5 have the meaning defined for any embodiment of the first aspect above; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: -77T is selected from T5 above and A is selected from the group consisting of preferably A is and R1 to R' and R12 to R'5 have the meaning defined for any embodiment of the first aspect above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which: T is selected from T6 above and A is selected from the group consisting of preferably A is and R1 to R9 and R12 to R15 have the defined meaning for any embodiment of the first aspect above, -78and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (1) or (II), supra, in which: R2 is selected from the group consisting of hydrogen, halogen, cyano, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(C1-C4 alkyl), -C(O)-N(Ci-C4-alkyl)2; -NRI2R13; -OR14; -SR15, -S(O)R15, -SO2R15; Cl-C4 alkyl, cycloalkyl-Ca-Có, alkenyl-C2-C4, cycloalkenyl-Cs-Có, quini I0-Q-C4 or phenyl-Ci-C4 alkyl, each of which is optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, -OH, cyano, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH (Ci-C4-alkyl), -C(O)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, -NH2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-Ci-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, - S-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and -SO2halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group consisting of 4- to 10-membered heterocycloalkyl, heterospirocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected substituents from the group consisting of halogen, cyano, -OH, oxo, -COOH, alkoxy-Ci-C4-C(O)-, -C(O)-NH2, -C(O)-NH(alkyl-Ci- C4), C(0)-N(Ci-C4-alkyl)2, Ci-C4-alkyl, Ci-C4-alkyl-C(O)-, halo-Ci-C4-alkyl having 1 to 5 halogen atoms , Ci-C4-alkoxy, hydroxy-Ci-C4-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, Ci-C4-halogenoalkoxy having 1 to 5 halogen atoms, C3-C6-cycloalkyl, -NH2, -NH (Ci-C4-alkyl), -N(Ci-C4-alkyl)2, and 4- to 10-membered heterocycloalkyl, -79R12 and R13 are independently selected from the group consisting of hydrogen, -NH(-C(O)-alkyl-Ci-C4), alkoxy-Ci-C4; alkyl-Ci-C4, cycloalkyl-Cs-Có, phenyl-alkyl-Ci-C4, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, - COOH, Ci-C4-alkoxy-C(0)-, -C(0)-NH2, C(O)-NH(C,-C4-alkyl), -C(O)-N(Ci-C4-alkyl )2, -NH-C(O)-Ci-C4-alkyl, -N(Ci-C4-alkyl)-(-C(0)-Ci-C4-alkyl), Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, haloCi-C4-alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Có, -ΝΗ2, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, -S-C1-C4-alkyl, -S(O)-Ci-C4-alkyl, -SO2-Ci-C4-alkyl, -S-halogeno-Ci-C4-alkyl having de 1 to 5 halogen atoms, -S(O)-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms, -SO2-halogenoalkyl-Ci-C4 having 1 to 5 halogen atoms and (alkoxy-CiC4 )2P(=O)-; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, -OH, oxo, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, Ci-C4-halogenalkoxy having 1 to 5 halogen atoms; Phenyl, benzo-cycloalkyl-Cs-Có, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 having of 1 to 5 halogen atoms, Ci-C4-alkoxy, halogen-Ci-C4-alkoxy having 1 to 5 halogen atoms; and a monocyclic or bicyclic heterocycle selected from the group of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen , cyano, -OH, oxo, C1-C4-alkyl, C4-halogen-Cj-alkyl having 1 to 5 halogen atoms, C4-Ci-alkoxy, C4-Ci-halogenalkoxy having 1 to 5 halogen atoms, R14 is selected from the group consisting of -80alkyl-Ci-C4, cycloalkyl-Cs-Có, . phenyl-Ci-C4-alkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, Ci-C4-alkyl, haloCi-C4-alkyl having 1 to 5 halogen atoms, Ci-C4-alkoxy, halogen-Ci-C4alkoxy having 1 to 5 halogen atoms, cycloalkyl-Cs-Ce; and heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, -OH, oxo, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, halogenalkoxy-Ci- C4 having 1 to 5 halogen atoms; R15 is selected from the group consisting of alkyl-Ci-C4, phenyl-alkyl-Ci-C4, each of which is optionally substituted with * 1, 2, or 3 substituents independently selected from the group consisting of halogen, -OH, cyano, alkyl-Cj-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci -C4 having 1 to 5 halogen atoms; heterocyclyl-Ci-C4-alkyl, wherein the heterocyclyl substituent is selected from the group consisting of 4- to 10-membered heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl, each of which is optionally substituted with 1,2 or 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl having 1 to 5 halogen atoms, C1-C4 alkoxy, C1-C4 haloalkoxy having 1 to 5 atoms halogen; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: R1 is hydrogen or methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. -81 In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: R2 is selected from the group consisting of hydrogen, chlorine, -NH(CH3), -N(CH3)2, methoxy, ethoxy, methyl, ethyl, propyl, isopropyl, cyclopropyl; and a monocyclic heterocycle selected from the group consisting of tetrahydropyran, morpholine, and thiomorpholine; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: R3 is selected from the group consisting of hydrogen, chloro, or methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: R4 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, methoxy, and trifluoromethyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: -82R5 is selected from the group consisting of hydrogen, fluoro, chloro, and methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: R6 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, and methoxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) or (II), supra, in which: Q is a substituted phenyl ring of the formula (Ql) (Q1) in which: Z1, Z2, Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 has 1 to 5 halogen atoms, hydroxy, alkoxy-Ci- C4, haloalkoxy-Ci-C4 has 1 to 5 halogen atoms, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2, 4- to 6-membered heterocyclyl, which is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, methyl, and cyano, -S-(Ci-C4-alkyl), S(O)-(Ci-C4-alkyl), -SO2-(Ci-alkyl -C4), or Z1 and Z2 form, together with the carbon atoms to which they are attached, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may be optionally substituted with -83one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z3, Z4, and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-halogenoalkyl having 1 to 5 halogen atoms, C1-C4-alkoxy, C1-alkoxy- C4-C(0)-, haloalkoxy-Ci-C4 having 1 to 5 halogen atoms, or Z2 and Z3 form, together with the carbon atoms to which they are connected, a 5- or 6-membered saturated or partially saturated heterocyclic ring, a 5-membered heteroaryl, or a 6-membered heteroaryl, each of which may optionally be substituted with one or two substituents selected from the group consisting of methyl, fluorine, and oxo, and Z', Z4 and Z5 are independently selected from the group consisting of hydrogen, halogen, cyano, alkyl-Ci-C4, haloalkyl-Ci-C4 having 1 to 5 halogen atoms, alkoxy-Ci-C4, haloalkoxy-Ci -C4 having 1 to 5 halogen atoms, preferably Z1 and Z5 are independently selected from the group consisting of hydrogen, halogen, alkyl-Ci-C4, and alkoxy-Ci-C4, Z2 and Z4 are independently selected from the group consisting of hydrogen, halogen, -OH, Ci-C4-alkyl, Ci-C4-alkoxy, -NH(Ci-C4-alkyl), -N(Ci-C4-alkyl)2 , haloCi-C4alkyl having 1 to 5 halogen atoms, haloCi-C4alkoxy having 1 to 5 halogen atoms, -S-(Ci-C4alkyl) and a 4 to 6 membered heterocycloalkyl, Y Z3 is selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy and -N(Ci-C4 alkyl)2, or Z1 and Z2 form, together with the carbon atoms to which they are connected, a 5-membered heterocycloalkyl or a 5-membered heteroaryl, each of which may be optionally substituted with one or two substituents selected from the group consisting of methyl , fluorine and oxo, Z3 and Z5 are hydrogen, and -84Z4 is selected from the group consisting of hydrogen alkoxy-Ci-C4-C(O)-, more preferably Z1 and Z5 are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, and methoxy, Z2 and Z4 are independently selected from the group consisting of hydrogen, fluoro, chloro, -OH, methyl, ethyl, -NHMe, -NMe2, trifluoromethyl, methoxy, trifluoromethoxy, -SMe, and morpholinyl, and Z3 is independently selected from the group consisting of hydrogen, fluorine, chlorine, methyl, methoxy, and -NMe2, even more preferably Q is selected from the group consisting of phenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-fluoro-3-chlorophenyl, 2-chloro-3-fluorophenyl, 2- chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-5-fluorophenyl, 2-chloro-6-fluorophenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,5- difluorophenyl, 3,5dichlorophenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 5-chloro-2-fluorophenyl, 2,3,5-trifluorophenyl and 2,3, 5-Trichlorophenyl and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In another embodiment of the first aspect, the present invention encompasses compounds of formula (I), supra, in which A is A3 or A4 and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In particular, in a further embodiment of the first aspect, the present invention encompasses combinations of two or more of the embodiments mentioned above under the heading further embodiments of the first aspect of the present invention. The present invention encompasses any subcombination within any embodiment or aspect of the present invention of compounds of the general formula (I) or (II), supra. The present invention encompasses the compounds of the general formula (I) which are disclosed in the Example Section of the present text, infra. Compounds according to the invention of the general formula (I) and (II) can be prepared according to schemes 1 to 6 as shown in the Experimental Section of the present invention (General Procedures). The described schemes and procedures illustrate synthetic routes for the compounds of the general formula (1) and (II) of the invention and are not intended to be restrictive. It is clear to the person skilled in the art that the order of the transformations as exemplified in schemes 1 to 6 can be modified in various ways. The order of transformations exemplified in these schematics is therefore not intended to be restrictive. Furthermore, interconversion of any of the substituents, T, Q, A, R1, R2, R3, R4, R5, or R6 can be accomplished before and / or after the exemplified transformations. These modifications may be such as the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution, or other reactions known to the person skilled in the art. These transformations include those that introduce functionality that allows for further interconversion of the substituents. Appropriate protecting groups and their introduction and cleavage are well known to those skilled in the art (see, for example, T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd Edition, Wiley 1999). Specific examples are described in the subsequent paragraphs. In the following, schemes 1 to 6 describe various routes for the preparation of compounds of the general formula (1) and (II). According to a second aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1N-T1, 1N-T2, 1N-T3,1N-T4,1N-T5, or 1N-T6: in which A, R1, R3, R4, R5, R6, and Q are as defined for the compound of the general formula (I) as defined supra, to react with a compound of the general formula 1F: R2H . 1F, in which R2 is NR12R13, OR14, or SR15, each as defined for the compound of general formula (I) as defined supra, thus providing a compound of general formula (I): EITHER Nx R1 (OR in which T, A, R1, R2, R3, R4, R5, R6, and Q are as defined above. According to an alternative embodiment of the second aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1M-T1 ,1M-T2,1M-T3,1M-T4,1M-T5, or 1M-T6: in which A, R1, R2, R3, R4, R5 and R6 are as defined for the compound of general formula (I) as defined above and in which Hal is halogen, particularly chlorine, bromine or iodine, for react with a compound of the general formula 1H: Q-B(OR)2 1H, in which Q is as defined for the compound of general formula (1) as defined above, and each R may be individually H or Me or both R are pinacolate, thus providing a compound of general formula (I ): (l) in which T, A, R1, R2, R3, R4, R5, R6 and Q are as defined above. According to an alternative embodiment of the second aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1W-T1 ,1W-T2,1W-T3,1W-T4,1W-T5, or 1W-T6: in which Q, R2, R3, R4, R5 and R6 are as defined for the compound of the general formula (I) as defined supra, to react with a compound of the general formula IV: HN'A iv, wherein R1 and A are as defined for the compound of general formula (I) as defined supra, thus providing a compound of general formula (I): you R1 (I) in which T, A, R', R2, R3, R4, R5, R6 and Q are as defined above. According to an alternative embodiment of the second aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula . 1X-T1,1X-T2,1X-T3,1X-T4,1X-T5, or 1X-T6: 1X-T1 1X-T3 1X-T4 1X-T5 1X-T6 in which Q, A, R', R3, R4, R5 and R6 are as defined for the compound of the general formula (I) as defined above, to react with a compound from the general formula 1Y: R2H 1Y, in which R2 is C'-C4-alkoxy which is optionally substituted as defined for the compound of general formula (I) defined supra, thus providing a compound of general formula (I): T lU R1 (I) in which T, A, R1, R3, R4, R5, R6 and Q are as defined above and R2 is C'-C4-alkoxy which is optionally substituted as defined above. According to an alternative embodiment of the second aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1N-T1 ,1N-T2, 1N-T3,1N-T4,1N-T5, or 1N-T6: in which A, R1, R3, R4, R5, R6, and Q are as defined for the compound of general formula (I) as defined supra, to react with a compound of general formula 2A: R2Met-X 2A, wherein R2 is C1-C4-alkyl, C3-C6-cycloalkyl, C2-C4-alkenyl, C3-C6-cycloalkenyl, C2-C4-alkynyl, phenyl-Ci-C4-alkyl, heterocyclyl-Ci-C4-alkyl , phenyl or a monocyclic or bicyclic heterocycle, each of which as defined for the compound of general formula (I) as defined above, Met is magnesium, or zinc, and X is chloro, bromo or iodo, thus providing a compound of the general formula (I): TNx I -1 R(I) in which T, A, R1, R3, R4, R5, R6 and Q are as defined above and R2 is C1-C4-alkyl, C3-C6-cycloalkyl, C2-C4-alkenyl, C3-cycloalkenyl- C6, C2-C4-alkynyl or phenyl-Ci-C4-alkyl, each of which is optionally substituted as defined above. -91 According to a third aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined supra, said processes comprise the step of allowing an intermediate compound of the general formula 1N-T1,1N- T2, 1N-T3, 1N-T4, 1N-T5, or 1N-T6: in which A, R1, R3, R4, R5, R6, and Q are as defined for the compound of the general formula (1) as defined supra, to react with a compound of the general formula 1F: R2H 1F, in which R2 is NR12R13, OR14, SR15 as defined for the compound of general formula (1) as defined above, thus providing a compound of general formula (I): T N R1 (I) in which T, A, R1, R2, R3, R4, R5, R6 and Q are as defined above. -92then optionally converting said compound into solvates, salts and / or solvates of said salts using the corresponding (i) solvents and / or (ii) bases or acids. According to an alternative embodiment of the third aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1M-T1 ,1M-T2,1M-T3, 1M-T4,1M-T5, or 1M-T6: in which A, R1, R2, R3, R4, R5 and R6 are as defined for the compound of general formula (I) as defined above and in which Hal is halogen, particularly chlorine, bromine or iodine, for react with a compound of the general formula 1H: Q-B(OR)2 1H, wherein Q is as defined for the compound of general formula (I) as defined above, and each R may be individually H or Me or both R are pinacolate, thus providing a compound of general formula (I ): (l) in which T, A, R1, R2, R3, R4, R5, R6 and Q are as defined above. then optionally converting said compound into solvates, salts and / or solvates of said salts using the corresponding (i) solvents and / or (ii) bases or acids. According to an alternative embodiment of the third aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1W-T1 ,1W-T2,1W-T3,1W-T4,1W-T5, or 1W-T6: 1W-T4 1W-T5 1W-T6 in which Q, R2, R3, R4, R5 and R6 are as defined for the compound of the general formula (I) as defined above, to react with a compound of the formula overall IV: HN'A iv, in which R1 and A are as defined for the compound of general formula (I) as defined supra, thus providing a compound of general formula (1): -94Nx R1 (I) in which T, A, R1, R2, R3, R4, R5, R6 and Q are as defined above, then optionally convert said compound into solvates, salts and / or solvates of said salts using the corresponding ( i) solvents and / or (ii) bases or acids. According to an alternative embodiment of the third aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined in IXT1, 1X-T2,1X-T3,1X-T4,1X-T5 or 1X-T6: 1X-T4 1X-T5 1X-T6 in which Q, A, R1, R3, R4, R5 and R6 are as defined for the compound of the general formula (I) as defined above, to react with a compound of the general formula 1Y: R2H 1Y, in which R2 is C1-C4-alkoxy which is optionally substituted as defined for the compound of general formula (1) defined supra, thus providing a compound of general formula (I): -95T hT R1 (I) in which T, A, R1, R2, R3, R4, R5, R6 and Q are as defined above and R2 is C1-C4alkoxy which is optionally substituted as defined above, then optionally converting said compound in solvates, salts and / or solvates of said salts using the corresponding (i) solvents and / or (ii) bases or acids. According to an alternative embodiment of the third aspect, the present invention encompasses processes for the preparation of compounds of the general formula (I) as defined above, said processes comprise the step of allowing an intermediate compound of the general formula 1N-T1 ,1N-T2,1N-T3, 1N-T4,1N-T5, or 1N-T6: 1N-T4 1N-T5 1N-T6 in which Q, A, R1, R3, R4, R5 and R6 are as defined for the compound of the general formula (I) as defined above, to react with a compound of the general formula 2A: R2Met-X 2A, in which R2 is Cj-C4-alkyl, Cs-Ce-cycloalkyl, C2-C4-alkenyl, Cs-Có-cycloalkenyl, C2-C4-alkynyl, phenyl-Ci-C4-alkyl, heterocyclyl-Ci-C4-alkyl , phenyl or a monocyclic heterocycle or -96bicyclic, each of which as defined for the compound of the general formula (I) as defined above, Met is magnesium or zinc, and X is chlorine, bromine or iodine, thus providing a compound of the general formula ( YO): T h U R1 (I) in which T, A, R1, R3, R4, R5, R6 and Q are as defined above and R2 is alkyl-Ci-Ci, cycloC3-C6alkyl, alkenyl-C2-C4, cycloalkenyl-Cs- Có, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted as defined above, then optionally converting said compound to solvates, salts and / or solvates of said salts using the corresponding (i ) solvents and / or (ii) bases or acids. The present invention encompasses processes for the preparation of compounds of the present invention of the general formula (1) and (Π), said processes comprise the steps described in the Experimental Section hereof. According to a fourth aspect, the present invention encompasses intermediates which are useful for the preparation of the compounds of the general formula (I) and (II), supra. In particular, the invention encompasses the intermediate compounds of the general formula (I-INT-T1), (IINT-T2), (Ι-ΓΝΤ-Τ3), (1-INT-T4), (I-INT-T5) and (I-INT-T6): (I-INT-T4) (I-INT-T5) (I-INT-T6) -97in which R2 is -OH or as defined for the compound of general formula (I) supra, R3, R4, R5, R6 and Q are as defined for the compound of general formula (I) supra, and RA is H or alkyl-Ci-C4, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. In particular], the invention also encompasses intermediates of the general formula (II-INTTl), (II-JNT-T2), (II-INT-T3), (Π-ΙΝΤ-Τ4), (1I-INT- T5) and (Π-ΙΝΤ-Τ6): in which R2 is -OH or as defined for the compound of general formula (I) supra, A, R1, R3, R4, R5 and R6 are as defined for the compound of general formula (I) supra, and Hal is halogen, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof. According to a fifth aspect, the present invention encompasses the use of said intermediate compounds for the preparation of a compound of the general formula (I), as defined above. -98In particular, the invention encompasses the use of the intermediate compounds of the general formula (I-INTTl), (I-INT-T2), (I-INT-T3), (I-INT-T4), (1- INT-T5) and (I-INT-T6): (I-INT-T5) (I-INT-T6) (I-INT-T4) in which R2 is -OH or as defined for the compound of general formula (I) supra, R3, R4, R5, R6 and Q are as defined for the compound of the general formula (1) supra, and RA is H or alkyl-Ci-C4, for the preparation of a compound of the general formula (I), as defined above. In particular, the invention also encompasses the use of intermediates of the general formula (II-INT-T1), (II-1NT-T2), (II-INT-T3), (II-INT-T4), ( 1I-INT-T5) and (II-INT-T6): (II-INT-T1) (II-INT-T2) (II-INT-T3) in which R2 is -OH as defined for the compound of general formula (I) supra, A, R1, R3, R4, R5 and R6 are as defined for the compound of general formula (I) supra, and Hal is halogen, for the preparation of a compound of the general formula (I), as defined above. The present invention encompasses the intermediates described in the Examples Section of the present text, infra. The compounds of the general formula (1) and (II) of the present invention can be converted into any salt, preferably pharmaceutically acceptable salts, as described herein, by any method known to the person skilled in the art. Similarly, any salt of a compound of general formula (I) and (II) of the present invention can be converted to the free compound, by any method known to a person skilled in the art. The compounds of the general formula (I) and (II) of the present invention demonstrate a valuable pharmacological spectrum of action, which could not be predicted. Surprisingly, it has been found that the compounds of the present invention interact effectively with Slo-1 and therefore it is possible that said compounds may be used for the treatment or prevention of diseases, preferably helminthic infections, particularly gastrointestinal helminth infections and extraintestinal, more particularly, gastrointestinal and extraintestinal infections with nematodes in humans and animals. The compounds of the present invention can be used for the control, treatment and / or prevention of helminth infections, in particular gastrointestinal and extraintestinal helminth infections. This method comprises administering to a mammal in need of it a -100 amount of a compound of the present invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective in treating the disorder. In an alternative aspect, this method comprises administering to birds, mainly cage birds or in particular poultry, in need, an amount of a compound of the present invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate , solvate or ester thereof; which is effective in treating the disorder. Specifically in the field of veterinary medicine, the compounds of the present invention are suitable, with favorable toxicity in warm-blooded animals, for controlling parasites, in particular helminths, which occur in animal husbandry and livestock breeding, breeding , zoo, laboratory, experimental and domestic animals. They are active against all or specific developmental stages of parasites, in particular helminths. Agricultural livestock includes, for example, mammals, such as sheep, goats, horses, donkeys, camels, buffaloes, rabbits, reindeer, fallow deer, and in particular cattle and pigs; o Poultry, such as turkeys, ducks, geese, and particularly chickens; or fish or crustaceans, for example in aquaculture. Domestic animals include, for example, mammals, such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets, or in particular dogs, cats; caged birds; reptiles; amphibians or aquarium fish. The present invention also provides methods for the treatment of helminth infections, particularly gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. These disorders have been well characterized in animals, and can be treated by administration of the pharmaceutical compositions of the present invention. The term treat or treatment as used herein is conventionally used, for example, in the management or care of a subject for the purpose of combating, alleviating, reducing, palliating, ameliorating the condition of a disease or disorder, such as a nematode infection. In particular, and particularly in the field of animal or veterinary health, the term "treat" or treatment includes prophylactic, metaphylactic or therapeutic treatment. Helminths pathogenic to humans or animals include, for example, acanthocephali, nematodes, pentastomates, and flatworms (eg, monogenea, cestodes, and flukes). -101 Examples of helminths include, but are not limited to: Monogenea: for example: Dactylogyrus spp., Gyrodactylus spp., Microbothrium spp., Polystoma spp., Troglocephalus spp. Cestodes: of the order of the Polymorphida, for example: Bothridium spp., Diphyllobothrium spp., Diplogonoporus spp., Ichthyobothrium spp., Ligula spp., Schistocephalus spp., Spirometra spp. from the order Cyclophyllida, for example: Andyra spp., Anoplocephala spp., Avitellina spp., Bertiella spp., Cittotaenia spp., Davaineas spp., Diorchis spp., Diplopylidium spp., Dipylidium spp., Echinococcus spp., Echinocotyle spp. ., Echinolepis spp., Hydatigera spp., Hymenolepis spp., Joyeuxiella spp., Mesocestoides spp., Moniezia spp., Paranoplocephala spp., Raillietina spp., Stilesia spp., Taenia spp., Thysaniezia spp., Thysanosoma spp. Flukes: of the Digenea class, for example: Austrobilharzia spp., Brachylaima spp., Calicophoron spp., Cátatropis spp., Clonorchis spp. Collyriclum spp., Cotylophoron spp., Cyclocoelum spp., Dicrocoelium spp., Diplostomum spp., Echinochasmus spp., Echinoparyphium spp., Echinostoma spp., Eurytrema spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp., Fischoederius spp. ., Gastrothylacus spp., Gigantobilharzia spp., Gigantocotyle spp., Heterophyes spp., Hypoderaeum spp., Leucochloridium spp., Metagonimus spp., Metorchis spp., Nanophyetus spp., Notocotylus spp., Opisthorchis spp., Ornithobilharzia spp. Paragonimus spp., Paramphistomum spp., Plagiorchis spp., Posthodiplostomum spp., Prosthogonimus spp., Schistosoma spp., Trichobilharzia spp., Troglotrema spp., Typhlocoelum spp. Nematodes: of the order Trichinellida, for example: Capillaria spp., Eucoleus spp., Paracapillaria spp., Trichinella spp., Trichomosoides spp., Trichuris spp. from the order of the Tylenchida, for example: Micronema spp., Parastrongyloides spp., Strongyloides spp. from the order Rhabditina, for example: Aelurostrongylus spp., Amidostomum spp., Ancylostoma spp., Angiostrongylus spp., Bronchonema spp., Bunostomum spp., Chabertia spp., Cooperia spp., Cooperioides spp., Crenosoma spp., Cyathostomum spp. Cyclococercus spp. Oesophagodontus spp. spp., -102 Ollulanus spp.; Ornithostrongylus spp. Oslerus spp. Ostertagia spp. ., Strongylus spp., Syngamus spp., Teladorsagia spp., Trichonema spp., Trichostrongylus spp., Triodontophorus spp., Troglostrongylus spp., Uncinaria spp. from the order of os Spirurida, for example: Acanthocheilonema spp., Anisakis spp., Ascaridia spp.; Ascaris spp., Ascarops spp., Aspiculuris spp., Baylisascaris spp., Brugia spp., Cercopithifilaria spp., Crassicauda spp., Dipetalonema spp., Dirofilaria spp., Dracunculus spp.; Draschia spp., Enterobius spp., Filaria spp., Gnathostoma spp., Gongylonema spp., Habronema spp., Heterakis spp.; Litomosoides spp., Loa spp., Onchocerca spp., Oxyuris spp., Parabronema spp., Parafilaria spp., Parascaris spp., Passalurus spp., Physaloptera spp., Probstmayria spp., Pseudofilaria spp., Setaria spp., Skjrabinema spp. ., Spirocerca spp., Stephanofilaria spp., Strongyluris spp., Syphacia spp., Thelazia spp., Toxascaris spp., Toxocara spp., Wuchereria spp. Acanthocephala: from the order Oligacanthorhynchida, for example: Macracanthorhynchus spp., Prosthenorchis spp.', from the order Moniliformida, for example: Moniliformis spp. from the order osPolymorphida, for example: Filicollis spp., from the order of the Echinorhynchida, for example: Acanthocephalus spp., Echinorhynchus spp., Leptorhynchoides spp. Pentastoma: of the order of the Porocephalida, for example: Linguatula spp. The compounds of the present invention can be used in particular during therapy and prevention, ie prophylaxis of helminth infections, particularly gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. Through the use of the compounds of the present invention for the control of animal parasites, in particular helminths, it is intended to reduce or prevent diseases, cases of deaths and reductions in yield (in the case of meat, milk, wool, skins, eggs , honey and the like), this to make possible a more economical and simple maintenance of the animals and to achieve a better welfare of the animals. The term control or control, as used herein with respect to the field of animal health, means that the compounds of the present invention are effective in reducing the incidence of the respective parasite in an animal infected with said parasites to harmless levels. More specifically, the term control, as used herein, means -103that the compounds of the present invention are effective in killing the respective parasite, inhibiting its growth or inhibiting its proliferation. According to a further aspect, the present invention encompasses compounds of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts, or mixtures. thereof, for use in the treatment or prevention of diseases, in particular helminth infections, in particular gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. The pharmaceutical activity of the compounds according to the invention can be explained by their interaction with the Slo-1 ion channel. According to a further aspect, the present invention encompasses the use of compounds of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts, or mixtures thereof, for the treatment or prevention of diseases, in particular helminth infections, in particular gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. According to a further aspect, the present invention encompasses the use of compounds of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts, or mixtures thereof, in a method for the treatment or prevention of diseases, in particular helminth infections, in particular gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. According to a further aspect, the present invention encompasses the use of a compound of the general formula (1), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable, or mixtures thereof, to make a pharmaceutical composition, preferably a medicament for the prevention or treatment of diseases, in particular helminth infections, in particular gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes. According to a further aspect, the present invention encompasses a method for the treatment and prevention of diseases, in particular helminth infections, -104particularly from gastrointestinal and extraintestinal helminth infections, more particularly from gastrointestinal and extraintestinal infections with nematodes, by using an effective amount of a compound of the general formula (I), as described supra, or stereoisomers, tautomers, N- oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures thereof. According to another aspect, the present invention encompasses compounds of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts thereof, and mixtures thereof, for use as an antiparasitic agent. According to another aspect, the present invention encompasses compounds of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts thereof. , or mixtures thereof, for use as an anthelmintic agent, in particular for use as a nematicidal agent, a platelmintitricidal agent, an acanthocephalic agent or a pentastomicidal agent. According to another aspect, the present invention encompasses pharmaceutical compositions, in particular a veterinary formulation, comprising a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture thereof, and one or more excipients, in particular one or more pharmaceutically acceptable excipients. Conventional procedures can be used to prepare such pharmaceutical compositions in appropriate dosage forms. According to another aspect, the present invention encompasses a process for preparing a pharmaceutical composition, in particular a veterinary formulation, comprising the step of mixing a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture thereof, with one or more excipients, in particular one or more pharmaceutically acceptable excipients. According to a further aspect, the present invention encompasses a method for the treatment and prevention of diseases, in particular helminth infections, particularly gastrointestinal and extraintestinal helminth infections, more particularly gastrointestinal and extraintestinal infections with nematodes, by means of use of a pharmaceutical composition, especially a veterinary formulation, comprising a -105 effective amount of a compound of the general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures thereof . Therefore, the present invention encompasses a method for the control of helminth infections in humans and / or animals by administering an anthelmintically effective amount of at least one compound of the general formula (I) or (II) supra to a being human or an animal in need. The present invention further comprises pharmaceutical compositions, in particular veterinary formulations, comprising at least one compound according to the invention, conventionally together with one or more suitable pharmaceutical excipients, and for use for the aforementioned purposes. The compounds according to the invention can act systemically and / or locally. For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonary, nasal, sublingual, lingual, buccal, rectally, dermal, transdermal, conjunctival, otic, or as an implant or stent. Said administration can be carried out prophylactically, metaphylactically or therapeutically. For these administration purposes, the compounds according to the invention can be administered in suitable administration forms. For oral administration, it is possible to formulate the compounds according to the invention into dosage forms which are known in the art to deliver the compounds of the invention rapidly and / or in a modified manner, such as tablets (coated or uncoated, e.g. example with enteric or controlled-release coatings that are delayed-dissolving or insoluble), tablets, films / wafers, films / lyophilisates, orally dissolving capsules (for example hard or soft gelatin capsules), dragees, granules, micropellets , chewable tablets (eg soft chews) powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds according to the invention in crystalline and / or amorphous and / or dissolved form in such dosage forms. Parenteral administration can occur by avoiding a resorption step (for example intravenously, intraarterially, intracardiacally, intraspinally or intralumbarly) or with inclusion of resorption (for example intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). For the For parenteral administration, inter alia, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders are suitable as administration forms. For the other routes of administration, for example, inhalation pharmaceutical forms [inter alia, powder inhalers, nebulizers], nasal drops, nasal solutions or nasal sprays are suitable; tablets / films / wafers or capsules for lingual, sublingual or buccal administration; suppositories, eye drops, eye ointments, eye baths, eye inserts, ear drops, ear sprays, ear powders, ear rinses, ear plugs; vaginal capsules, aqueous suspensions (lotions, shake mixes), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (eg patches), milks, pastes, foams, pipettes, dispersible powders, implants or stents. The compounds according to the invention can be incorporated into the indicated administration forms. This can be done in a manner known per se, by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, but are not limited to: • fillers and carriers (eg cellulose, microcrystalline cellulose (such as eg Avicel®), lactose, mannitol, starch, calcium phosphate (such as eg DiCafos® )), • ointment bases (for example, petrolatum, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols), • suppository bases (for example, polyethylene glycols, cocoa butter , hard fat), • solvents (eg water, ethanol, isopropanol, glycerol, propylene glycol, medium chain triglyceride fatty oils, liquid polyethylene glycols, paraffins), • surfactants, emulsifiers, dispersants or wetting agents (eg sodium dodecyl sulphate) , lecithin, phospholipids, fatty alcohols (such as Lanette®), sorbitan fatty acid esters (such as Span®), polyoxyethylene sorbitan fatty acid esters (such as po r example Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, e.g. Pluronic®), -107buffers, acids and bases (for example, phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine), isotonicity agents (for example, glucose, chloride of sodium), adsorbents (for example, highly dispersed silicas), viscosity increasing agents, gel formers, thickeners, and / or binders (for example, polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, starch, carbomers, polyacrylic acids ( such as, for example, Carbopol®); alginates, gelatin), disintegrants (for example, modified starch, sodium carboxymethylcellulose, sodium starch glycolate (such as, for example, Explotab®), cross-linked polyvinylpyrrolidone, croscarmellose sodium (such as, for example, example, AcDiSol®)), flow regulators, lubricants, slip and mold release agents (for example, magnesium stearate, stearic acid, talc, highly disperse silicas (such as, for example, Aerosil®)), coating materials (for example, sugars, shellac) and film formers for rapidly dissolving or modified diffusion films or membranes (for example , polyvinylpyrrolidones (such as, for example, Kollidon®), poly(vinyl alcohol), hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit® )), capsule materials (for example, gelatin, hydroxypropylmethylcellulose), synthetic polymers (for example, polylactides, polyglycolides, polyacrylates, polymethacrylates (such as, for example, Eudragit®), polyvinylpyrrolidones (such as, for example, Kollidon®) , poly(vinyl alcohols), poly(vinyl acetates), polyethylene oxides, polyethylene glycols and their copolymers and block copolymers), plasticizers ( for example, polyethylene glycols, propylene glycol, glycerol, triacetin, triacetyl citrate, dibutyl phthalate), penetration enhancers, -108- • stabilizers (for example, antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate), • preservatives (for example, parabens, sorbic acid, thiomersal, chloride benzalkonium, chlorhexidine acetate, sodium benzoate), • colorants (eg inorganic pigments such as, for example, iron oxides, titanium dioxide), • flavorings, sweeteners, taste and / or odor masking agents. The present invention further relates to a pharmaceutical composition comprising at least one compound according to the invention, conventionally together with one or more suitable pharmaceutical excipients, and its use in accordance with the present invention. According to another aspect, the present invention encompasses pharmaceutical combinations, in particular medicaments, comprising at least one compound of the general formula (I) of the present invention and at least one or more additional active ingredients, especially for the treatment and / or prevention of an endo and / or ectoparasiticide infection. The term endoparasite in the present invention is used as it is known to those skilled in the art, and refers in particular to helminths. The term ectoparasite in the present invention is used as known to those skilled in the art, and refers in particular to arthropods, particularly insects or mites. In particular, the present invention encompasses a pharmaceutical combination, in particular a veterinary combination, comprising: • one or more of the first active ingredients, in particular compounds of the general formula (I) as defined above, and • one or more additional active ingredients, especially one or more endo and / or ectoparasiticides. The term combination in the present invention is used as known to those skilled in the art, and such combination may be a fixed combination, a non-fixed combination, or a kit of parts. The term a fixed combination in the present invention is used as known to those skilled in the art and is defined as a combination in which, for example, a first -109active ingredient, such as one or more compounds of the general formula (I) of the present invention, and another additional active ingredient are present together in a unit dose or in a single entity. An example of a fixed combination is a pharmaceutical composition in which a first active ingredient and a further active ingredient are present in a mixture for simultaneous administration, such as in a formulation. Another example of a fixed combination is a pharmaceutical combination in which a first active ingredient and a further active ingredient are present in a unit without being a mixture. A variable combination or kit of elements is used in the present invention, as known to those skilled in the art, and is defined as a combination in which a first active ingredient and a further active ingredient are present in more than one unit. An example of a variable combination or kit of elements is a combination where the first active ingredient and the additional active ingredient are present separately. Components of the variable combination or kit of items may be administered separately, sequentially, simultaneously, concurrently, or staggered over time. The compounds of the present invention may be administered as the sole pharmaceutical agent or in combination with one or more pharmaceutically active ingredients where the combination does not cause unacceptable adverse effects. The present invention also encompasses such pharmaceutical combinations. For example, the compounds of the present invention can be combined with known ectoparasiticides and / or endoparasiticides. One or more other active ingredients which are specified herein by their common names are known and described, for example, in The Pesticide Manual (The Pesticide Manual 16th Ed., British Crop Protection Council 2012) or can be searched on the internet (by example at http: / / www.alanwood.net / pesticides). The classification is based on the current IRAC mode of action classification scheme at the time of filing of this patent application. Examples of ectoparasiticides and / or endoparasiticides are insecticides, acaricides and nematicides, and include in particular: (1) Acetylcholinesterase (AChE) inhibitors, such as, for example, carbamates, for example alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxime, butoxycarboxime, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb , methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiophanox, triazamate, trimetacarb, XMC and xylylcarb; or organophosphates, eg acephate, azamethifos, ethylazinphos, methylazinphos, cadusafos, chlorethoxyphos, chlorfenvinphos, chlormephos, methylchlorpyrifos, coumaphos, cyanophos, S -110methyldemeton, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprofos, famfur, fenamifos, fenitrothion, fenthion, fostiazate, heptenophos, imiciaphos, isofenphos, O-(methoxyaminothiophosphoryl) isonoxathionipropyl, salicylate malathion, mecarbam, methamidophos, metidathion, mevinphos, monocrotophos, naled, omethoate, methyloxydemeton, methylparathion, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, methylpyrimiphos, profenofos, propetamfos, prothiophos, pyraclofos, pyridafenthion, quinlfotepyrimphos, telumphos Temephos, Terbufos, Tetrachlorvinphos, Thiometon, Triazophos, Trichlorfon, and Vamidothion. (2) GABA-gated chloride channel blockers, such as, for example, organochlorinated cyclodienes, eg, chlordane and endosulfan, or phenylpyrazoles (fiproles), eg, ethiprole and fipronil. (3) Modulators of sodium channels, such as, for example, pyrethroids, for example, acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, s-cyclopentenyl isomer of bioallethrin, bioresmethrin, cycloprothrin , cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zetacypermethrin, (IR)-trans isomer of cyphenothrin, deltamethrin, (EZ)-( IR) of empentrin, esfenvalerate, etofenprox, fenpropatrin, fenvalerate, flucitrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, (IR)-trans isomer of phenothrin, prallethrin, pyrethrins (pyrethrum), resmethrin, silafluofen , tefluthrin, tetramethrin, isomer (IR) of tetramethrin, tralomethrin and transfluthrin, or DDT or methoxychlor. (4) Competitive modulators of the nicotinic acetylcholine receptor (nAChR), such as, for example, neonicotinoids, eg, acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam, or nicotine or sulfoxaflor or flupyradifurone. (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR), such as, for example, spinosyns, eg, spinetoram and spinosad. (6) Allosteric modulators of glutamate (GluCl)-gated chloride channels, such as, for example, avermectins / milbemycins, eg, abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone mimics, such as, for example, juvenile hormone analogues, eg, hydroprene, quinoprene and methoprene, or phenoxycarb or pyriproxyfen. (9) Modulators of chordotonal organs, such as, for example, pymetrozine or flonicamid. -111 (IO) Mite growth inhibitors, such as clofentezine, hexythiazox and diflovidazine or etoxazole (12) Mitochondrial ATP synthase inhibitors, such as ATP disrupters, such as diafenthiuron or ATP compounds organotin, for example, azocycline, cytoxatin and fembutatin oxide, or propargite or tetradifon. (13) Uncouplers of oxidative phosphorylation by altering the proton gradient, such as, for example, chlorfenapyr, DNOC, and sulframid. (14) Nicotinic acetylcholine receptor channel blockers, such as, for example, bensultap, cartap hydrochloride, thiocylam and thiosultap sodium. (15) Chitin biosynthesis inhibitors, type 0, such as, for example, bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. (16) Chitin biosynthesis inhibitors, type 1, eg buprofezin. (17) Molt disruptors (particularly for the genus Diptera, ie Diptera), such as, for example, chromazin. (18) Ecdysone receptor agonists, such as, for example, chromafenozide, halofenozide, methoxyfenozide, and tebufenozide. (19) Octopamine receptor agonists, such as, for example, amitraz. (20) Inhibitors of electron transport of mitochondrial complex III, such as, for example, hydramethylnon, or acequinocyl or fluacrypyrim. (21) Inhibitors of electron transport of mitochondrial complex I, such as, for example, from the METI group of acaricides, eg, phenazaquin, fenpyroximate, pyrimidifen, pyridabene, tebufenpyrad and tolfenpyrad or rotenone (Derris). (22) Voltage-gated sodium channel blockers, such as, for example, indoxacarb or metaflumizone. (23) Acetyl CoA carboxylase inhibitors, such as, for example, tetronic and tetramic acid derivatives, eg, spirodiclofen, spiromesifene and spirotetramat. -112- (25) Inhibitors of electron transport of mitochondrial complex II, such as, for example, beta-ketonitrile derivatives, for example, cienopyrafen and cyflumethophene, and carboxyanilides, such as, for example, piflubumide. (28) Ryanodine receptor modulators, such as, for example, diamides, for example, chlorantraniliprole, cyantraniliprole and flubendiamide, other active ingredients, such as, for example, afidopiropene, afoxolaner, azadirachtin, benclothiaz, benzoximate, biphenazate, broflanilide, bromopropylate, chinomethionate, chloroprathrin, cryolite, cyclaniliprol, cycloxaprid, cyhalodiamide, dichloromethiozthiaz, dicofol, epsilon-methofluthrin, epsilon-momfluthrin, flomethoquine, fluazaindolizine, fluensulfone, flufenerim, fluphenoxystrobin, flufiprole, fluhexaphon, fluopyram, fluralaner, fluralaner heptafluthrin, imidaclothin, iprodione, kappa-bifenthrin, kappa-tefluthrin, lotilaner, meperfluthrin, paichongding, pyridalyl, pyrifluquinazon, pyriminostrobin, spirobudiclofen, tetramethylfluthrin, tetraniliprol, tetrachlorantraniliprole, thioxazaphen, thiofluoximate, triflumezopyrim, and iodomethane; in addition, preparations based on Bacillus firmus (1-1582, BioNeem, Votivo), and also the following compounds: 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl} -3-(trifluoromethyl)-1H-1,2,4triazol-5-amine (known from patent W02006 / 043635) (CAS 885026-50-6), {1'-[(2E)-3-(4-chlorophenyl) prop-2-en-l-yl]-5-fluorospiro[indole-3,4'-piperidin]-l(2H)-yl}(2-chloropyridin-4yl)methanone (known from patent W02003 / 106457) ( CAS 637360-23-7), 2-chloro-N-[2-{1 -[(2E)3-(4-chlorophenyl)prop-2-en-l-yl]piperidin-4-yl}-4- (trifluoromethyl)phenyl]isonicotinamide (known from patent W02006 / 003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxyl,8-diazaspiro[ 4.5]dec-3-en-2-one (known from WO 2010052161) (CAS 1225292-170), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-oxo-carbonate 1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl (known from patent EP2647626) (CAS 1440516-42-6), 4-(but-2-yn-l-yloxy)-6-(3,5dimethylpiperidin-1 -yl)-5-fluoropyrimidine (known from patent W02004 / 099160) (CAS 79291458-0), PF1364 (known from patent JP2010 / 018586) (CAS 1204776-60-2), N-[(2E)-l -[(6chloropyridin-3-yl)methyl]pyridin-2(1H)-ylidene]-2,2,2-trifluoroacetamide (known from patent WO2012 / 029672) (CAS 1363400-41-2), (3£) -3-[l-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-l,l,ltrifluoro-propan-2-one (known from patent WO2013 / 144213) (CAS 1461743-15- 6), V-[3(benzylcarbamoyl)-4-chlorophenyl]-l-methyl-3-(pentafluoroethyl)-4-(trifluoromethyl)-l / / -pyrazolo-5-carboxamide (known from patent WO2010 / 051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N[4-chloro-2-methyl-6-(methylcarbamoyl)phenyl]-2-(3-chloro-2-pyridyl)pyrazolo-3-carboxamide ( known from patent CN 103232431) (CAS 1449220-44-3), 4-(5-(3,5-dichlorophenyl)-4,5-dihydro-5(trifluoromethyl)-3-isoxazolyl]-2-methyl-N -(cis-l-oxide-3-thiethanyl)-benzamide, 4-(5- (3,5-113dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(trans-l-oxide-3-thiethanyl)benzamide and 4-[(5S) -5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N(cis-l-oxide-3-thiethanyl)benzamide (known from the patent WO 2013 / 050317 Al) (CAS 133262883-7), N-[3-chloro-l-(3-pyridinyl)-lH-pyrazol-4-yl]-N-ethyl-3-[(3,3,3 -trifluoropropyl)sulfinyl]propanamide, (+)-N-[3-chloro-l-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3trifluoropropyl)sulfinyl ]-propanamide and (-)-N-[3-chloro-l-(3-pyridinyl)-lH-pyrazol-4-yl]-N-ethyl-3[(3,3,3-trifluoropropyl)sulfinyl]- propanamide (known from patents WO 2013 / 162715 A2, WO 2013 / 162716 A2, US 2014 / 0213448 Al) (CAS 1477923-37-7), 5-[[(2E)-3-chloro-2-propen-lyl ]amino]-l-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfmyl]-1H-pyrazolo-3-carbonitrile (known from patent CN 101337937 A) (CAS 1105672-77- 2), 3-bromo-N-[4-chloro2-methyl-6-[(methylamino)thioxomethyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxam ida, (liudaibenjiaxuanán, known from patent CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro2-[[(l,l-dimethylethyl)amino]carbonyl]-6-methylphenyl]-l-(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-lHpyrazolo-5-carboxamide ( known from WO 2012 / 034403 Al) (CAS 1268277-22-0), N[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]- 3-bromo-1-(3-chloro-2-pyridinyl)-1Hpyrazolo-5-carboxamide (known from WO 2011 / 085575 Al) (CAS 1233882-22-8), 4-[3[2,6- dichloro-4-[(3,3-dichloro-2-propen-l-yl)oxy]phenoxy]propoxy]-2-methoxy-6-(trifluoromethyl)pyrimidine (known from patent CN 101337940 A) (CAS 1108184- 52-6); (2E)- and 2(Z)-2-[2-(4-cyanophenyl)-l-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(difluoromethoxy)phenyl]-hydrazinecarboxamide (known from CN patent 101715774 A) (CAS 1232543-85-9); 3-(2,2dichloroethenyl)-2,2-dimethyl-4-(1H-benzimidazol-2-yl)phenyl-cyclopropanecarboxylic acid ester (known from CN 103524422 A) (CAS 1542271-46-4); (4aS)-7-chloro-2,5-dihydro- acid methyl ester. 2- [[(methoxycarbonyl)[4-[(trifluoromethyl)thio]phenyl]amino]carbonyl]-indeno[1,2-e][1,3,4]oxadiazin- 4a(3H)-carboxylic (known from CN 102391261 A) (CAS 1370358-69-2); 6-deoxy-3-Oethyl-2,4-di-O-methyl-,1-[N-[4-[l-[4-(l,1,2,2,2-pentafluoroethoxy)phenyl]-l H-1,2,4-triazol-3yl]phenyl]carbamate]-α-L-mannopyranose (known from US patent 2014 / 0275503 Al) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)- 3-aza-bicyclo[3.2.1]octane (CAS 1253850-56-4), (8-anti)-8-(2-cyclopropylmethoxy-4-trifluoromethylphenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl )-3-aza-bicyclo[3.2.1]octane (CAS 933798-27-7), (8-syn)8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin- 3-yl)-3-azabicyclo[3.2.1]octane (known from patents WO 2007040280 Al, WO 2007040282 Al) (CAS 934001 -66-8) and N-[3-chloro-1 -(3 -pyridini 1)-1 H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)thio]propanamide (known from WO 2015 / 058021 Al, WO 2015 / 058028 Al) (CAS 1477919 -27-9) and -114N-[4-(aminothioxomethyl)-2-methyl-6-[(methylamino)carbonyl]phenyl]-3-bromo-1-(3-chloro-2-pyridinyl)1H-pyrazolo-5-carboxamide (known from patent CN 103265527 A) (CAS 1452877-50-7), 5(l,3-dioxan-2-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]-pyrimidine (known from WO 2013 patent / 115391 Al) (CAS 1449021-97-9), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-l-methyl,8-diazaspiro[4.5]dec-3-en -2-one (known from WO 2010 / 066780 Al, WO 2011 / 151146 Al) (CAS 1229023-34-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-l-methyl- l,8-diazaspiro[4.5]decane- 2,4-dione (known from WO 2014 / 187846 Al) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-l-methyl-2-oxo acid ethyl ester -l,8-diazaspiro[4.5]dec-3-en-4-yl-carbonic acid (known from WO 2010 / 066780 Al, WO 2011151146 Al) (CAS 1229023-00-0), N-[l-[(6 -chloro-3-pyridinyl)methyl]-2(1H)-pyridinylidene]-2,2,2-trifluoro-acetamide (known from DE 3639877 Al, WO2012029672 Al) (CAS 1363400-41-2), [N(E )]-N-[l-[(6-chloro-3-pyridinyl)methyl]2(lH)-pyridinylidene]-2,2,2-trifluoro-acetamide (known from WO 2016005276 Al) (CAS 168956603-7) , [N(Z)]-N-[l-[(6-chloro-3-pyridinyl)methyl]-2(lH)-pyridinylidene]-2,2,2-trifluoro-acetamide, (CAS 1702305-40- 5), 3-ene7o-3-[2-propoxy-4-(trifluoromethyl)phenoxy]-9-[[5-(trifluoromethyl)-2pyridinyl]oxy]-9-azabicyclo[3.3.1]nonane (known of WO2011 / 105506 Al, WO 2016 / 133011 Al) (CAS 1332838-17-1). Active ingredients with unknown or non-specific mode of action, eg, fentrifanil, fenoxacrim, cycloprene, chlorobenzilate, chlordimeform, flubenzimine, dicyclanil, amidoflumet, quinomethionate, triaratene, clothiazobene, tetrasul, potassium oleate, petroleum, methoxadiazone, gosiplure, flutenzine, bromopropylate, cryolite; Active ingredients from other classes, e.g. butacarb, dimethylan, cloethocarb, phosphocarb, ethylpyrimiphos, ethylparathion, methacryphos, isopropyl o-salicylate, trichlorfon, sulprofos, propafos, sebufos, pyridathion, protoate, dichlofenthion, demeton-S-methylsulfbna, isazofos , cyanofenphos, dialifos, carbophenothion, autathiophos, methylaromfenvinphos, ethylazinphos, ethylchlorpyrifos, fosmethylan, iodofenphos, dioxabenzophos, formothion, phonofos, flupyrazofos, fensulfothion, etrimfos; organochlorines, eg camfechlor, lindane, heptachlor; or phenylpyrazoles, eg acetoprol, pyrafluprole, pyriprole, vaniliprole, sisapronil; or isoxazolines, eg sarolaner, afoxolaner, lotilaner, fluralaner; pyrethroids, eg cis- or trans-methophyutrin, profluthrin, flufenprox, flubrocitrinate, fubfenprox, fenfluthrin, protrifenbute, pyresmethrin, RUI5525, terallethrin, cis-resmethrin, heptafluthrin, bioethanemethrin, biopermethrin, phenpyrithrin, cis-cypermethrin, cis-permethrin, -115 clocitrin, lambda-cyhalothrin, clovaportrin, or halogenated carbon-hydrogen (HCH) compounds; neonicotinoids, eg, nithiazine; dichloromezothiaz, triflumezopyrim; macrocyclic lactones, eg nemadectin, ivermectin, latidectin, moxidectin, selamectin, eprinomectin, doramectin, emamectin benzoate; milbemycin oxime; triprene, epophenonane, diofenolan; Biological compounds, hormones or pheromones, eg natural products, eg thuringiensin, codlemone or neem components; dinitrophenols, eg dinocap, dinobuton, binapacryl; benzoylureas, eg fluazuron, penfluron; amidine derivatives, eg chlormebufrom, ciazole, demiditraz; Acaricides against bee hive varroas, eg organic acids, eg formic acid, oxalic acid. Non-limiting examples of insecticides and acaricides that are of particular interest for use in animal health are and include in particular [ie Mehlhorn et al Encyclpaedic Reference of Parasitology 4th Edition (ISBN 978-3-662-43978-4)] : Effectors on arthropod ligand-gated chloride channels: chlordane, heptachlor, endoculfan. Dieldrin, bromocyclone, toxaphene, lindane, fipronil, pyriprol, sisapronil, afoxolaner, fluralaner, sarolaner, lotilaner, fluxamethamide, broflanilide, avermectin, doramectin, eprinomectin, ivermectin, milbemycin, moxidectin, selamectin; Arthropod octopaminergic receptor modulators: amitraz, BTS27271, ciazole, demiditraz; Effectors on arthropod voltage-gated sodium channels: DDT, methoxychlor, metaflumizone, indoxacarb, cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II, allethrin, alphacypermethrin, bioallethrin, betacyfluthrin, cyfluthrin, cyhalothrin, cypermethrin , deltamethrin, etofenprox, fenvalerate, flucythrinate, flumethrin, halfenprox, permethrin, phenothrin, resmethrin, tau-fluvalinate, tetramethrin; -116 Effects on arthropod nicotinic cholinergic synapses (acetylcholine esterase, acetylcholine receptors): bromopripilate, bendiocarb, carbaryl, methomyl, promacil, propoxur, azamethophos, chlorfenvinphos, chlorpyrifos, coumaphos, cythioate, diazinon, dichlorvos, dicrotophos, dimethofur, ethion, famthion , fenitrothion, fenthion, heptenophos, malathion, naled, phosmet, phoxim, phthalofos, propetamphos, temefos, tetrachlorvinphos, trichlorfon, imidacloprid, nitenpyram, dinotefuran, spinosad, spintoram; Effectors in arthropod developmental processes: cyromazine, dicyclanil, diflubenzuron, fluazuron, lufenuron, triflumuron, fenoxycarb, hydroprene, methoprene, pyriproxyfen, fenoxycarb, hydroprene, S-methoprene, pyriproxyfen. Illustrative active ingredients from the group of endoparasiticides, as additional active ingredient or other active ingredient of the present invention, include, but are not limited to, compounds with anthelmintic activity and compounds with antiprotozoal activity. Compounds with anthelmintic activity include, but are not limited to, the following compounds with nematicidal, trematicidal, and / or cestocidal activity: from the class of macrocyclic lactones, for example: eprinomectin, abamectin, nemadectin, moxidectin, doramectin, selamectin, lepimectin, latidectin, milbemectin, ivermectin, emamectin, milbemycin; from the class of benzimidazoles and probenzimidazoles, for example: oxibendazole, mebendazole, triclabendazole, thiophanate, parbendazole, oxfendazole, netobimine, fenbendazole, febantel, thiabendazole, cyclobendazole, cambendazole, albendazole sulfoxide, albendazole, flubendazole; from the class of depsipetids, preferably cyclic depsipetids, in particular 24-membered cyclic depsipetids, for example: emodepside, PF1022A; from the class of tetrahydropyrimidines, for example: morante!, pyrante!, oxantel; from the class of imidazothiazoles, for example: butamisole, levamisole, tetramisole; from the class of aminophenylamidines, for example: amidantel, deacylated amidantel (dAMD), tribendimidine; from the class of aminoacetonitriles, for example: monepantel; from the class of parahercuamides, for example: parahercuamide, derquantel; from the class of salicylanilides, for example: tribromsalan, bromoxanide, brotianide, clioxanide, closantel, niclosamide, oxyclozanide, rafoxanide; -117from the class of substituted phenols, for example: nitroxinil, bithionol, disphenol, hexachlorophene, niclofolan, meniclofolan; from the class of organophosphates, for example: trichlorfon, naphthalophos, dichlorvos / DDVP, crufomate, coumaphos, haloxon; from the class of piperazinones / quinolines, for example: praziquantel, epsiprantel; from the class of piperazines, for example: piperazine, hydroxyzine; from the class of tetracyclines, for example: tetracycline, chlortetracycline, doxycycline, oxytetracycline, rolitetracycline; of various other classes, for example: bunamidine, niridazole, resorantel, omfalotine, oltipraz, nitroscanate, nitroxinil, oxamniquine, mirasan, miracil, lucanthone, hicanthone, hetolin, emetine, diethylcarbamazine, dichlorophen, diamfenetide, clonazepam, bephenium, amoscanate, clorsulon. Ingredients with antiprotozoal activity of the present invention include, but are not limited to, the following active ingredients: from the class of triazines, for example: diclazuril, ponazuril, letrazuril, toltrazuril; from the class of polyether ionophores, for example: monensin, salinomycin, maduramycin, narasin; from the class of macrocyclic lactones, for example: milbemycin, erythromycin; from the class of quinolones, for example: enrofloxacin, pradofloxacin; from the class of kinins, for example: chloroquine; from the class of pyrimidines, for example: pyrimethamine; from the class of sulfonamides, for example: sulfaquinoxaline, trimethoprim, sulfaclozine; from the class of thiamines, for example: amprolium; from the class of lincosamides, for example: clindamycin; from the class of carbanilides, for example: imidocarb; from the class of nitrofurans, for example: nifurtimox; from the class of quinazolinone alkaloids, for example: halofuginon; of various other classes, for example: oxamniquine, paromomycin; -118of the class of vaccines or antigens from microorganisms, for example: Babesia canis rossi, Eimeria tenella, Eimeria praecox, Eimeria necatrix, Eimeria mitis, Eimeria maxima, Eimeria brunetti, Eimeria acervulina, Babesia canis vogeli, Leishmania infantum, Babesia canis , Dictyocaulus viviparus. Optionally, and if their functional groups allow it, all the active ingredients of the present invention named as other or additional can form salts with suitable bases or acids. Based on known standard laboratory techniques for evaluating compounds useful for the treatment of helminth infections, by standard toxicity assays, and by standard pharmacological assays to determine treatment of previously identified conditions in animals, and by comparison of these results with Based on the results of known active ingredients or medicaments that are used for the treatment of these conditions, the effective dosage of the compounds of the present invention can be readily determined for the treatment of each desired indication. The amount of active ingredient to be administered during the treatment of one of these conditions can vary widely according to considerations such as the particular compound and dosage unit used, the mode of administration, the period of treatment, age, and sex. of the subject being treated and the nature and extent of the condition being treated. The total amount of active ingredient to be administered is generally in the range from about 0.001 mg / kg to about 200 mg / kg of body weight per day and preferably from about 0.01 mg / kg to about 20 mg / kg of body weight. body per day Clinically useful dosing schedules vary in a range between dosing one to three times per day to dosing once every four weeks. Furthermore, it is possible that during drug washout, when a subject does not receive the corresponding dose for a certain period of time, the drug washout is beneficial for the overall balance between drug effect and tolerance. In addition, it is possible to have long-acting treatments, where the subject receives treatment once for more than four weeks. A unit dose may contain from about 0.5 mg to about 1500 mg of active ingredient, and may be administered one or more times per day or less than once per day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections and the use of infusion techniques, will preferably be from 0.01 to 200 mg / kg of total body weight. The daily rectal dosing regimen -119average will preferably be from 0.01 to 200 mg / kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg / kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg, administered one to four times per day. The transdermal concentration will preferably be that required to maintain a daily dose of 0.01 to 200 mg / kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg / kg of total body weight. Of course, the specific initial and continuing dosing regimen for each subject will vary according to the nature and severity of the condition as determined by the attending physician, the activity of the specific compound employed, the age and general condition of the subject, the time of administration, the route of administration, the rate of excretion of the drug, combinations of drugs and the like. The desired mode of treatment and amount of dosage of a compound according to the present invention, or a pharmaceutically acceptable salt, ester or composition thereof, can be assessed by those skilled in the art, using conventional treatment tests. EXPERIMENTAL SECTION Abbreviations: atm standard atmosphere DAD diode array detector DMSO dimethyl sulfoxide ELSD evaporative light scattering detector ES1 electrospray ionization h hour(s) LC-MS liquid chromatography-coupled mass spectrometry min minute(s) NMR nuclear magnetic resonance spectrometry Rt time retention TLC thin layer chromatography The various aspects of the invention described in this application are illustrated by the following examples which are not intended to limit the invention in any way. -120 The exemplary test experiments described herein serve to illustrate the present invention and the present invention is not limited to the examples given. EXPERIMENTAL SECTION - GENERAL PART All reagents, for which the synthesis is not described in the experimental part, are commercially available, or are known compounds or can be formed from known compounds by procedures known to a person skilled in the art. Compounds and intermediates produced according to the processes of the invention may require purification. The purification of organic compounds is well known to those skilled in the art and there may be several ways to purify the same compound. In some cases, it is not necessary to purify. In some cases, the compounds can be purified by crystallization. In some cases, the impurities can be agitated using a suitable solvent. In some cases, compounds can be purified by chromatography, particularly flash column chromatography, using, for example, pre-packaged silica gel cartridges, for example Biotage SNAP KP-Sil® or KP-NH® cartridges in combination with a Biotage autopurification system. (SP4® or Isolera Four®) and eluents such as hexane / ethyl acetate or dichloromethane / methanol gradients. In some cases, compounds can be purified by preparative HPLC using, for example, a Waters autopurifier equipped with a diode array detector and / or an on-line electrospray ionization mass spectrometer in combination with a pre-packed reverse phase column. and eluents such as water and acetonitrile gradients which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia. In some cases, the purification procedures described above can provide those compounds of the present invention that possess sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention that is sufficiently basic, a trifluoroacetate or formate salt, for example, or, in the case of a compound of the present invention that is sufficiently acidic, an ammonium salt, for example. Such a salt can be converted into its free base or free acid form, respectively, by various procedures known to the person skilled in the art, or it can be used as salts in subsequent biological tests. It is to be understood that the specific form (eg, salt, free base, etc.) of a compound of the present invention, in isolation and as described herein, is not necessarily the only form in which said compound it can be applied to a biological assay in order to quantify the specific biological activity. -121 ANALYTICAL METHODS analytical liquid chromatography Analytical LC-MS (UP) was performed by means of different equipment as described below. Masses (m / z) are reported from positive mode electrospray ionization unless negative mode (ESI-) is indicated. II method: Instrument Type: Waters UPLC System; column: Zorbax Eclipse Plus C18, 50mm x 2.1mm, 1.8 pm; eluent A: acetonitrile + 1 ml of formic acid / L, eluent B: Millipore water + 0.9 ml of formic acid / L; gradient: 0.0 min 10% A —» 1.7 min 95% A —> 2.40 min 95% A —► 2.41 min 10% A —> 2.50 min 10% A; oven: 55 °C; flow: 0.85 ml / min; UV detection: 210nm. Waters SQD2 MS Detector: 100-1000 Amu, ES-ionization, positive or negative. L2 method: Instrument type: Agilent 1290; column: Zorbax Eclipse Plus C18, 50mm x 2.1mm, 1.8 pm; eluent A: acetonitrile + 1 ml of formic acid / L, eluent B: Millipore water + 0.9 ml of formic acid / L; gradient: 0.0 min 10% A —> 1.8 min 95% A —> 2.50 min 95% A —* 2.52 min 10% A —> 2.60 min 10% A; oven: 55 °C; flow: 1ml / min; UV detection: 210nm. Agilent MS Detector: 100-1000 Amu, ES-ionization, positive or negative. L3 method: MS instrument type: Agilent Technologies 6130 Quadrupole LC-MS; HPLC instrument type: Agilent Technologies 1260 Infinity; column: Waters XSelect (C18, 30x2.1mm, 3.5p); flow: 1ml / min; column temperature: 35 °C; mobile phase A: 0.1% formic acid in acetonitrile; mobile phase B: 0.1% formic acid in water; lin. gradient: t = 0 min 5% A, t = 1.6 min 98% A, t = 3 min 98% A; detection: DAD (220-320 nm); Detection: MSD Mass Range (ESI pos / neg): 100 - 800; detection: ELSD (PL-ELS 2100): gas flow 1.2 ml / min, gas temperature: 70 °C, neb: 50 °C. L4 method: MS instrument type: Agilent Technologies 6130 Quadrupole LC-MS; HPLC instrument type: Agilent Technologies 1260 Infinity; column: Waters XSelect (Cl8, 50x2.1mm, 3.5p); flow: 0.8 ml / min; column temperature: 35 °C; mobile phase A: 0.1% formic acid in acetonitrile; mobile phase B: 0.1% formic acid in water; lin. gradient: t = 0 min 5% A, t = 3.5 min 98% A, t = 6 min 98% A; detection: DAD (220-320 nm); detection: MSD mass range (ESI -122pos / neg): 100 - 800; detection: ELSD (PL-ELS 2100): gas flow 1.2 ml / min, gas temperature: 70 °C, neb: 50 °C. L5 method: MS instrument type: Agilent Technologies LC / MSD SL; HPLC instrument type: Agilent Technologies 1100 Series; column: Waters XSelect (C18, 30x2.1mm, 3.5μ); flow: 1ml / min; column temperature: 25 °C, eluent A: 95% acetonitrile + 5% 10 mM ammonium bicarbonate in water; eluent B: 10 mM ammonium bicarbonate in water pH=9.0; lin. gradient: t = 0 min 5% A, t = 1.6 min 98% A, t = 3 min 98% A; detection: DAD (220-320 nm); Detection: MSD Mass Range (ESI pos / neg): 100 - 800. L6 method: MS instrument type: Agilent Technologies LC / MSD SL; HPLC instrument type: Agilent Technologies 1100 Series; column: Waters XSelect (C18, 50x2.1mm, 3.5μ; flow: 0.8 mL / min; column temperature: 25 °C; eluent A: 95% acetonitrile + 5% ammonium 10 mM sodium bicarbonate ammonium in water, eluent B: 10 mM ammonium bicarbonate in water pH = 9.0, gradient lin: t = 0 min 5% A, t = 3.5 min 98% A, t = 6 min 98% A Detection: DAD (220-320 nm) Detection: MSD Mass Range (ESI pos / neg): 100-800. For the following liquid chromatography methods: LCMS analyzes were performed on a SHIMADZU LCMS consisting of a UFLC 20AD detector and LCMS 2020 MS. The diode array detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) that is operated in positive or negative mode. The mass spectrometer was scanned between m / z 90-900 with a scan time of 0.5-1.0 s. Liquid Chromatography-Mass Spectrometry MI Method: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 x 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.80 min with a time total execution of 2.10 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M2: The column used was EVO, 2.6 pm, 3.0 x 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for -1234.20 min with a total execution time of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M3: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M4: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M5: The column used was a Kinetex EVOC 18.2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M6: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 2.60 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M7: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.80 min with a time total execution of 3.30 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M8: -124 The column used was CORTEOS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M9: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 4.20 min with a time total execution of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry MÍO Method: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Mil Method: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M12: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M13: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: TFA at -1250.05% in MeCN) for 1.70 min with a total running time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M14: The column used was an Ascends Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M15: The column used was an Ascentis Express C18, 2.7 pm, 2.1 x 50mm. A linear gradient was applied, starting at 70% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M16: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method MI7: The column used was CORTECS C18+ 100A, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.60 min with a total time of execution of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M18: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 90% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. -126Liquid Chromatography-Mass Spectrometry Method M19: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.60 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M20: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M21: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.09% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M22: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M23: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M24: -127 The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M25: The column used was a Kinetex EVO Cl 8.2.6 pm, 4.6 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.75 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.80 mL / min. Liquid Chromatography-Mass Spectrometry Method M26: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 4.90 min with a time total execution of 5.30 min. The column temperature was set at 45 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M27: The column used was Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M28: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M29: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: TFA at -1280.05% in MeCN) for 4.60 min with a total running time of 5.30 min. The column temperature was set at 40 °C with a flow rate of 1.20 ml / min. Liquid Chromatography-Mass Spectrometry Method M30: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.80 min with a time total execution of 3.30 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M31: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 4.70 min with a time total run of 5.00 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M32: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 5.20 min with a time total execution of 5.70 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M33: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.20 min with a time total execution of 2.60 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M34: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. -129 Liquid Chromatography-Mass Spectrometry Method M35: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M36: The column used was CORTECS C18+ 100A, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 2.60 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M37: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.60 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M38: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.80 min with a time total run of 2.00 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M39: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 70% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 5.70 min with a time total execution of 6.50 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M40: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 60% A (A: 0.05% TFA in water) and ending at 95% B (B: TFA at -1300.05% in MeCN) for 2.70 min with a total running time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M41: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.80 min with a total run time of 2.00 min. The column temperature was set at 45 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M42: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M43: The column used was a Kinetex EVO Cl 8 100A, 2.6 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.60 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M44: The column used was HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 100% B (B: MeCN) over 2.60 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M45: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 3.10 min with a time total execution of 3.60 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. -131 Liquid Chromatography-Mass Spectrometry Method M46: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.10 min with a time total execution of 2.60 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M47: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 4.20 min with a time total execution of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M48: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 80% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 5.00 min with a time total execution of 5.60 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M49: The column used was Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NH4HCO3+NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 1.10 min with a total run time of 2 00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M50: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.00 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 0.80 mL / min. Liquid Chromatography-Mass Spectrometry Method M5Í: The column used was a Kinetex EVO Cl 8 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H2O ​​in water) and ending at 95% B (B: MeCN) -132 for 1.70 min with a total running time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M52: The column used was an Ascends Express C18, 2.7 pm, 2.1 x 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M53: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M54: The column used was Omega, 3.0 pm, 2.1 χ 30 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.60 min with a total running time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M55: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NH4HCO3 + NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 1.80 min with a total run time of 2 00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M56: The column used was a Kinetex EVO C18, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M57: -133 The column used was a Kinetex EVO, 2.6 pm, 4.6 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.80 mL / min. Liquid Chromatography-Mass Spectrometry Method M58: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NH4HCO3 + NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 2.70 min with a total run time of 3 00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M59: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.80 min with a time total run of 3.00 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M60: The column used was a Kinetex 2.6 pm EVO C18 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.80 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M61: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.03% NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 1.60 min with a total execution time of 1.80 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M62: The column used was Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NH4HCO3 + NH3H2O ​​in water) and ending at 95% B. -134(B: MeCN) for 1.80 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M63: The column used was a Kinetex 2.6 pm EVO Cl 8 100A, 2.6 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) for 2.70 min with a total run time of 2.90 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M64: The column used was an XBridge C18, 2.5 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M65: The column used was a Kinelex 2.6u EVO XB-C18, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.80 min with a time total run of 3.00 min. The column temperature was set at 45 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M66: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.60 min with a time total execution of 1.80 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M67: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. -135Liquid Chromatography-Mass Spectrometry Method M68: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.60 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M69: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.03% NHjLLO in water) and ending at 95% B (B: Acetonitrile) over 1.60 min with a total run time of 1.80 min. . The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M70: The column used was a Kinetex 2.6 um EVO C18 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 5.00 min with a total run time of 5.60 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M71: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 2.60 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M72: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 4.20 min with a total run time of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M73: The column used was a Kinetex 2.6 um EVO C18 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B. -136(B: MeCN) for 1.80 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M74: The column used was a Kinetex 2.6 um EVO C18 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.80 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M75: The column used was an XBridge C18, 2.5 pm, 3.0 x 50mm. A linear gradient was applied, starting at 90% A (A: 0.04% NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 1.80 min with a total run time of 2.00 min. . The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M76: The column used was an XBridge C18, 2.5 pm, 3.0 * 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.80 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M77: The column used was an XBridge C18, 2.5 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M78: The column used was an XBridge C18, 2.5 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 70% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M79: -137 The column used was a Kinetex EVO Cl 8.2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 60% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 5.00 min with a time total execution of 5.30 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M80: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 60% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 5.00 min with a time total execution of 5.30 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M81: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 40% A (A: 0.03% NH3H2O ​​in water) and ending at 95% B (B: MeCN) over 2.60 min with a total execution time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M82: The column used was a Kinelex 2.6u EVO XB-C18, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.80 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M83: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 5.20 min with a time total execution of 5.70 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M84: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in water). -138in MeCN) for 5.20 min with a total execution time of 5.70 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M85: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.60 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M86: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 70% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 4.80 min with a total execution time of 5.20 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M87: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M88: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.80 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M89: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 100% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. -139Liquid Chromatography-Mass Spectrometry Method M90: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M91: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 4.20 min with a time total execution of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M92: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3) and ending at 95% B (B: MeCN) over 4.0 min with a total run time of 5.6 miri. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M93: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 3.50 min with a total run time of 4.50 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M94: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3) and ending at 95% B (B: MeCN) for 1.8 min with a total running time of 2.0 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M95: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: TFA at -140- 0.05% in MeCN) for 1.60 min with a total run time of 1.80 min. The column temperature was set at 40 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M96: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 x 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.7 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M97: The column used was a Shim-pack XR-ODS, 3.0 pm, 3.0 * 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.65 min with a time total execution of 1.90 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M98: The column used was an Ascends Express 0 8, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 1.7 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M99: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.04% NH4OH in water) and ending at 95% B (B: MeCN) for 1.70 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M100: The column used was a Kinetex EVO Cl 8 100A, 2.6 pm, 3.0 x 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) for 5.20 min with a total run time of 5.60 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. -141 Liquid Chromatography-Mass Spectrometry Method M101: The column used was a Kinetex XB-C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.60 min with a time total execution of 1.90 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI02: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 1.65 min with a time total execution of 1.90 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI03: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 6.5 mM NH4HCO3+NH3H2O ​​in water) and ending at 100% B (B: MeCN) for 1.80 min with a total run time of 2 00 min. The column temperature was set at 45 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method MI04: The column used was an InertSustain AQ-C18, 3.0 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H2O ​​in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.70 min with a total time of execution of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M105: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 1.70 min with a total run time of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M106: The column used was a Kinelex 2.6u EVO XB-C18, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B -142(B: 0.05% TFA in MeCN) for 2.50 min with a total run time of 6.00 min. The column temperature was set at 45 °C with a flow rate of 1.50 mL / min. Liquid Chromatography-Mass Spectrometry Method M107: The column used was a Kinetex EVO C18, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI08: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) for 4.60 min with a total run time of 5.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M109: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 75% A (A: 6.5 mM NH4HCO3+NH3H2O ​​in water) and ending at 100% B (B: MeCN) for 6.00 min with a total run time of 6 .60 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method Mi 10: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 1.80 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 11: The column used was a Kinetex EVO C18,2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 70% A (A: 0.1% FA in water) and ending at 80% B (B: 0.1% FA in MeCN) for 4.8 min with a time total run of 5.2 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. -143Liquid Chromatography-Mass Spectrometry Method M112: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 65% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) for 5.00 min with a time total execution of 5.60 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 13: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) for 2.70 min with a total run time of 2.95 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 14: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.05% TFA in water) and ending at 60% B (B: 0.05% TFA in MeCN) for 5.00 min with a time total execution of 5.60 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 15: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 1.6 min with a time total run of 1.8 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 16: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 4.7 min with a time total run of 5.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 17: The column used was CORTECS C18+, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in -144MeCN) for 1.60 min with a total execution time of 1.90 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 18: The column used was a Kinetex EVO Cl 8,2,6 pm, 3.0 * 50 mm. A linear gradient was applied, starting at 95% A (A: 0.03% NH3H20 in water) and ending at 95% B (B: MeCN) for 1.60 min with a total run time of 1.80 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 19: The column used was a Kinetex EVO C18 100A, 2.6 pm, 3.0 χ 50mm. A linear gradient was applied, starting at 70% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.70 min with a total run time of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M120: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 5 mM NH4HCO3) and ending at 95% B (B: MeCN) over 1.6 min with a total run time of 1.8 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M121: The column used was an XSelect CSH Cl 8, 2.5 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.75 min with a time total run of 2.00 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M122: The column used was a Kinetex EVO Cl 8 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 75% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 5.00 min with a total run time of 5.60 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. -145Liquid Chromatography-Mass Spectrometry Method M123: The column used was an Xselect CSH C18, 2.5 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.7 min with a time total run of 2 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M124: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.1% FA in MeCN) for 1.70 min with a time total run of 2.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method MI25: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NFLHCO3+NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 4.7 min with a total run time of 5 min. 0 min The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M126: The column used was Omega, 3.0 pm, 2.1 χ 30 mm. A linear gradient was applied, starting at 95% A (A: 0.09% FA in water) and ending at 95% B (B: 0.1% FA in MeCN) for 1.37 min with a time total execution of 1.50 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M127: The column used was a Kinetex EVO Cl 8 100A, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 70% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 5.2 min with a total run time of 5.60 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI 28: The column used was CORTECS C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in water). -146in MeCN) for 4.4 min with a total run time of 5.0 min. The column temperature was set at 45 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M129: The column used was a Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 6.5 mM NH4HCO3+NH3H2O ​​in water) and ending at 95% B (B: MeCN) for 4.8 min with a total run time of 5 min. ,1 min. The column temperature was set at 45 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method MI30: The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 70% A (A: 5 mM NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.7 min with a total run time of 3.0 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Liquid Chromatography-Mass Spectrometry Method M131: The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50mm. A linear gradient was applied, starting at 90% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) for 2.70 min with a time total run of 3.00 min. The column temperature was set at 40 °C with a flow rate of 1.00 mL / min. Liquid Chromatography-Mass Spectrometry Method M132: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.1% FA in water) and ending at 100% B (B: 0.05% FA in MeCN) for 1.60 min with a time total execution of 1.80 min. The column temperature was set at 40 °C with a flow rate of 1.20 mL / min. Ή NMR data 1H NMR data were determined with a Bruker Avance 400 (equipped with a flow cell (60 µl volume), or with a Bruker AVIIII 400 equipped with a 1.7 mm CPTCI cryo probe head, or with a Bruker AVII 400 (400.13 MHz) equipped with a 5 mm probe head, or with a Bruker AVII 600 (600.13 MHz) equipped with a 5 mm TCI cryo probe head, or with a Bruker AVIIII 600 (601.6 MHz) equipped with a CPMNP cryo probe head of -1475mm or with a Bruker AVIIII 500 (500.13MHz) equipped with a 5mm broadband head or 5mm Prodigy™ probe head, with tetramethylsilane as reference (0.0) and solvents CD3CN, CDCI3 or dó-DMSO. Alternative Ή and 13C NMR instrument types: Bruker DMX300 (Ή NMR: 300 MHz; 13C NMR: 75 MHz), Bruker Avance III 400 (Ή NMR: 400 MHz; 13C NMR: 100 MHz), Bruker 400 Ultrashield ( Ή NMR: 400 MHz; 13C NMR: 100 MHz) or Bruker Mercury Plus 300 / 400 NMR Spectrometer. Chemical shifts (δ) are shown in parts per million [ppm]; the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. = width; coupling constants are shown in Hertz [Hz], NMR Peak Lists The Ή NMR data of the selected examples are written in the form of Ή NMR peak lists. For each signal peak the δ-value in ppm and the signal intensity are listed in brackets. Between the δ- value the signal intensity pairs are semicolons that function as separators. Therefore, the peak list of an example has the following form: δι (intensityi); 62 (intensified);........; δ, (intensity¡);......; δη (intensityn) The intensity of the sharp signals is correlated with the height of the signals on a printed example of an NMR spectrum in cm and shows the actual relationships of the signal intensities. From broad signals, multiple peaks or the center of the signal and their relative intensity compared to the strongest signal in the spectrum can be displayed. For the calibration of the chemical shift for Ή spectra, tetramethylsilane and / or the chemical shift of the solvent used is used, especially in the case of spectra measured in DMSO. Therefore, in the NMR peak lists, the tetramethylsilane peak can, but does not necessarily, occur. The Ή NMR peak lists are similar to the classical ’H NMR printouts and therefore generally contain all peaks, which are listed in the classical NMR interpretation. -148 In addition, they can show as signals of classical Ή NMR prints of solvents, stereoisomers of the target compounds, which are also the object of the invention, and / or impurity peaks. To show composite signals in the delta range of solvents and / or water, the usual solvent peaks, for example, DMSO peaks in DMSO-De and the water peak are shown in the Ή NMR peak lists and normally They have a high intensity average. The stereoisomeric peaks of the target compounds and / or the impurity peaks usually have on average a lower intensity than the peaks of the target compounds (for example >90% pure). Such stereoisomers and / or impurities may be normal for the specific preparation process. Therefore the peaks can help to recognize the reproduction of our preparation process through products to identify traces”. An expert, who calculates the peaks of the target compounds with known procedures (MestreC, ACD simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed using additional intensity filters. This isolation would be similar to the selection of relevant peaks in the classical NMR interpretation of *H. More details on describing NMR data with peak lists can be found in the Research Disclosure Database Citation of NMR Peaklist Data within Patent Applications, Issue 564025. Microwave Biotage™ Initiator, Microwave Synthesizer; temperature range: 40 °C - 250 °C; pressure range: 0-20 bar; power range: 0 - 400 W. -149 EXPERIMENTAL SECTION - GENERAL PROCEDURES The synthesis of the compounds of formula (I) can be carried out according to, or in analogy, with the following schemes (Schemes 1-6). In the present and in the general context of the present invention, cross-links indicate cis / trans mixtures. Scheme 1 to prepare a compound (I) with T = Τ' (I-Tl) Tl-a aminopyridines can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R=Me or R,R=pinacolate) as described in the European Journal of Organic Chemistry, 2012 (31), 6248-6259, on Tl-b aryl- or hetaryl-substituted aminopyridines. Said substituted aminopyridines can easily be converted with (alkoxymethylene)malonates Tl-c dissolved in the corresponding solvent of alcohol or toluene, preferably under boiling conditions, into (pyrid-3ylaminomethylene)-malonates Tl-d or without any solvent as described in the WO document -15020060135551. Ring closure is performed in high-boiling solvents, preferably in diphenyl ether or xylol, to achieve Tl-e aza-quinolone carboxylic esters as described in WO 2002004444. Tle-azaquinolone carboxylic esters can be converted in the corresponding Tl-f chloro azaquinolines in the presence of chlorinating agents such as phosphorous oxychloride as described in WO 2008154447 with similar azaquinolines. Depending on the nature of the R2H nucleophile, chloro aza-quinolones Tl-f react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, A / TV-diisopropylethylamine , diazabicycloundecane, sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the azaquinolone carboxylic esters Tl-g as described in document WO 199703074 . Alternatively, Tl-f can be converted with certain organic Grignard or metal R2Met-X compounds, e.g., Ci-C4-alkyl-Met-X, C3-C6cycloalkyl-Met-X, C2-C4-alkenyl-Met-X, Cs-Ce-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-Ci-C4-alkyl-Met-X (Met = Mg, Zn; X = I, Br, Cl) introducing alkyl0- C1-C4, cycloalkyl-Cs-Có, alkenyl-C2-C4, cycloalkenyl-Cs-Ce, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted as defined above for the R2 group, as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in azaquinolone carboxylic esters Tl-g. Intermediate esters Tl-g react under hydrolytic conditions to produce aza-quinoline carboxylic acids Tl-h as described with similar syntheses in CN 102199152. Final products I-Tl are obtained by amide coupling conditions, for example, by carboxylic acid chlorides formed from Tl-h which are combined with amines R'-NH-A under basic conditions, for example pyridine, triethylamine or jV,7V-diisopropylethylamine, or by amide formation from the carboxylic acids Tl-h which are combined with amines R'-NH-A and dehydration reagents, for example, jV-(3-dimethylaminoisopropyl)-jV'-ethylcarbodiimide-hydrochloride (EDC). For example, similar syntheses are described in WO 2015014768. Scheme 2a to prepare a compound (I) with T = T2 (I-T2) -151 - T2-a aminopyridines can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R-Me or R,R = pinacolate) as described in the Journal of Organic Chemistry, 1999, 64(26), 9430-9443, on T2-b aryl- or hetaryl-substituted aminopyridines. Such aminopyridines can be easily converted with (alkoxymethylene)malonates T2-c dissolved in the corresponding solvent of alcohol or toluene, preferably under boiling conditions, into (pyrid-4-ylaminomethylene)-malonates T2-d as described in the Journal of Medicinal Chemistry, 2007, 50(22), 5471-5484, or without any solvent as described in Medicinal Chemistry Letters, 2012, 3(1), 74-78. Ring closure is performed in high boiling solvents, preferably in diphenyl ether or xylol, to achieve aza-quinolone carboxylic esters T2-e as described in WO 2016196961. Intermediate esters T2-e react under hydrolytic conditions to produce aza-quinolone T2-f carboxylic acids as described with similar syntheses in WO 2009036412. Aza-quinolone T2-f carboxylic acids can be converted to the corresponding chloro aza-quinoline T2-g in the presence of agents chlorination as phosphorus oxychloride as described in WO 2016196961 with similar aza-quinolines. The -152Acid chloride is formed simultaneously and can easily be converted with amines R'-NH-A to amides T2-h in the presence of bases such as triethylamine. Depending on the nature of the R2H nucleophile, the chlorine aza-quinolones T2-h react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, ΛζΝ-diisopropylethylamine, diazabicycloundecane , sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the final compounds I-T2. Alternatively, T2-h can be converted with certain organic Grignard or metal R2Met-X compounds, for example, Ci-C4-alkyl-Met-X, Cs-Có-cycloalkyl-Met-X, C2-C4-aIkenyl-Met- X, Cs-Có-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-Ci-C4-alkyl-Met-X (Met = Mg, Zn; X = I, Br, Cl) introducing Ci-C4-alkyl, Cs-Ce-cycloalkyl, C2-C4-alkenyl, C3Cs-cycloalkenyl, C2-C4-alkynyl or phenyl-Ci-C4-alkyl, each of which is optionally substituted as defined above for the R2 group, as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in final compounds I-T2. Scheme 2b to prepare a compound (I) with T = T2 (I-T2) -153Aminopyridines T2-a can be easily converted with (alkoxymethylene)malonates T2-c dissolved in the corresponding solvent of alcohol or toluene, preferably under boiling conditions, into (pyrid-4-ylaminomethylene)-malonates T2-i as described in the Journal of Medicinal Chemistry, 2007, 50(22), 5471-5484, or without any solvent as described in Medicinal Chemistry Letters, 2012, 3(1), 74-78. Ring closure is performed in high boiling solvents, preferably diphenyl ether or xylol, to achieve aza-quinolone carboxylic esters T2-j as described in WO 2016196961. Intermediate esters T2-j react under hydrolytic conditions to produce T2-k aza-quinolone carboxylic acids as described with similar syntheses in WO 2009036412. T2-k aza-quinolone carboxylic acids can be converted to the corresponding T2-1 amides by amide coupling conditions, for example , by carboxylic acid chlorides formed from T2-k which are combined with amines R'-NH-A under basic conditions, for example pyridine, triethylamine or ΛζΤν-diisopropylethylamine, or by amide formation from T2 carboxylic acids -k which are combined with amines R'-NH-A and dehydration reagents, for example, 7V-(3-dimethylaminoisopropyl)-jV'-ethylcarbodiimide-hydrochloride (EDC). For example, similar syntheses are described in WO 2009036412. The amides of aza-quinolones T2-1 can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R=Me or R,R=pinacolate) as described with similar reactions in WO 2015144001, in T2-m aryl or hetaryl substituted aza-quinolone amides. Aza-quinolone T2-m amides can be converted to the corresponding chlorine aza-quinoline T2-h in the presence of chlorinating agents such as phosphorus oxychloride or oxalyl chloride as described in WO 2008154447 with similar aza-quinolines. Depending on the nature of the R2H nucleophile, the chlorine azaquinolones T2-h react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, N,Ndiisopropylethylamine, diazabicycloundecane , sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the final compounds I-T2. Alternatively, T2-h can be converted with certain organic Grignard or metal R2Met-X compounds, e.g., Ci-Ci-alkyl-Met-X, Ca-Ce-cycloalkylMet-X, C2-C4-alkenyl-Met-X, Cs-Có-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-CiC4-alkyl-Met-X (Met = Mg, Zn; X = I, Br, Cl) introducing alkyl-Ci- C4, cycloalkyl-Cj-Có, alkenyl-C2-C4, cycloalkenyl-Cs-Có, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which -154 is optionally substituted as defined supra for the group R2, as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in final I-T2 compounds. Scheme 3 to prepare a compound (I) with T - Ί3 (I-T3) T3-a aminopyridines can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)z (R=H; R=Me or R,R=pinacolate) as described in WO 2015170693 on aphyllo- or hetaryl-substituted aminopyridines T3-b. Such aminopyridines can be easily converted with (alkoxymethyl)malonates T3c dissolved in the corresponding solvent of alcohol or toluene, preferably under boiling conditions, into (pyrid-3-ylaminomethylene)-malonates T3-d as described in the US document. 20140336182, or without any solvent as described in the Journal of the American Chemical Society, 1946, 68, 1204-1208. Ring closure is performed in high boiling solvents, preferably in diphenyl ether or xylol, to achieve azaquinolone T3-e carboxylic esters as described in WO 2013132376. The T3-e intermediate esters react under hydrolytic conditions to produce aza-quinolone T3-f carboxylic acids as described with similar syntheses in WO 20060223843. The T3-f carboxylic acids can be converted to the corresponding T3-g acid chlorides in the presence of -155chlorination as phosphorus oxychloride as described in WO 2006125974 with similar azaquinolines. The acid chloride can easily be converted with amines R'-NH-A to amides T3-h in the presence of bases such as triethylamine. Depending on the nature of the nucleophile R2H, the chloro aza-quinolones T3-h react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, ΛζΜ-diisopropylethylamine, diazabicycloundecane , sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the final compounds I-T3. Alternatively, T3-h can be converted with certain organic Grignard or metal R2Met-X compounds, e.g., Ci-C4-alkyl-Met-X, Cs-Cs-cycloalkyl-Met-X, C2-C4-alkenyl-Met- X, Cs-Có-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-Ci-C4-alkyl-Met-X (Met = Mg, Zn; X = I, Br, Cl) introducing Ci-C4 alkyl, Cj-Có-cycloalkyl, C2-C4-alkenyl, CsCó-cycloalkenyl, C2-C4-alkynyl or phenyl-Ci-Ci-alkyl, each of which is optionally substituted as defined above for the R2 group, as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in final compounds I-T3. Scheme 4 to prepare a compound (I) with T =F (I-T4) -156T4-a aminopyrimidines can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R=Me or R,R=pinacolate) as described in the papers WO 2008134679 or WO 2009112461 on T4-b aryl or hetaryl substituted pyrimidines. Subsequently, T4-b can be easily converted to pyrimidinyl ester T4-c under autoclave conditions and carbon monoxide atmosphere in the presence of methanol as described in WO 199835967. The next step involves acrylester T4-d which can be condensed with T4 -c to provide aza-quinolones as T4-e as described in the Journal of the Chemical Society [Section C: Organic] (1967),(18),1745-1750. Intermediates T4-e react under hydrolytic conditions to produce aza-quinolone carboxylic acids T4-f as described with similar syntheses in WO 2009089263. The T4-f carboxylic acids can be converted to the corresponding T4-g acid chlorides in presence of chlorinating agents such as phosphorus oxychloride as described in EP 115469 with similar naphthyridines. The acid chloride can easily be converted with amines R'-NH-A to amides T4-h in the presence of bases such as triethylamine. Depending on the nature of the R2H nucleophile, the chloro azaquinolones T4-h react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, N,Ndiisopropylethylamine, diazabicycloundecane , sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the final compounds I-T4. Alternatively, T4-h can be converted with certain organic Grignard or metal R2Met-X compounds, e.g., Ci-C4-alkyl-Met-X, Cs-Ce-cycloalkylMet-X, C2-C4-alkenyl-Met-X, Ca-Có-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-CiC4-alkyl-Met-X (Met = Mg, Zn; X = I, Br, Cl) introducing alkyl-Ci- C», cycloalkyl-Cs-Ce, alkenyl-C2-C4, cycloalkenyl-Cs-Có, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted as defined above for the group R2, as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in final compounds I-T4. Procedure 5 to prepare a compound (I) with 1=16 (I-T5) -157- NaOAc, EtOH, H NaN02. HQ. AcOH base, H,O Fd' hydroxy base The 2-halogenanilines T5-a can be readily converted to oxoacetohydrazonoyl cyanides T5b in a two-step diazotization-condensation reaction with 2-cyanoacetamide as described in the Journal of Medicinal Chemistry, 2015, 58(14), 5437-5444. Cyclization of T5-b to cinnoline carboxamides T5-c occurs in the presence of Lewis acids, for example aluminum trichloride, as described in WO 2013148603. The amino functions of T5-c can be saponified in the presence of bases of hydroxyl, eg potassium hydroxide, to obtain cinnoline carboxylic acid T5-d as described in WO 2004016615. T5-d can be readily chlorinated, eg with phosphorus oxychloride, into cinnoline carboxylic acid chloride T5-e as described in WO 2012162254. The acid chloride can be converted with amines R'-NH-A to amides T5-f in the presence of bases such as triethylamine as described in WO 2012162254. Depending on the nature from the nucleophile R2H, the chlorine T5-f cinnolines react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, potassium t-butylate, triethylamine, N,N-diisopropylethylamine, diazabicycloundecane, hydride sodium, lithium hydroxide, sodium hydroxide, -158 potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain cinnoline T5-g carboxamides as described in Bioorganic & Medicinal Chemistry Letters, 2013, 23(1), 71-74. Alternatively, T5-f can be converted with certain organic Grignard or metal R2Met-X compounds, for example, Ci-C4-alkyl-Met-X, Cj-Cé-cycloalkyl-Met-X, C2-C4alkenyl-Met-X, Cj-Cs-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-Ci-Cj-alkyl-MetX (Met = Mg, Zn; X = I, Br, Cl) introducing alkyl-Ci- C4, cycloalkyl-Cj-Có, alkenyl-C2-C4, cycloalkenyl-C3-C6, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted as defined above for the group R2 , as described in the Journal of Medicinal Chemistry, 2013, 56(3), 1023-1040. Finally, T5-g can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R=Me or R,R=pinacolate) as described in WO 2013148603 to provide the final I-T5 compounds. Scheme 6 to prepare a compound (I) with T = A (I-T6) 250 Ό T6-a aminopyridazines can be converted via a Suzuki cross-coupling reaction with boronic acids or boronic esters Q-B(OR)2 (R=H; R=Me or R,R-pinacolate) -159 as described in WO 2014143241 in aryl or hetaryl substituted aminopyridazines T6-b. Such aminopyridazines can be easily converted with (alkoxymethylene)malonates T6-c dissolved in the corresponding solvent of alcohol or toluene, preferably under boiling conditions, into (pyridazin-4-ylaminomethylene)-malonates T6-d as described with similar reactions in the US 20140336182, or without any solvent as described in the Journal of the American Chemical Society, 1946, 68, 1204-1208. Ring closure is performed in high-boiling solvents, preferably in diphenyl ether or xylol, to achieve 8-oxo-5,8-dihydropyrido[3,2-c]pyridazine T6-e carboxylic esters as described in WO 2013132376. Intermediate esters T6-e react under hydrolytic conditions to produce 8-oxo-5,8-dihydropyrido[3,2-c]pyridazine-7-carboxylic acids T6-f as described with similar syntheses in WO 2013132376. WO 20060223843. T6-f carboxylic acids can be converted to the corresponding T6-g acid chlorides in the presence of chlorinating agents such as phosphorous oxychloride as described in WO 2006125974 with similar azaquinolines. Acid chloride can easily be converted with amines R'-NH-A to amides T6-h in the presence of bases such as triethylamine. Depending on the nature of the nucleophile R2H, the 8-chloro-pyrido[3,2-c]pyridazine-7-carboxamides T6-h react with R2H in the presence of a base, e.g. sodium ethylate, sodium methylate, t - potassium butylate, triethylamine, N,Ndiisopropylethylamine, diazabicycloundecane, sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate or the like, to obtain the final compounds 1-T6. Alternatively, T6-h can be converted with certain organic Grignard or metal R2Met-X compounds, for example, Ci-C4-alkyl-Met-X, Cs-Có-cycloalkylMet-X, C2-C4-alkenyl-Met-X, Ca-Có-cycloalkenyl-Met-X, C2-C4-alkynyl-Met-X or phenyl-CiC4-alkyl-Met-X (Met = Mg, Zn; X = 1, Br, Cl) introducing alkyl-Ci- C4, cycloalkyl-Cs-Có, alkenyl-C2-C4, cycloalkenyl-Cj-Ce, alkynyl-C2-C4 or phenyl-alkyl-Ci-C4, each of which is optionally substituted as defined above for the group R2 , as described in Tetrahedron Letters, 2000, 41(33), 6387-6391 for example, in final compounds I-T6. EXPERIMENTAL SECTION - EXAMPLES Intermediate (T1) 2-(3,5-dichlorophenyl)pyridin-3-amine (Tl-b-1) -160- 2-bromopyridin-3-amine, 2.00 g (11.6 mmol), 3,5-dichlorophenylboronic acid, 3.30 g (17.3 mmol), tris(dibenzylideneacetone)dipalladium, 0.50 g (0, 6 mmol), tri-tert-butylphosphine tetrafluoroborate 0.30 g (1.2 mmol) and potassium fluoride 2.00 g (34.7 mmol) were dissolved in 80 mL tetrahydrofuran and 20 mL water . The mixture was stirred at 60 °C overnight. The solvent was removed in vacuo. Water was added, the mixture was extracted with ethyl acetate and the combined organic phases were dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10:1) to give 1.40 g (51%) of the product as a yellow solid. LC-MS (Method M34): Rt = 0.77 min; m / z = 239 (M+1)+. 2-(2,3-dichlorophenyl)pyridin-3-amine (Tl-b-2) This compound was synthesized by the same procedure as described in Tl-b-1 to provide 1.56 g (62%) of the product as a yellow solid. LC-MS (Method M34): R, = 0.82 min; m / z = 239 (M+1)+. Diethyl ({[2-(3,5-dichlorophenyl)pyridin-3-yl]amino}methylene)malonate (Tl-d-1) -161Cl Cl 0‘ 2-(3,5-Dichlorophenyl)pyridin-3-amine, 1.40 g (5.6 mmol) and diethyl 2-(ethoxymethylene)-malonate, 3.80 g (17.6 mmol), were dissolved in 30 ml of toluene. The resulting mixture was stirred at 110 °C overnight. The solvent was removed in vacuo and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1:2) to give 2.40 g (40%) of the product as a yellow solid. LC-MS (Method M20): Rt = 1.32 min; m / z = 409 (M+1)+. Diethyl ({[2-(2,3-dichlorophenyl)pyridin-3-yl]amino}methylene)malionate (Tl-d-2) cr Cl. This compound was synthesized by the same procedure as described in Tl-d-1 to provide 2.10 g (70%) of the product as a yellow oil. LC-MS (Method M20): Rt = 1.19 min; m / z = 409 (M+1)+. Ethyl 8-(3,5-dichlorophenyl)-4-oxo-1,4-dihydro-1,7-naphthyridine-3-carboxylate (Tl-e-1) -162Cl Cl or Diethyl ({[2-(3,5-dichlorophenyl)pyridin-3-yl]amino}methylene)malonate, 2.40 g (5.9 mmol) was dissolved in 50 mL diphenyl ether. The resulting mixture was stirred at 230 °C for 30 minutes. After cooling to room temperature, 500 mL of petroleum ether was added and the precipitated solid was collected by filtration to give 460 mg (9%) of the product as a brown solid. LC-MS (MI7 Method): Rt = 0.77 min; m / z = 363 (M+1)+. Ethyl 8-(2,3-dichlorophenyl)-4-oxo-1,4-dihydro-1,7-naphthyridine-3-carboxylate (Tl-e-2) or or cl' Cl. EITHER This compound was synthesized by the same procedure as described in Tl-e-1 to provide 460 mg (21%) of the product as a brown solid. LC-MS (Method M20): Rt = 0.93 min; m / z = 363 (M+1)+. Ethyl 4-chloro-8-(3,5-dichlorophenyl)-1,7-naphthyridine-3-carboxylate (Tl-f-1) -163- Ethyl 8-(3,5-dichlorophenyl)-4-oxo-1,4-dihydro-1,7-naphthyridine-3-carboxylate, 460 mg (1.3 mmol) was dissolved in 10 mL of phosphorous oxychloride. The resulting mixture was stirred at 100 °C for 2 hours. The solvent was removed in vacuo to provide 460 mg (crude) of the product as a black oil. < LC-MS (Method M20): R, = 1.55 min; m / z = 381 (M+1)+. Ethyl 4-chloro-8-(2,3-dichlorophenyl)-1,7-naphthyridine-3-carboxylate (Tl-f-2) This compound was synthesized by the same procedure as described in Tl-f-1 to provide 460 mg (55%) of the product as a black oil. LC-MS (Method M3): Rt = 1.32 min; m / z = 381 (M+1)+. Ethyl 8-(3,5-dicIrophenyl)-4-(dimethylamino)-1,7-naphthyndine-3-carboxylate (Tl-g-1) -164- Ethyl 4-chloro-8-(3,5-dichlorophenyl)-1,7-naphthyridine-3-carboxylate, 230 mg (0.6 mmol) was dissolved in 10 mL tetrahydrofuran. Dimethylamine, 3.0 mL (2M in tetrahydrofuran, 6.0 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour. The solvent was removed in vacuo. Water was added, the mixture was extracted with ethyl acetate and the combined organic phases were dried over anhydrous sodium sulfate. The solvent was removed in vacuo to provide 230 mg (crude) of the product as a brown oil. LC-MS (Method M21): Rt = 1.24 min; m / z = 390 (M+1)+. Ethyl 8-(2,3-dichlorophenyl)-4-(dimethylamino)-1,7-naphthyridine-3-carboxylate (Tl-g-2) This compound was synthesized by the same procedure as described in Tl-g-1 to provide 210 mg (63%) of the product as a brown solid. LC-MS (Method M3): Rt = 1.14 min; m / z = 390 (M+1)+. Ethyl 8-(3,5-dichlorophenyl)-4-(morpholin-4-yl)-1,7-naphthyridine-3-carboxylate (Tl-g-3) -165- Ethyl 4-chloro-8-(3,5-dichlorophenyl)-1,7-naphthyridine-3-carboxylate, 260 mg (crude) was dissolved in 5 mL tetrahydrofuran. Morpholine, 310 mg (5.2 equiv) was added. The resulting mixture was stirred at room temperature for 1 hour. The solvent was removed in vacuo. Water was added, the mixture was extracted with ethyl acetate and the combined organic layers were dried over anhydrous sodium sulfate to give 230 mg (78%) of the product as a white solid. LC-MS (Method M21): R, = 1.23 min; m / z = 432 (M+1)+. Ethyl 8-(3,5-dichlorophenyl)-4-(morpholin-4-yl)-1,7-naphthyridine-3-carboxylate (Tl-g-4) This compound was synthesized by the same procedure as described in Tl-g-3 to provide 200 mg (64%) of the product as a yellow solid. LC-MS (Method M21): R, = 1.19 min; m / z=432(M+1)+. 8-(3,5-dichlorophenyl)-4-(dimethylamino)-1,7-naphthyridine-3-carboxylic acid (Tl-h-1) -166- Ethyl 8-(3,5-dichlorophenyl)-4-(dimethylamino)-1,7-naphthyridine-3-carboxylate, 230 mg (0.6 mmol) was dissolved in 4.0 mL tetrahydrofuran and 1.0 mL of water. Lithium hydroxide, 140 mg (5.9 mmol) was added at room temperature. The resulting mixture was stirred at 60 °C overnight. After cooling to room temperature, the solvent was removed in vacuo. The mixture was extracted with ethyl acetate and the pH of the aqueous phase was adjusted to 7 with 2N hydrogen chloride solution. The precipitated solid was filtered off, washed with water and air dried to give 130 mg (57%) of the product as a yellow solid. LC-MS (Method M21): Rt = 0.81 min; m / z = 362 (M+1)+. 8-(2,3-dichlorophenyl)-4-(dimethylamino)-1,7-naphthyridine-3-carboxylic (Tl-h-2) This compound was synthesized by the same procedure as described in Tl-h-1 to provide 190 mg (89%) of the product as a yellow solid. LC-MS (Method M3): Rt = 0.82 min; m / z = 362 (M+1)+. 8-(3,5-Dichlorophenyl)-4-(morpholin-4-yl)-í,7-naphthyridine-3-carboxylic acid (Tl-h-3) -167- This compound was synthesized by the same procedure as described in Tl-h-1 to provide 100 mg (44%) of the product as a yellow solid. LC-MS (Method M21): Rt = 1.00 min; m / z = 404 (M+1)+. 8-(2,3-Dichlorophenyl)-4-(morpholin-4-yl)-1,7-naphthyridine-3-carboxylic acid (Tl-h-4) This compound was synthesized by the same procedure as described in Tl-h-1 to provide 160 mg (73%) of the product as a yellow solid. LC-MS (Method M3): Rt = 0.99 min; m / z = 404 (M+1)+. Examples (T1) Example Tl-1 -1688-(3,5-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-(dimethylamino)-1,7-naphthyridine-3-carboxamide 8-(3,5-Dichlorophenyl)-4-(dimethylamino)-1,7-naphthyridine-3-carboxylic acid, 120 mg(0.3 mmol), (S)chroman-4-amine, 60 mg (0. 4 mmol), HATU, 189 mg (0.5 mmol), ΛζΑ-diisopropylethylamine, 129 mg (1.0 mmol), were dissolved in 3 mL of VV-dimethylformamide. The resulting mixture was stirred at room temperature for 2 hours. The solvent was removed in vacuo and the residue was purified by preparative HPLC to give 36 mg (20%) of the product as a yellow solid. LC-MS (Method M30): R, = 1.61 min; m / z = 493 (M+1)+. *H NMR (400 MHz, DMSO-rf«): δ [ppm] = 2.05-2.08 (m, 1H), 2.19-2.24 (m, 1H), 3.11 (s , 6H), 4.22-4.31 (m, 2H), 5.25 (q, 1H), 6.80 (d, 1H), 6.94 (t, 1H), 7.18 (t, 1H), 7.38 (d, 1H), 7.73 (s, 1H), 8.06-8.09 (m, 3H), 8.65 (d, 1H), 8.74 (s, 1H ), 9.18 (d, 1H). Example Ti-2 8-(2,3-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-(dimethylamino)-1,7-naphthyridine-3-carboxamide -169 This compound was synthesized by the same procedure as described in Example TI-1 to provide 74 mg (29%) of the product as a yellow solid. LC-MS (Method M36): Rt = 1.20 min; m / z = 493 (M+1)+. Ή-NMR (400 MHz, DMSO-< / ti): δ [ppm] = 2.01-2.07 (m, 1H), 2.17-2.20 (m, 1H), 3.16 (s , 6H), 4.17-4.29 (m, 2H), 5.22 (q, 1H), 6.79 (d, 1H), 6.92 (t, 1H), 7.14-7, 19 (m, 1H), 7.34 (d, 1H), 7,407.49 (m, 2H), 7.7-7.8 (m, 1H), 8.13 (d, 1H), 8.57 (s, 1H), 8.64 (d, 1H), 9.16(d, 1H). Example Tl-3 8-(3,5-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-(morphoIin-4-yl)-1,7- naphthyridine-3carboxamide EITHER. Cl Cl This compound was synthesized by the same procedure as described in Example TI -1 to provide 78 mg (57%) of the product as a light yellow solid. LC-MS (M35 Method: Rt = 1.85 min; m / z = 535 (M+l)+. Ή NMR (400 MHz, DMSO-ok): δ [ppm] = 2.07-2.11 (m, 1H), 2.20-2.27 (m, 1H), 3.31-3.40 (m, 4H), 3.87-3.90 (m, 4H), 4.24-4.30 (m, 2H), 5.27 (q, 1H), 6.81 (d, 1H), 6.95 (t, 1H), 7.19 (t, 1H), 7.41 (d, 1H), 7.74 (t, 1H), 8.06-8.10 (m, 3H), 8 .71 (d, 1H), 8.83 (s, 1H), 9.28 (d, 1H). Example Tl-4 8-(2,3-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-(morphoIin-4-yl)-1,7-naphthyridine-3-carboxamide -170- This compound was synthesized by the same procedure as described in Example TI-1 to provide 59 mg (29%) of the product as a yellow solid. LC-MS (Method M37): Rt = 1.60 min; m / z = 535 (M+1)+. Ή NMR (400 MHz, DMSO-rfe): δ [ppm] = 2.03-2.08 (m, 1H), 2.18-2.23 (m, 1H), 3.32-3.33 (m, 4H), 3.88 (m, 4H), 4.22-4.48 (m, 2H), 5.24 (q, 1H), 6.78-6.80 (m, 1H), 6.91 (t, 1H), 7.11-7.20 (m, 1H), 7.35-7.51 (m, 3H), 7.75-7.78 (m, 1H), 8, 08 (d, 1H), 8.67-8.69 (m, 2H), 9.25 (d, 1H). Intermediate (T2) 3-(2,3-dichlorophenyl)pyridin-4-amine (T2-b-l) 3-bromopyridin-4-amine, 2.00 g (11.6 mmol), 2,3-dichlorophenylboronic acid, 3.30 g (17.3 mmol), tris(dibenzylideneacetone)dipalladium, 530 mg (0.6 mmol ), tri-tert-butylphosphine tetrafluoroborate, 335 mg (1.2 mmol) and potassium fluoride, 2.00 g (34.7 mmol), were dissolved in 40 mL tetrahydrofuran and 10 mL water. The mixture was stirred at 110 °C overnight. The solvent was removed in vacuo. Water was added, the mixture was extracted with ethyl acetate and the combined organic phase was dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the residue was purified. -171 by silica gel column chromatography (dichloromethane / methanol = 20:1) to give 1.90 g (59%) of the product as a yellow solid. LC-MS (Method M33): Rt = 1.22 min; m / z = 239 (M+1)+. Diethyl ({[3-(2,3-dicIorophenyl)pyridin-4-yl]amino}methylene)malonate (T2-d-l) 3-(2,3-Dichlorophenyl)pyridin-4-amine, 1.90 g (8.0 mmol) and diethyl 2-(ethoxymethylene)-malonate, 5.70 g (23.8 mmol), were dissolved in 30 ml of toluene. The resulting mixture was stirred at 110 °C overnight. The solvent was removed in vacuo and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate - 1:2) to give 1.10 g (33%) of the product as a yellow oil. LC-MS (Method M33): Rt = 1.52 min; m / z = 409 (M+1)+. Ethyl 8-(2,3-dichlorophenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate (T2-e-1) 1000 mL of diphenyl ether was placed in a three-necked flask, and diethyl ({[3-(2,3dichlorophenyl)pyridin-4-yl]amino}methylene)malonate, 1.00 g (2, 4 mmol), dissolved in 100 ml of diphenyl ether. The resulting mixture was stirred at reflux for 10 minutes. After cooling to room temperature, the reaction system was washed five times with 4N hydrogen chloride solution. The aqueous phase was lyophilized and then purified with a Cl8 reverse phase column to provide 540 mg (61%) of the product as a yellow solid. -172 LC-MS (Method M31): Rt = 1.93 min; m / z = 363 (M+1)+. 8-(2,3-dichlorophenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid (T2-f-1) Cl 0 Cl ooh Ethyl 8-(2,3-dichlorophenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate, 540 mg (1.5 mmol) was dissolved in 16 mL tetrahydrofuran and 4 mL of water. Lithium hydroxide, 625 mg (14.9 mmol) was added at room temperature. The resulting mixture was stirred at 60 °C overnight. After cooling to room temperature, the solvent was removed in vacuo. The mixture was extracted with ethyl acetate and the pH of the aqueous phase was adjusted to 7 with 2N hydrogen chloride solution. The precipitated solid was filtered off, washed with water and air dried to give 300 mg (50%) of the product as a white solid. LC-MS (Method M17): Rt = 0.80 min; m / z = 335 (M+1)+. 4-Chloro-8-(2,3-dichlorophenyl)-1,6-naphthyridine-3-carbonyl chloride (T2-g-1) ClO Cl Cl Cl 8-(2,3-Dichlorophenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid, 250 mg (0.8 mmol) was dissolved in 5 mL of toluene. A / N-Diisopropylethylamine, 289 mg (2.2 mmol) was added at room temperature. The resulting mixture was stirred at 60 °C for 1 hour. Phosphorus oxychloride was added. -173 572 mg (3.7 mmol) at 60 °C. The resulting mixture was stirred at 60 °C for 30 minutes. The solvent was removed in vacuo to provide 250 mg (crude) of the product as a brown oil. The residue was used directly in the next step without further purification. 4-chloro-8-(2,3-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-1,6-naphthyridine-3-carboxamide (T2-h-2) Cl· Cl. 4-chloro-8-(2,3-dichlorophenyl)-l,6-naphthyridine-3-carbonyl chloride 250 mg (0.7 mmol) and (S)chroman-4-amine 120 mg (0.8 mmol) were dissolved in 5 ml of dichloromethane. Triethylamine, 340 mg (3.4 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 30 minutes. The solvent was removed in vacuo to provide 250 mg (crude) of the product as a brown oil. LC-MS (Method M17): Rt = 1.06; m / z = 484 (M+1)+. Diethyl {|(3-bromopyridin-4-yl)amino|methylene}malonate (T2-Í-1) 3-bromopyridin-4-amine, 2.00 g (11.6 mmol) and diethyl 2-(ethoxymethylene)malonate, 7.49 g (34.7 mmol) were dissolved in 50 mL of toluene. The resulting mixture was stirred at 110 °C overnight. After cooling to room temperature, the solvent was removed in vacuo. The residue was purified -174 by column chromatography on silica gel (petroleum ether / ethyl acetate = 2:3) to give 3.50 g (88%) of the product as a brown solid. LC-MS (Method M20): Rt = 0.86 min; m / z = 343 / 345 (M+l)+. Ethyl 8-bromo-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate (T2-j-1) or or br Diethyl {[(3-bromopyridin-4-yl)amino]methylene}malonate, 3.00 g (8.7 mmol) was dissolved in 50 mL diphenyl ether. The resulting mixture was stirred at 230 °C for 40 minutes. After cooling to room temperature, 500 ml of petroleum ether was added, the precipitated solid was collected by filtration to give 1.42 g (50%) of the product as a brown solid. LC-MS (MI2 Method): Rt = 0.59 min; m / z = 297 / 299 (M+1)+. 8-bromo-4-oxo-l,4-dihydro-l,6-naphthyridine-3-carboxylic acid (T2-k-l) or or Ethyl 8-bromo-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate, 1.42 g (4.8 mmol) was dissolved in 40.0 mL tetrahydrofuran and 10 mL water . Lithium hydroxide, 1.15 g (47.8 mmol) was added at room temperature. The resulting mixture was stirred at 65 °C overnight. After cooling to room temperature, the solvent was removed in vacuo. The mixture was extracted with ethyl acetate and the pH of the aqueous phase was adjusted to 7 with 2N hydrogen chloride solution. The precipitated solid was filtered off, washed with water and air dried to give 1.10 g (86%) of the product as a white solid. -175 LC-MS (Method M12): Rt = 0.56 min; m / z = 269 / 271 (M+1)+. 8-Bromo-N-|(4S)-3,4-dihydro-2H-chromen-4-yl]-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxamide (T2-I-1) 8-Bromo-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid, 600 mg (2.2 mmol), (S)-chroman- 4-amine, 400 mg (2.7 mmol), HATU, 1.27 g (3.3 mmol), ΛζΝ-diisopropylethylamine, 865 mg (6.7 mmol) were dissolved in 10 mL of ΛζΑ-dimethylformamide. The resulting mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated sodium chloride solution. The precipitation was collected by filtration, washed with water and dried in vacuo to give 650 mg (73%) of the product as a white solid. LC-MS (Method M20): Rt = 0.94 min; m / z = 400 / 402 (M+l)+. 8-(3,5-Dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxamide ( T2-m-l) 8-Bromo-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxamide, 450 mg (1.1 mmol), 3,5-dichlorophenylboronic acid, 322 mg (1.7 mmol), tris(dibenzylideneacetone)dipalladium, 52 mg (0.06 mmol), tri-tert-butylphosphine tetrafluoroborate, 33 -176mg (0.1mmol) and potassium fluoride, 196mg (3.4mmol) were dissolved in 8ml tetrahydrofuran and 2ml water. The mixture was stirred at 60 °C overnight. The solvent was removed in vacuo. After cooling to room temperature, water was added, the mixture was extracted with ethyl acetate and the combined organic phases were dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20:1) to give 420 mg (40%) of the product as a yellow solid. LC-MS (Method M29): Rt = 3.21 min; m / z = 466 (M+1)+. Ή NMR (300 MHz, DMSO-uk): δ [ppm] = 2.04-2.09 (m, 1H), 2.20-2.27 (m, 1H), 4.15-4.20 (m, 1H), 4.29-4.34 (m, 1H), 5.24 (q, 1H), 6.82-6.93 (m, 2H), 7.18-7.26 (m , 2H), 7.70 (d, 2H), 7.84 (d, 1H), 8.64-8.68 (m, 2H), 9.39 (s, 1H), 10.10 (d, 1H), 11.98-11.99 (m, 1H). 8-(2,3-Dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxamide ( T2-m-2) This compound was synthesized by the same procedure as described in T2-m-l to provide 460 mg (70%) of the product as a yellow solid. LC-MS (Method M30): R, = 1.73 min; m / z = 466 (M+1)+. *H NMR (300 MHz, DMSO-rfe): δ [ppm] = 2.03-2.08 (m, 1H), 2.18-2.24 (m, 1H), 4.14-4, 20 (m, 1H), 4.28-4.35 (m, 1H), 5.23 (q, 1H), 6.82-6.93 (m, 2H), 7.18-7.27 ( m, 2H), 7.54-7.63 (m, 2H), 7.90 (d, 1H), 8.62-8.66 (m, 2H), 9.43 (s, 1H), 10 .06 (d, 1H), 12.02 (br, 1H). 4-chloro-8-(3,5-dicIrophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-1,6-naphthyridine-3-carboxamide (T2-h-1) -177- 8-(3,5-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxamide, 200 mg (0.4 mmol), V,7V-diisopropylethylamine, 166 mg (1.29 mmol) were dissolved in 10 mL of toluene. The resulting mixture was stirred at 80 °C for 1 hour. After cooling to room temperature, phosphorous oxychloride, 329 mg (2.1 mmol) was added dropwise. The resulting mixture was stirred at room temperature for 10 minutes. The solvent was removed in vacuo to give 200 mg (crude) of the product as a brown oil which was used without further purification in the next step. LC-MS (M2 Method): Rt = 2.71 min; m / z = 484 (M+1)+. 4-chloro-8-(2,3-dichlorophenyl)-N-|(4S)-3,4-dihydro-2H-chromen-4-yl]-1,6-naphthyridine-3-carboxamide (T2-h-2) This compound was synthesized by the same procedure as described for T2-h-1 to give 300 mg (crude) of the product as an orange oil which was used without further purification in the next step. LC-MS (Method M20): Rt = 1.17 min; m / z = 484 (M+1)+. -178 Examples (T2) Example T2-1 8-(3,5-dichlorophenyl)-N-|(4S)-3,4-dihydro-2H-chromen-4-yl]-4-(dimethylamino)-1,6-naphthyridine-3-carboxamide Dissolved (4-chloro-8-(3,5-dichlorophenyl)-N-[(4S)-3,4-dihydro-2H-chromen-4-yl]-1,6-naphthyridine-3-carboxamide, 100 mg ( 0.2 mmol) in 5 mL tetrahydrofuran Dimethylamine, 1.0 mL (2M in tetrahydrofuran, 2.1 mmol) was added The resulting mixture was stirred at room temperature for 1 hour The solvent was removed in vacuo. Water was added, the mixture was extracted with ethyl acetate and the combined or...

Claims

1. A compound of the general formula (1), excluding its therapeutic application in humans, FORMULA 1 characterized in that the compound is selected from the group consisting of (60 formulas follow) and stereoisomers, tautomers and salts thereof, and mixtures thereof. Sole Claim